

AUTHOR INDEX

Arthritis and Rheumatism, Volume 39, Numbers 1-12, 1996

A

Aarden LA, 2083
 Aaron LA, 436, 2086
 Abad LW, 1115
 Abe E, 567
 Abney E, 495
 Abrahamowicz M, 370, 2084
 Abramson SB, 9, 1905
 Abu-Shakra M, 1050
 Adams E, 347
 Adebajo AO, 711, 1437
 Agbalika F, 1610
 Aglas F, 1608
 Ahern MJ, 216, 1970
 Ahlqvist J, 1071
 Ahonen J, 996
 Ahrens D, 1576
 Akama H, 1259
 Akizuki M, 1308, 1313
 Alarcón GS, 403, 436, 1172, 1802, 2086
 Alarcón-Segovia D, 1934
 Albert ED, 868
 Alberts KR, 436, 2086
 Alepa FP, 2004, 2013, 2021
 Alexander RW, 436, 2086
 Aliabadi P, 648
 Allain J, 1760
 Alldersea J, 1763
 Allen NB, 175
 Allen SH, 746
 Alten R, 41
 American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, 1, 713, 723
 American College of Rheumatology Audiovisual Aids Subcommittee, 2078
 American College of Rheumatology Task Force on Osteoporosis Guidelines, 1791
 Anand A, 1765
 Anand A, 1765
 Anand N, 1765
 Anaya J-M, 1875
 Anderson CJ, 1664
 Anderson LJ, 880
 Anderson RJ, 1021, 2004, 2013, 2021
 Ando S, 855
 Andrade LEC, 1643
 Aono H, 197
 Aoyagi T, 1267
 Appelboom T, 1608
 Arakawa M, 330, 1338, 1728
 Arana RM, 182, 352
 Arbeit LA, 1747
 Arbustini E, 1222
 Arenas J, 1869
 Armadans-Gil L, 1138

Armona J, 1016
 Arner EC, 709
 Arnett FC, 1151, 1355, 1362, 1507, 1833
 Asche C, 1931
 Ashby AM, 1922
 Atherton D, 1041
 Atkinson JP, 180, 891
 Austin J, 1391
 Authier F-J, 1423
 Awad JA, 1146
 Aydelotte MB, 478, 1896
 Azuma M, 110

B

Bachman TR, 325
 Bacon P, 363
 Badger AM, 504
 Baethge BA, 93
 Baeuerle PA, 583
 Baird SM, 2066
 Baker SK, 1566
 Bal F, 1073
 Balestra DJ, 2021
 Balestrieri G, 758
 Bañares AA, 1277
 Bandara G, 820
 Bansal AS, 705
 Barchowsky A, 574
 Bardin T, 335, 1192, 1319
 Barker J, 137
 Barnett ML, 623
 Barozzi L, 1524, 2074
 Barquin N, 810
 Barthel H-R, 1860
 Bartz-Bazzanella P, 868
 Bavington C, 1430
 Beardmore TD, 93
 Beilke MA, 610
 Belec L, 1423
 Bellamy N, 357
 Bellucci AM, 704
 Belmont HM, 9
 Ben-Chetrit E, 1213
 Benedict L, 1300
 Benekli M, 2062
 Bengtsson A, 1654
 Benjamin N, 643
 Bennett GL, 1566
 Bennett RM, 1627
 Benor DE, 1529
 Béress R, 1066
 Berlin G, 1519
 Bernhard G, 711
 Berruti V, 1030
 Biamonti G, 1669
 Bias WB, 1362
 Bijl JA, 52
 Bijlsma JWJ, 297, 829, 1766
 Billingham MEJ, 1556
 Birchmore D, 698
 Bird H, 1400
 Birkenhäger JC, 81
 Birrell FN, 711
 Bjarnason I, 1998
 Bjornsson J, 1922
 Black CM, 1041
 Blackburn WD Jr., 1072, 1263, 2004, 2013, 2021
 Blades S, 583
 Blake DR, 583
 Blanc F, 1166
 Blanchard JL, 610
 Blanco R, 1016, 1073
 Blier C, 1254
 Bloch DA, 979
 Blomberg J, 1654
 Blossche C, 257
 Bluhm G, 1802
 Bodeutsch C, 297, 783
 Boerbooms AMT, 1266
 Bologna C, 1166
 Bologna SG, 1475
 Bombardieri S, 363
 Borghi C, 1524
 Boumba DS, 767
 Bourrat L, 1166
 Bowlin T, 1703
 Bowman S, 1608
 Boyle DL, 923
 Bradbeer JN, 504
 Bradley LA, 357, 436, 2086
 Brandt KD, 235
 Branigan PJ, 1740
 Braun J, 41
 Breedveld FC, 266, 396, 1077, 1937, 1961
 Bremell T, 1596
 Brennan FR, 1430
 Bresnahan B, 115
 Brezinschek RI, 844
 Bridges AJ, 353, 532
 Brinckerhoff CE, 574
 Broketa G, 1338
 Brooks RH, 1102
 Brown M, 1768
 Buchner E, 204
 Bucki B, 335, 1319
 Budiman-Mak E, 2004, 2013, 2021
 Bulbul R, 950
 Bunce M, 1768
 Buoncompagni A, 883
 Burger H, 81
 Burmester GR, 1258, 1860
 Burton DW, 2066
 Buttgerit F, 1258
 Buxbaum J, 2004, 2021
 Byrd SN, 1606
 Byrd V, 914
 Byron K, 1264

C

Cabello A, 1869
 Cabral AR, 1934

Cailleux N, 1439
 Calamia KT, 1132
 Çalgüneri M, 2062
 Calin A, 1768
 Callahan L, 1931
 Callegari PE, 950
 Cameron HD, 1362
 Campion GV, 1092
 Campos Y, 1869
 Candell-Riera J, 1138
 Cannon GW, 325, 1102, 1677, 2004, 2013, 2021
 Cantini F, 1062
 Canvin J, 1913
 Caporali R, 1669
 Cardenal A, 245, 252
 Carlson PJ, 904
 Carnevale K, 698
 Caron JP, 1535
 Carpenter AB, 1178
 Carruthers DM, 1208
 Cassidy JT, 746
 Castagnone D, 1030
 Castell M, 204
 Castell-Conesa J, 1138
 Catalano M, 1092
 Cattaruzzi P, 226
 Caubarrere I, 535
 Cauli A, 52, 137
 Çelik I, 2062
 Cereijo MJ, 1073
 Champy R, 1192, 1319
 Chan B, 1931
 Chan EKL, 1643
 Chan SY, 706
 Chang CP, 950
 Chang PP, 638
 Chapman PT, 1371
 Charmley P, 931
 Chary-Valckenaere I, 736
 Chatham WW, 1072
 Cheng J, 1611
 Cherot P, 1610
 Cheung NT, 884
 Chevalier X, 1760
 Choudhury D, 698
 Chou T, 330
 Choy EHS, 52
 Christophers E, 1066
 Chui Y-L, 1980
 Ciccarelli A, 1222
 Cicuttini FM, 988
 Ciruelo E, 2028
 Clancy RM, 1905
 Clarke AE, 979
 Claudepierre P, 1760
 Clavaguera MT, 1244
 Cleary ML, 638
 Clegg DO, 403, 1802, 2004, 2013, 2021
 Cloutier J-M, 968
 Cobeta-Garcia JC, 2088

AUTHOR INDEX

Arthritis and Rheumatism, Volume 39, Numbers 1-12, 1996

A

Aarden LA, 2083
 Aaron LA, 436, 2086
 Abad LW, 1115
 Abe E, 567
 Abney E, 495
 Abrahamowicz M, 370, 2084
 Abramson SB, 9, 1905
 Abu-Shakra M, 1050
 Adams E, 347
 Adebajo AO, 711, 1437
 Agbalika F, 1610
 Aglas F, 1608
 Ahern MJ, 216, 1970
 Ahlqvist J, 1071
 Ahonen J, 996
 Ahrens D, 1576
 Akama H, 1259
 Akizuki M, 1308, 1313
 Alarcón GS, 403, 436, 1172, 1802, 2086
 Alarcón-Segovia D, 1934
 Albert ED, 868
 Alberts KR, 436, 2086
 Alepa FP, 2004, 2013, 2021
 Alexander RW, 436, 2086
 Aliabadi P, 648
 Allain J, 1760
 Alldersea J, 1763
 Allen NB, 175
 Allen SH, 746
 Alten R, 41
 American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, 1, 713, 723
 American College of Rheumatology Audiovisual Aids Subcommittee, 2078
 American College of Rheumatology Task Force on Osteoporosis Guidelines, 1791
 Anand A, 1765
 Anand A, 1765
 Anand N, 1765
 Anaya J-M, 1875
 Anderson CJ, 1664
 Anderson LJ, 880
 Anderson RJ, 1021, 2004, 2013, 2021
 Ando S, 855
 Andrade LEC, 1643
 Aono H, 197
 Aoyagi T, 1267
 Appelboom T, 1608
 Arakawa M, 330, 1338, 1728
 Arana RM, 182, 352
 Arbeit LA, 1747
 Arbustini E, 1222
 Arenas J, 1869
 Armadans-Gil L, 1138

Armona J, 1016
 Arner EC, 709
 Arnett FC, 1151, 1355, 1362, 1507, 1833
 Asche C, 1931
 Ashby AM, 1922
 Atherton D, 1041
 Atkinson JP, 180, 891
 Austin J, 1391
 Authier F-J, 1423
 Awad JA, 1146
 Aydelotte MB, 478, 1896
 Azuma M, 110

B

Bachman TR, 325
 Bacon P, 363
 Badger AM, 504
 Baethge BA, 93
 Baeuerle PA, 583
 Baird SM, 2066
 Baker SK, 1566
 Bal F, 1073
 Balestra DJ, 2021
 Balestrieri G, 758
 Bañares AA, 1277
 Bandara G, 820
 Bansal AS, 705
 Barchowsky A, 574
 Bardin T, 335, 1192, 1319
 Barker J, 137
 Barnett ML, 623
 Barozzi L, 1524, 2074
 Barquin N, 810
 Barthel H-R, 1860
 Bartz-Bazzanella P, 868
 Bavington C, 1430
 Beardmore TD, 93
 Beilke MA, 610
 Belec L, 1423
 Bellamy N, 357
 Bellucci AM, 704
 Belmont HM, 9
 Ben-Chetrit E, 1213
 Benedict L, 1300
 Benekli M, 2062
 Bengtsson A, 1654
 Benjamin N, 643
 Bennett GL, 1566
 Bennett RM, 1627
 Benor DE, 1529
 Béress R, 1066
 Berlin G, 1519
 Bernhard G, 711
 Berruti V, 1030
 Biamonti G, 1669
 Bias WB, 1362
 Bijl JA, 52
 Bijlsma JWJ, 297, 829, 1766
 Billingham MEJ, 1556
 Birchmore D, 698
 Bird H, 1400
 Birkenhäger JC, 81
 Birrell FN, 711
 Bjarnason I, 1998
 Bjornsson J, 1922
 Black CM, 1041
 Blackburn WD Jr., 1072, 1263, 2004, 2013, 2021
 Blades S, 583
 Blake DR, 583
 Blanc F, 1166
 Blanchard JL, 610
 Blanco R, 1016, 1073
 Blier C, 1254
 Bloch DA, 979
 Blomberg J, 1654
 Blossche C, 257
 Bluhm G, 1802
 Bodeutsch C, 297, 783
 Boerbooms AMT, 1266
 Bologna C, 1166
 Bologna SG, 1475
 Bombardieri S, 363
 Borghi C, 1524
 Boumba DS, 767
 Bourrat L, 1166
 Bowlin T, 1703
 Bowman S, 1608
 Boyle DL, 923
 Bradbeer JN, 504
 Bradley LA, 357, 436, 2086
 Brandt KD, 235
 Branigan PJ, 1740
 Braun J, 41
 Breedveld FC, 266, 396, 1077, 1937, 1961
 Bremell T, 1596
 Brennan FR, 1430
 Bresnahan B, 115
 Brezinschek RI, 844
 Bridges AJ, 353, 532
 Brinckerhoff CE, 574
 Broketa G, 1338
 Brooks RH, 1102
 Brown M, 1768
 Buchner E, 204
 Bucki B, 335, 1319
 Budiman-Mak E, 2004, 2013, 2021
 Bulbul R, 950
 Bunce M, 1768
 Buoncompagni A, 883
 Burger H, 81
 Burmester GR, 1258, 1860
 Burton DW, 2066
 Buttgerit F, 1258
 Buxbaum J, 2004, 2021
 Byrd SN, 1606
 Byrd V, 914
 Byron K, 1264

C

Cabello A, 1869
 Cabral AR, 1934

Cailleux N, 1439
 Calamia KT, 1132
 Çalgüneri M, 2062
 Calin A, 1768
 Callahan L, 1931
 Callegari PE, 950
 Cameron HD, 1362
 Campion GV, 1092
 Campos Y, 1869
 Candell-Riera J, 1138
 Cannon GW, 325, 1102, 1677, 2004, 2013, 2021
 Cantini F, 1062
 Canvin J, 1913
 Caporali R, 1669
 Cardenal A, 245, 252
 Carlson PJ, 904
 Carnevale K, 698
 Caron JP, 1535
 Carpenter AB, 1178
 Carruthers DM, 1208
 Cassidy JT, 746
 Castagnone D, 1030
 Castell M, 204
 Castell-Conesa J, 1138
 Catalano M, 1092
 Cattaruzzi P, 226
 Caubarrere I, 535
 Cauli A, 52, 137
 Çelik I, 2062
 Cereijo MJ, 1073
 Champy R, 1192, 1319
 Chan B, 1931
 Chan EKL, 1643
 Chan SY, 706
 Chang CP, 950
 Chang PP, 638
 Chapman PT, 1371
 Charmley P, 931
 Chary-Valckenaere I, 736
 Chatham WW, 1072
 Cheng J, 1611
 Cherot P, 1610
 Cheung NT, 884
 Chevalier X, 1760
 Choudhury D, 698
 Chou T, 330
 Choy EHS, 52
 Christophers E, 1066
 Chui Y-L, 1980
 Ciccarelli A, 1222
 Cicuttini FM, 988
 Ciruelo E, 2028
 Clancy RM, 1905
 Clarke AE, 979
 Claudepierre P, 1760
 Clavaguera MT, 1244
 Cleary ML, 638
 Clegg DO, 403, 1802, 2004, 2013, 2021
 Cloutier J-M, 968
 Cobeta-Garcia JC, 2088

Cobianchi F, 1669
 Coblyn J, 1021
 Cockerill FR III, 1260
 Cohen MR, 2004, 2013, 2021
 Colditz GA, 657
 Coleman M, 1970
 Collin P, 1733
 Combe B, 1166
 Combitchi D, 623
 Concardi M, 1222
 Conte CG, 677
 Cook AD, 1720
 Cooke SP, 1609
 Coon CI, 574
 Cooper SM, 1802
 Copland M, 643
 Cormack J, 216
 Costa AM, 1062
 Coste J, 1166
 Cotch MF, 87
 Couderc L-J, 535
 Coumbe A, 583
 Coyte PC, 1931
 Craft J, 146, 1886
 Cripps D, 532
 Criswell LA, 931, 1818
 Crofford LJ, 125
 Cronstein BN, 1951
 Cuéllar ML, 272
 Cush JJ, 1102, 2004, 2013, 2021
 Cwyfan-Hughes S, 1556
 Czyzyk J, 592

D

D'Agati V, 698
 Daggett R, 2082
 Dahi MR, 1077
 Dang H, 1875
 Danoff D, 370, 979, 2084
 Darke C, 1768
 da Silva F, 2070
 David J, 1041
 Davies E, 1763
 Davies J, 181
 Davies NM, 321
 Davies SR, 1896
 Dawes PT, 884
 Dawson-Hughes B, 415
 Dayal AK, 23
 Deapen DM, 1840
 de Crescenzo G, 1222
 Defer G-L, 1423
 Deftos LJ, 2066
 Degos J-D, 1423
 de Graeff-Meeder ER, 1826
 de Groot K, 1052
 de Jong J, 297
 de la Cruz J, 2028
 Della Casa-Alberighi O, 1006
 Del Papa N, 758
 DeMarco DM, 1808
 de Mattei M, 1524
 Dempster DW, 277
 Deng DH, 1300
 Deng J-S, 1300
 Denno K, 629
 de Paulis A, 1222

De Pità O, 704
 Deutscher SL, 1266
 Devulder B, 1161
 de Wilde PCM, 297, 783
 Diaz LA Jr., 125
 Di Cesare PE, 1905
 Dick T, 868
 Dijkman BAC, 396, 1491
 Dinarello CA, 1115
 Dion E, 335
 Dixey J, 181
 Dolhain RJEM, 1961
 Dolnikowski G, 1115
 Domingo-Morera JA, 2088
 Dowell SF, 880
 Doyle DV, 988
 Drevlow BE, 257
 Drucker Y, 615
 Duffy J, 1922
 Duncan H, 1802
 Durban E, 1362
 Duvoisin B, 1406
 Dykhuizen R, 643

E

Eddy A, 671
 Edwards C III, 1703
 Eggemeijer F, 396
 Eggens U, 41
 Eguchi K, 463, 1267
 Eimon A, 182, 352
 El-Gabalawy H, 1913
 Elkon K, 671, 1613, 1833
 Elli A, 1030
 Elliott JE, 1840
 Elliott MJ, 1082
 Emery H, 1703
 Emery P, 1720
 Emkey RD, 277
 Emlen W, 1441
 Emmrich F, 204
 Emura I, 330
 England AJ, 643
 England JD, 610
 Epstein WV, 1773
 Erdman DD, 880
 Ernerudh J, 1519
 Ertenli I, 2062
 Escalante A, 93
 Esdaile JM, 370, 979, 2084
 Espinoza LR, 272
 Esquivel-Valerio J, 93
 Etherington J, 988
 Euler HH, 1066
 Evans CH, 820
 Evill CA, 216

F

Facchini A, 1199
 Fairfax MJ, 180
 Fantini F, 1006
 Fauci AS, 1754
 Favaro L, 1524
 Fazzi P, 1074
 Feldmann M, 495, 1082
 Feldt JMV, 950

Felson DT, 536, 648, 682
 Feltkamp TEW, 297
 Ferguson PJ, 880
 Fernandes JC, 1535
 Fernández-Gutiérrez B, 1277
 Fernández-Sueiro JL, 1016
 Fernihough JK, 1556
 Fernsten P, 592
 Ferraccioli G, 1006
 Ferrara N, 1566
 Ferri C, 1074
 Ferri S, 1062, 1524
 Fiandra E, 2074
 Fifield J, 427
 Fine PR, 101
 Finger DR, 151, 1921
 Finkel M, 1292
 Firestein GS, 923, 1781
 Fischer D-C, 454
 FitzGerald O, 115
 Flammaing M-P, 535
 Flechtenmacher J, 478, 1896
 Flory CM, 1292
 Focherini MC, 1199
 Fogle M, 283
 Follansbee WP, 677
 Fonollosa-Pla V, 1138
 Formelli F, 1021
 Førre O, 351, 1491
 Fortin P, 363
 Fossel AH, 1055
 Fowler SE, 1802
 Fox DA, 125, 1102
 Fox RI, 195
 Franch A, 204
 Frank MB, 1769
 Fratto J, 1300
 Frazer IH, 705
 Freedman RR, 1189
 French DL, 1747
 Frenkel SR, 1905
 Freundlich B, 950
 Fries JF, 64, 616, 979
 Fritzler MJ, 1151, 1355, 1635
 Frizziero L, 1199
 Fryer A, 1763
 Fujii T, 686, 1313
 Fujimoto N, 885
 Fujimura T, 1376
 Fujisaku A, 1466
 Fujisawa K, 197
 Furuya H, 877
 Furuya T, 1259

G

Gabriel S, 73, 1073, 1260, 1385, 1932
 Gaffney K, 583
 Galarza-Delgado D, 93
 Galea-Lauri J, 820
 Galeazzi M, 704
 Galíndez Agirregoikoa E, 881
 Gallatin M, 1913
 Gangji V, 1608
 Garcia CO, 272
 García J, 354
 García Vivar ML, 881

García-del-Castillo H, 1138
 García-Nieto V, 354
 Gardiner P, 1400
 Gattorno M, 883
 Gause A, 1419
 Ge Q, 1588, 1769
 Gejyo F, 1728
 Gelpi C, 692
 Geng C, 968, 1535
 Gennes C, 335
 Genth E, 868, 1860
 Georgescu HI, 820
 Georgescu L, 1833
 Georgou TA, 1711
 Gérard HC, 1740
 Gerli R, 2074
 Gerster JC, 1406
 Gertner E, 355
 Gherardi RK, 1423
 Ghivizzani SC, 820
 Giandoni MB, 151
 Gibbs H, 705
 Gil M, 1244
 Gilkeson GS, 894
 Gillot J-M, 1161
 Ginzler E, 363
 Girardelli CR, 704
 Gironimi G, 979
 Gladman D, 363, 1050
 Glass DN, 1703
 Gmelig-Meyling FHJ, 829
 Godeau P, 335
 Godolphin JL, 1430
 Goel A, 1926
 Goel N, 1613
 Gold KN, 1102
 Golden BD, 1926
 Golden HE, 2086
 Goldenberg D, 1852
 Goldman D, 2046
 Goldsmith C, 363
 Goldstein R, 1151, 1355, 1507
 Golstein M, 1608
 Gomez-Reino JJ, 1869, 2028
 Gonzalez de Etxabarri S, 881
 Gonzalez-Crespo MR, 1869
 González-Gay MA, 1016, 1073
 Gonzalez-Vela C, 1016, 1073
 Gordon G, 1092
 Goronzy JJ, 904, 1132, 1265, 1499
 Gough A, 1720
 Goupille P, 711
 Gourley MF, 379
 Grabowski PS, 643
 Granston AS, 171
 Gratacos J, 692
 Gravalles EM, 1021
 Greenwald RA, 1455
 Griffiths MM, 1677
 Gripenberg-Lerche C, 1238
 Grobbee DE, 81
 Grom AA, 1703
 Gross WL, 1052
 Gruber BL, 1747
 Guidali L, 758

Gutiérrez-Ureña S, 272
Gutschmidt HJ, 1066

H

Haag MA, 257
Haakenson CM, 2004, 2013, 2021
Haas AL, 245, 252
Hachulla E, 1161
Hagiwara E, 379
Haines GK, 810, 1566
Hajeer AH, 1109
Hallahan CW, 1754
Hall LD, 1327
Hall ND, 181
Halloran MM, 810, 1566
Hally RJ, 341
Hamasaki K, 877
Hamilton AS, 1840
Hamilton VH, 979
Handel ML, 1021
Handley CJ, 1990
Hanly J, 363
Hannan MT, 648
Hannonen P, 996
Hara M, 1259
Hardin JA, 146, 1886
Hardy K, 2082
Harley JB, 283, 1664
Harmer IJ, 538
Harper J, 1041
Harris PA, 988
Harrison WB, 1491
Hart DJ, 988
Hart DNJ, 1287
Hart JJ, 1761
Hartman WJ, 1115
Hasanuma T, 446
Hasegawa H, 330, 1728
Hashimoto H, 855
Haskard DO, 1371
Haskell CJ, 1566
Haslock DI, 1422
Hasson N, 1041
Hasty KA, 235
Hasunuma T, 197, 1410
Hatron P-Y, 1161
Haubeck H-D, 454
Hausdorf G, 1860
Häuselmann HJ, 478
Hawker G, 1931
Hay E, 363
Hayashi T, 567
Hazes JMW, 266, 1937
Hazleman BL, 711, 1437
He X, 1499
Hebbar M, 1161
Heck L, 1391
Helfgott SM, 304
Heller M, 1052
Helsen MMA, 797
Helve T, 996
Henderson WG, 2004, 2013, 2021
Hené RJ, 297, 1766
Herbelin A, 1192
Herborn G, 162, 1935

Hernández-García C, 1277
Heyse SP, 1802
Hibbs JB Jr., 1677
Hiepe F, 41
Higashida J, 2021
Hillman LS, 746
Hina A, 1319
Hino I, 1259
Hino K, 1685
Hirakata M, 146, 1886
Hirano H, 1685
Hirano T, 629
Hirohata S, 836, 1483
Hirokawa K, 855
Hiroki A, 1376
Hitraya EG, 1347
Hoch SO, 863
Hochberg MC, 1125
Hodge TJ, 1362
Hoffman GS, 87, 1754
Hoffman P, 1913
Hoffman RW, 1266
Hoffmann A, 454
Hofman A, 81
Hogan PG, 705
Hoidal JR, 1677
Holly JMP, 1556
Holthuysen AEM, 1545
Hook EW III, 1172
Hopkins R, 1400
Horiki T, 152
Horwitz DA, 1840
Hosaka S, 1566
Hoshina Y, 152
Howard RF, 1362
Hsieh A, 347
Hubert H, 64
Hubscher O, 182, 352
Huch K, 1896
Hudson AP, 1740
Huebsch L, 1246
Huecksteadt TP, 1677
Hüge W, 41
Hunder GG, 73, 169, 1073, 1932
Hünig T, 204
Hunninghake GW, 1711
Hunt M, 1082
Hunter DJ, 657
Hyland VJ, 467

I

Ichikawa K, 1466
Ichikawa Y, 152
Ikeda Y, 446
IL-1RA Arthritis Study Group, 1092
Ilic MZ, 1990
Imonitie V, 950
Inada K, 152
Inman RD, 2021
Inoh M, 287
Inoko H, 152, 938
Irimajiri S, 146, 1308
Isenberg D, 363, 537
Ishida H, 1612
Ishihara K, 629
Islam SMM, 351

Isomäki P, 386, 1693
Isshi K, 1483
Issler H, 663
Ito K, 792, 1769
Ito S, 1728
Itoh K, 836, 1376
Itoh M, 629
Iwata K, 463

J

Jackson CG, 1102
Jacobs C, 257
Jacobson EW, 1808
Jacobson PB, 1292
Jacques P, 648
Jagralapudi SP, 1178
Jamali F, 321
Jamar F, 1371
James JA, 1588
Janin A, 1161
Jarek MJ, 1921
Jasin HE, 567, 1072
Jaulhac B, 736
Javier R-M, 736
Jelaska A, 1338
Jenkins K, 1430
Jerez R, 1860
Jiménez SA, 341, 1347
Jobanputra P, 709, 1430
John S, 1419
Johnson KJ, 1432
Johnson P, 101
Jolliffe VA, 1208
Joly P, 2070
Jones J, 363
Jones P, 1763
Joosten LAB, 797, 1545
Jorgensen C, 335, 1166
Joseph L, 370, 2084
Jover JA, 1277
Juji T, 1769

K

Kaburaki J, 686, 938
Kahl LE, 1475
Kahn SJ, 1218
Kaisho T, 629
Kalden JR, 1435, 1860
Kaltschmidt C, 583
Kalunian K, 363
Kamel OW, 638
Kamihagi K, 539
Kammer GM, 23
Kammerer WA, 1754
Kanekura S, 534
Kani K, 1027
Kanterewicz E, 692
Kanungo J, 1886
Kapadia RD, 504
Karaarslan Y, 2062
Karlborg J, 706
Karlson EW, 657, 1021
Karopoulos C, 1990
Kary S, 41
Kashiwazaki S, 1259
Kaslow RA, 87
Kastner DL, 2080
Kasukawa R, 1612
Katamine S, 463
Katayama M, 539
Kater L, 297, 783, 1766
Kato T, 446
Kato Y, 539
Katsikis PD, 495
Katz JN, 177, 1939
Kaufman GI, 87
Kavanaugh AF, 180
Kawabe Y, 1267
Kawakami A, 1267
Kayser C, 904
Keelan ETM, 1371
Kehayias JJ, 415
Keller E, 868
Kelly RH, 1178
Kennedy M, 682
Kerr LD, 1438
Kerttula TO, 1733
Kew RR, 1747
Kieber-Emmons T, 950
Kieval RI, 304
Kilburn KH, 1935
Kimura H, 1728
King M-C, 931
Kingsley GH, 52
Kinne RW, 204
Kiraz S, 2062
Kirsch AH, 125
Kitajima I, 534
Kiuchi H, 287
Klinman DM, 379
Kluin PM, 1077
Kobayashi S, 1466
Kobune Y, 629
Koch AE, 810, 1566, 1576
Koehnke RK, 1711
Kohem CL, 844
Kohsaka H, 110
Koike T, 1466
Kolluri S, 1711, 1818
Kong L, 1875
Konwinski MF, 698
Korn JH, 1338
Korpela M, 1733
Koskimies S, 943
Kotzin BL, 2035
Kovacs B, 600
Kozora E, 2035
Krammer PH, 1613
Krayenbühl JC, 1491
Krejs GJ, 1608
Kremer JM, 1070
Kruize AA, 297, 1766
Kuchera SL, 1292
Kuettner KE, 478, 1896
Kühne A, 41
Kühnlein P, 204
Kuipers JG, 1892
Kuis W, 1826
Kuntz J-L, 736
Kurata N, 287
Kurien BT, 1664
Kuroda T, 330, 1728
Kus ML, 583
Kuwana M, 686, 938

L

La Civita L, 1074
 Lafeber FPJG, 1829
 Lai K-N, 1980
 Lalwani ND, 1432
 Landay A, 257
 Landman J-O, 396
 Landry M, 1406
 Langford CA, 1262, 1754
 Laposata M, 1808
 Larget-Piet B, 1760
 Larsson M, 1519
 Lassalle P, 1161
 Latchman DS, 537
 Lau CS, 706
 Lau YL, 706
 Lauret P, 2070
 Laxer RM, 671
 Leaird K, 1151
 Lebovics RS, 1754
 Lebsack ME, 1092
 LeClair B, 1246
 Lee BO, 629
 Lee LA, 1427
 Lee S, 379
 Leflaucheur J-P, 1423
 Lefkowitz JB, 894
 Legouffe M-C, 1166
 Leirisalo-Repo M, 943, 996
 Leisen JCC, 1802
 Leitch DN, 1422
 le Loët X, 2070
 LeRoy EC, 1151
 Lesch ME, 1292
 Leung DTM, 1980
 Leung JCK, 1980
 Lévesque H, 1439
 Levine JA, 169
 Levy D, 648
 Levy M, 1213
 Levy Y, 1423
 Lew RA, 1055
 Liang GC, 171
 Liang M, 363, 657
 Libman B, 352
 Li F, 950
 Li LL, 125
 Li Y, 370, 2084
 Lie JT, 9
 Lim P-L, 1980
 Lin H, 1430
 Lindsay R, 277
 Linke RP, 1932
 Lioté F, 1192, 1319
 Lipsky PE, 183, 844, 1102
 Listing J, 41
 Liu GT, 1875
 Liu MF, 110
 Liu NY, 1808
 Ljungdahl A, 959
 Lockwood M, 1208
 Loizou S, 538
 Lookabaugh J, 1092
 Loose LD, 1263
 López I, 2028
 Lorenz T, 1102
 Lotz M, 552

Love LA, 1254
 Lovis R, 257
 Luggen ME, 403, 2004, 2013
 Lui S-F, 1980
 Lundgren N, 1115
 Luukkainen R, 386, 1693
 Luyrink L, 1703
 Lynch DH, 1613
 Lynch KD, 177
 Lyssy J, 277

M

Ma GM, 1913
 Ma K-N, 403
 Macchioni P, 1199
 MacGregor AJ, 732
 Macia M, 354
 Mack TM, 1840
 Mackay IR, 1720
 MacKenzie T, 370, 2084
 Mackworth-Young C, 538
 Maddison P, 181, 363
 Maeda H, 351
 Maeda T, 1611, 1685
 Magaro M, 1006
 Mahmud T, 1998
 Mahomed N, 1939
 Mahowald ML, 2004, 2013, 2021
 Maier A, 1021
 Maier R, 552
 Maini RN, 495, 1077, 1082
 Maisiak R, 101, 1391
 Mäki M, 1733
 Makkena R, 2004, 2013, 2021
 Maksymowych W, 351
 Malcolm A, 1327
 Maldonado MA, 1606
 Manaster BJ, 2004, 2013, 2021
 Manger B, 1435
 Mangge H, 884
 Manicourt D-H, 885
 Mantovani A, 758
 Manzi S, 1178
 Mapp PI, 583
 Marchesoni A, 137
 Marcolongo R, 704, 1006
 Marcus DM, 1619
 Marie I, 1439
 Mariette X, 1610
 Marines AL, 93
 Marini R, 1062
 Marinò I, 1222
 Marks C, 1436
 Marok R, 583
 Marone G, 1222
 Marshall PS, 355
 Martel-Pelletier J, 968, 1535
 Martens PB, 169
 Martin MA, 1869
 Martin MY, 436, 2086
 Martinez A, 863
 Martínez-Taboada VM, 1016
 Marubini E, 1006
 Maruyama I, 534
 Maryordomo L, 1435
 Mascagni B, 1030
 Mason T, 1385

Masuda I, 245, 252
 Masuko K, 446
 Matsuhashi N, 877
 Matsumura M, 1308
 Matsuoka N, 1267
 Matsuoka Y, 146, 1308
 Matsuura E, 1466
 Matsuzaki G, 1376
 Matteson EL, 1102, 1132, 1922, 2078
 Matthey DL, 884
 May KP, 489
 Mayes MD, 1189
 Mayr W, 454
 Mayskiy M, 1852
 McAlindon TE, 648
 McCarthy TG, 1132, 1499
 McCarty DJ, 245, 252, 1436, 1931
 McColl SR, 226
 McCue PA, 341
 McCune WJ, 1102
 McDermott MT, 489
 McDonnell J, 1234
 McEvoy F, 1400
 McFadden EA, 1075
 McKeehan WL, 914
 McKendry RJR, 1246
 McMurray RW, 1075
 McQuillan J, 427
 Medsger TA Jr., 677, 1125, 1178
 Medvedeff ED, 515
 Mehta CL, 532
 Meinders AE, 1077
 Mejias E, 2004, 2013, 2021
 Mejjad O, 2070
 Melchiorri C, 1199
 Meliconi R, 1199
 Menkès CJ, 1937
 Mercill D, 489
 Meroni PL, 758
 Mertz LE, 1132
 Meunier A, 1319
 Meurer M, 1860
 Meydani SN, 415
 Michal L, 478
 Michels H, 1932
 Mierau R, 868
 Miescher PA, 1491
 Mihatsch MJ, 1491
 Mikhail IS, 1802
 Miller FW, 1254
 Miller GG, 914
 Miltenburg AMM, 1961
 Mimori T, 686, 1308, 1313, 1507
 Mimura T, 877
 Mineau F, 1535
 Mingrone M, 93
 MIRA Trial Group, 1802
 Mita S, 197
 Mitchison NA, 41
 Mitnick HJ, 1926
 Mitra R, 125
 Mitsui H, 1769
 Miyachi K, 1308
 Miyasaka N, 110, 773
 Miyata K, 534

Mizushima Y, 446
 Molina JF, 272
 Mollenhauer JA, 1896
 Montazel J-L, 1760
 Montecucco C, 1669
 Monteil H, 736
 Moore V, 1234
 Morado IC, 1277
 Moreland LW, 257, 1172
 Morfeld D, 64, 616
 Morgan JG, 403
 Morinet F, 1610
 Moriuchi J, 152
 Morley BJ, 663
 Morris CJ, 583
 Morrow JD, 1146
 Mossey C, 1852
 Möttönen T, 996
 Moulds JM, 1362
 Mountz JD, 1611
 Moutsopoulos HM, 767, 1833
 Mowat A, 1608
 Mu H, 931
 Mukai M, 1466
 Mukaida M, 560
 Mulherin D, 115
 Muraoka O, 629
 Murray KJ, 1703
 Muscat C, 2074
 Musset L, 335

N

Nachamkin I, 950
 Nagataki S, 463, 1267
 Nakai Y, 446
 Nakajima A, 877
 Nakamura H, 836
 Nakamura S, 539, 1376
 Nakano M, 330, 1728
 Nandra D, 988
 Naparstek Y, 1027
 Naredo E, 1435
 Narváez J, 1244
 Narváez JA, 1244
 Navarro J, 354
 Nelson AM, 1385
 Nelson B, 1102
 Nelson JL, 191, 1767
 Nemoto O, 560
 Nepveu K, 352
 Nettleman MD, 1818
 Neuner R, 1802
 Newman J, 732
 Newman PM, 467
 Ng LWK, 1980
 Nguyen K, 1125
 Niccoli L, 1062
 Nickerson-Nutter CL, 515
 Nickoloff BJ, 125
 Niedbala MJ, 1576
 Nieuw Amerongen AV, 57
 Nishi J, 534
 Nishi S-I, 1728
 Nishioka K, 197, 446, 1410
 Nita I, 820
 Nived O, 363, 1654
 Nojima Y, 877

Nolla-Solé JM, 1244
Nölle B, 1052
Nomoto K, 1376
Norden D, 950
Norsworthy P, 663
Noshiro M, 539
Nuki G, 1430
Numaga J, 351
Nuovo GJ, 1747

O

Obata K, 885
Ochi T, 629, 836
Odding E, 81
Oddis CV, 1300
O'Donnell JL, 1287
O'Driscoll P, 64
O'Fallon WM, 1385
Ogawa A, 1769
Ogawa N, 1875
Ohno K, 330
Ohsone Y, 1308
Ohya Y, 1376
Okada Y, 539
Okamoto H, 539
Okano Y, 938
Okubo M, 1612
Okumura K, 110
Olivieri I, 1062, 1524, 2074
Ollier W, 1109, 1763
Olsen NJ, 1102
Olsson T, 959
Olszewski J, 1234
Ono W, 252
Opalka B, 454
Openshaw SJ, 1677
Oppenheimer-Marks N, 844
Oriente P, 1006
Origuchi T, 463
Orinstein MH, 157, 1438
Ortiz-Bravo E, 1192, 1319
Ozawa T, 330

P

Padula A, 1524
Paimela L, 996
Palayew K, 671
Paleolog EM, 1082
Pan H, 539
Panayi GS, 52, 137
Panchal P, 347
Panos RJ, 1566
Papapoulos SE, 396
Papo T, 335
Parhami N, 2021
Parker A, 1970
Parry S, 495
Partanen J, 943, 1733
Pasero G, 1006, 1074
Passo MH, 1703
Paulsen J, 1052
Paulus HE, 403
Pauwels EKJ, 396
Pavlica P, 1524
Paxton G, 1362
Pearce G, 663

Peebles CL, 1643
Pelegri C, 204
Pelletier J-P, 968, 1535
Peppmüller PH, 746
Perkins SL, 325
Perlmutter DL, 1125
Perney P, 1166
Peter DT, 216
Peters AM, 1371
Peterson LS, 1385
Petri M, 363, 2046
Petrovsky N, 179
Pflugrad D, 711
Pfreundschuh M, 1419
Picco P, 883
Pickrell MB, 1427
Piémont Y, 736
Pierro A, 1524
Piette J-C, 335
Pillemer SR, 1802
Pipitone N, 137
Pipitone V, 1006
Pipkorn R, 1654
Pistoia V, 883
Pitzalis C, 52, 137
Ploski R, 351
Plotz PH, 1027
Polisson RP, 403
Pollard KM, 1151
Pols HAP, 81
Polvi A, 1733
Pope RM, 257, 1566, 1576
Portioli I, 1006
Pourel J, 736
Prakken ABJ, 1826
Pras E, 2080
Press J, 671
Prevoo MLL, 34
Priolo F, 1006
Prudhommeaux F, 1192, 1319
Pruzanski W, 1263
Pryor BD, 1475
Puddu P, 704
Puéchal X, 1937
Puhl W, 1896
Pulsatelli L, 1199
Punnonen J, 386, 1693

Q

Quarto Di Palo F, 1030
Quillard A, 335
Quismorio FP Jr., 1936

R

Rachow JW, 1711
Radice A, 758
Rafi SS, 1998
Rahman A, 537
Rainer F, 1608
Rairie JE, 1178
Rakoff D, 671
Rall LC, 415, 1115
Ralston SH, 643
Ramsey-Goldman R, 1178
Rappoport G, 1406
Ratnaik S, 1264

Rattner JB, 1355, 1635
Rau R, 162, 1935
Raybourne RB, 1892
Reboul P, 968
Reda DJ, 2004, 2013, 2021
Rediske JJ, 1905
Rees J, 1355
Reichlin M, 522, 1427, 1664
Reid DM, 643
Reinhold-Keller E, 1052
Reisine S, 427
Renz M, 1769
Reveille JD, 1151, 1355, 1362, 1507, 1802, 1833
Rey C, 1319
Rhoades ER, 283
Ricci JL, 1905
Rich E, 1172
Richardson BC, 1432
Richter M, 363
Rieman DJ, 504
Rigby SP, 1609
Rijkers GT, 1826
Rivest C, 1254
Rivolto R, 1030
Robbins PD, 820
Roberts LJ II, 1146
Roberts-Thomson PJ, 216, 1970
Robinson BG, 467
Roca RP, 1035
Rodríguez F, 1491
Rodríguez-Sánchez JL, 692
Rodríguez-Valverde V, 1016
Rose NR, 1615
Rosen CJ, 1115
Rosenbaum J, 1765
Rossetti RG, 1808
Rothfield NF, 292
Roubenoff R, 415, 1115
Roubey RAS, 1444, 1606
Rowley MJ, 1720, 1990
Rowse PE, 1432
Ruddy S, 887
Ruderman EM, 1021, 2086
Ruffelli M, 704
Rush D, 648
Ruthazer R, 1852

S

Saag KG, 1711, 1818
Saario R, 386
Sachthep S, 1264
Saeki T, 1728
Saint-Marcoux B, 1760
Saito I, 110, 773
Sajjadi FG, 923
Sakashita E, 1685
Sakinene E, 1596
Sakurai H, 110
Salter DM, 1430
Salvarani C, 73, 1073, 1199, 1932
Sampath TK, 1896
Sanchez-Guerrero J, 363, 657, 1055
Sánchez-Márquez A, 1244
Santamaria JM, 881
Sany J, 335, 1166
Sarkar SK, 504
Sasaki T, 629
Satakeda H, 539
Saulsbury FT, 880
Sawitzke AD, 325
Schantz A, 52
Scherrmann J-M, 1213
Schiltz C, 1192, 1319
Schmid C, 1852
Schmid TM, 1896
Schmidt CB, 204
Schrieber L, 467
Schrier DJ, 1292
Schroeder JO, 1066
Schumacher HR Jr., 950, 1740, 2004, 2013, 2021, 2080
Schur PH, 1055, 1069
Schütte HE, 81
Schwartz DA, 1711
Scofield RH, 283, 1664
Scorza R, 1030
Scott DGI, 1208
Scott DL, 1998
Seelig HP, 1769
Segarra C, 1166
Sekiguchi K, 1685
Seldin MF, 1613
Sems KM, 1818
Senécal J-L, 796, 1254
Sereika SM, 1178
Sexton DJ, 175
Sfikakis PP, 600
Shah MR, 1566
Shapiro DL, 1934
Sharp GC, 863, 1266
Sharp JT, 1436, 1802
Shaw M, 592
Shbeeb MI, 1132, 1260, 1922
Sheehan TJ, 427
Shen V, 277
Sherry DD, 1218
Shimada K, 855
Shimizu M, 1308
Shimpei M, 539, 560
Shimuta M, 773
Shinpei M, 478
Shinohara M, 1376
Shiota M, 792, 1769
Shiozawa K, 1685
Shiozawa S, 1685
Shoenfeld Y, 758, 1262
Sibilia J, 736
Sibley J, 616
Sieper J, 41
Silman AJ, 732, 1109
Silverman ED, 671
Silverman SL, 2004, 2013, 2021
Simeón C-P, 1138
Sinacore JM, 257
Singer JZ, 403
Singer NG, 125
Singh G, 64, 616
Sinico RA, 758
Sironi M, 758
Skeith KJ, 321
Skogh T, 1519

Skopouli FN, 767
 Slingsby JH, 663
 Smeenk RJT, 2083
 Smeets TJM, 1077
 Smith C, 137
 Smith EA, 1151
 Smith GN Jr., 235
 Smith MD, 216, 1970
 Snaith M, 363
 Sneller MC, 1262, 1754
 Snowden N, 1763
 So AKL, 538
 Söderström K-O, 1238
 Soler-Soler J, 1138
 Song S-Y, 1980
 Sorbi D, 1747
 Sörensen H, 41
 Soriano ER, 181
 Spector TD, 988
 Speizer FE, 657
 Sperber K, 157
 Sperling RI, 1021
 Spiera H, 1438, 1934
 St. Clair EW, 1102
 Stablein DM, 1436
 Stafford HA, 1664
 Stalla F, 883
 Steen V, 403, 677, 1125
 Stein CM, 1146, 1435
 Stein-Picarella M, 1576
 Steinberg AD, 1766
 Stevens K, 1234
 Stohl W, 1840
 Straaton KV, 101
 Strand V, 1102
 Strange R, 1763
 Stroup GB, 504
 Stuhlmüller B, 1860
 Sturfelt G, 363, 1654
 Sullivan KE, 2046
 Sullivan KF, 863
 Sumida T, 1410, 1611
 Summers KL, 1287
 Sun D, 863
 Sundry JS, 175
 Suwa A, 146, 1886
 Swaak TJG, 2083
 Sweeney C, 698
 Swezey RL, 2083
 Swift BA, 504
 Symmons D, 363
 Szekanecz Z, 810

T

Tada N, 330
 Taggart A, 1400
 Taguchi Y, 330
 Tak PP, 1077
 Takahara J, 287
 Takahashi K, 539
 Takahashi T, 855
 Takasaki Y, 855
 Takashima H, 463
 Takaya M, 152
 Takeda Y, 146, 1886
 Takeuchi K, 855

Talal N, 1875
 Talar-Williams C, 1754
 Tan EM, 1643
 Tan F, 1362
 Tanaka G, 877
 Taniguchi A, 1259
 Tanner SB, 1146
 Tardif G, 968, 1535
 Targoff IN, 146, 692, 1507, 1588, 1769
 Targonski P, 87
 Tarkowski A, 959, 1596
 Tatsis E, 1052
 Taylor DJ, 884
 Taylor PC, 1077
 Taylor T, 2004, 2013
 Tellus M, 1264
 Temming JE, 1808
 Terauchi K, 773
 ter Haar NT, 1961
 Terkeltaub RA, 2066
 Tessier PA, 226
 Theocharis S, 600
 Thomas JW, 914
 Thomas R, 183
 Thomine E, 2070
 Thomine JM, 2070
 Thompson KM, 538
 Thompson LL, 2035
 Thonar EJ-MA, 478, 885, 1896
 Tilley B, 1802
 Tincani A, 758
 Tirri G, 1906
 Tissot B, 1166
 To SST, 467
 Toebes EA, 1826
 Toivanen A, 1238
 Toivanen P, 386, 1238, 1693
 Tokuda M, 287
 Tokunaga K, 1769
 Tomassini C, 2074
 Tomer Y, 1262
 Tomita T, 836
 Török TJ, 880
 Tortorella C, 844
 Tortorella MD, 709
 Toth L, 1654
 Traina-Dorge V, 610
 Trentham DE, 623, 1802
 Triana-Alexander M, 436, 2086
 Triantafillou S, 1970
 Trivedi P, 1041
 Trotta F, 1006
 Tsai C, 125
 Tsokos GC, 600
 Tsuboi M, 1267
 Tsubota K, 773
 Tsuchiya N, 792, 1769
 Tsuji K, 152
 Tsutsumi A, 1466
 Tugwell P, 1491
 Turgeon P-P, 1254
 Turner MW, 706
 Tuttleman M, 1802
 Tyler JA, 1327
 Tzioufas AG, 767

U

Uchiyama M, 152
 Ueda H, 1259
 Uguccioni M, 1199
 Ulbrich N, 41
 Urowitz M, 363, 1050
 Uson J, 1435
 Usuda H, 330

V

Vadas P, 1263
 Vahlquist A, 1519
 Vahlquist C, 1519
 Vaishnav AK, 663
 Valat JP, 711
 Valkema R, 396
 Valkenburg HA, 81
 van Bijsterveld OP, 297
 Vancheeswaran R, 1041
 van Daele PLA, 81
 van de Loo FAJ, 797, 1545
 van den Berg WB, 797, 1545
 van den Bersselaar LAM, 1545
 Vandenbroucke JP, 266
 van den Hoogen FHJ, 783, 1266
 van de Putte LBA, 34, 783, 1266, 1545
 van der Heide A, 297
 van der Heiden AN, 1961
 van de Rijn M, 638
 van der Kwaak H, 57
 van der Reijden WA, 57
 van der Vieren M, 1913
 van der Zee R, 1826
 van Eden W, 1826
 van Gestel A, 34, 535
 van Lent PLEM, 1545
 van Paassen HC, 396
 van Riel P, 34, 535
 van Rijswijk MH, 34
 van Rooijen N, 1545
 van Roon JAG, 829
 van Roy JLAM, 829
 van 't Hof MA, 34
 van Venrooij WJ, 783
 Vaqué-Rafart J, 1138
 Varga J, 341
 Variakojis D, 638
 Vasey FB, 2004, 2013, 2021
 Vasquez A, 1767
 Vázquez-Abad D, 292
 Veerman ECI, 57
 Venables PJW, 1609
 Verbruggen G, 308
 Verga L, 1222
 Vernant J-C, 535
 Veys EM, 308
 Via CS, 600
 Vilarde M, 1138
 Vilcek J, 552
 Vincenti MP, 574
 Visco D, 1234
 Vissink A, 57
 Vittecoq O, 2070

Vogelgesang S, 600
 Voskuyl AE, 266, 1937

W

Waase I, 904
 Wallace CA, 1218
 Wallace DJ, 1936
 Walmsley M, 495
 Walport MJ, 538, 663
 Wang B, 950
 Ward JH, 325
 Ward JR, 403, 2004, 2013, 2021
 Ward RH, 2004, 2013, 2021
 Warner NB, 1507
 Warnke RA, 638
 Watanabe T, 330, 1728
 Watson M, 341
 Watson PJ, 1327
 Watts RA, 1208
 Weathers PE, 1362
 Weaver AL, 2082
 Weerasinghe D, 1609
 Weibel RE, 1529
 Weinblatt ME, 177, 1021
 Weiner DB, 950
 Weisberg JS, 277
 Weisman MH, 1125, 2004, 2013, 2021
 Weissman B, 648
 West SG, 489, 2035
 Westedt ML, 266, 396
 Westman P, 943
 Weyand CM, 904, 1265, 1499
 White B, 1035, 1125
 White BM, 1808
 White LA, 574
 White MB, 101
 Whitehead CM, 1635
 Wicks I, 1264
 Wigley FM, 1035, 1125
 Wilder RL, 1027, 2080
 Wilkins J, 1913
 Williams CA, 616
 Williams HJ, 403
 Williams KM, 1892
 Williams LA, 1287
 Williams RO, 495
 Williams WV, 950
 Willkens RF, 403, 1436
 Winfield JB, 592
 Winkfein RJ, 1635
 Winyard PG, 583
 Wisbey H, 844
 Wisniewski H-G, 552
 Wolman RL, 988
 Wong K-C, 1980
 Woo P, 1041
 Woody J, 52, 1082
 Wooten C, 2046
 Wordsworth P, 1768
 Worthington J, 1109
 Wortmann R, 1436
 Wrigglesworth JM, 1998
 Wright EA, 177

Wrigley JM, 101
Wu Y, 1588

X

Xoma RA Investigator Group,
1102

Y

Yamada A, 1376
Yamada H, 560
Yamaguchi A, 792, 1769

Yamamoto K, 197, 446
Yanagida T, 836
Yanni G, 137
Yano T, 855
Yarboro C, 403, 1027
Yazaki Y, 877
Yelin E, 711, 1931
Yerg DE, 87
Yodoi J, 773
Yoshihara Y, 539
Yoshinaga M, 534
Yoshino S, 446, 836

Yoshinoya S, 1769
Youssef PP, 216, 1970
Yu DTY, 1892
Yung RL, 1432

Z

Zegers BJM, 1826
Zeidler H, 1892
Zeuner RA, 1066
Zhang F, 1664
Zhang W, 522

Zhang Y, 648, 1238
Zhao H, 504
Zhao X-M, 914
Zhao Y-X, 959
Zhong W, 1499
Zhou T, 1611
Zignego AL, 1074
Ziminski CM, 403
Zink A, 41
Zoma A, 363
Zuber M, 1419
Zurier RB, 1808
Zwinderman AH, 266, 1937

SUBJECT INDEX

Arthritis & Rheumatism, Volume 39, Numbers 1-12, 1996

A

- Acetabular reconstruction, in revision total hip arthroplasty, 1939
- A-chain genes, C1q deficiency in SLE and, 663
- Achilles tendon, nucleotide pyrophosphohydrolase in articular cartilage and, 245
- Acidic pro-drugs, mitochondrial uncoupling and, 1998
- Acinic cells, SS-B/La antigen in labial salivary glands in Sjögren's syndrome and, 783
- Acne, drug therapy in RA and, 723
- Acquired immunodeficiency syndrome (AIDS)
 - hydroxychloroquine in, 157
 - Mycobacterium kansasii* septic arthritis in, 881
 - RA and, 1436
- Actin filaments, effect of nitric oxide on chondrocytes and, 1905
- Active RA
 - cyclosporine in, 1006
 - gamma-linolenic acid in, 1808
 - guidelines for management of, 713
 - low-dose intravenous immunoglobulin in, 1027
 - recombinant human IL-1 receptor I in, 257
- Activin A, recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
- Activities of daily living
 - acute musculoskeletal symptoms and, 1
 - in Spanish-language outcome questionnaire, 93
- Acute anterior uveitis, HLA-DR8 and, in AS, 351
- Acute febrile toxic reaction, after MTX and azathioprine in RA, 1016
- Acute inflammation
 - leukotriene synthesis inhibitors in, 515
 - MSU crystal-induced, TGF β in, 1192
 - MTX and, 1951
- Acute malignant hypertension, in cryocryoglobulinemia, 335
- Acute monarticular arthritis, Rocky Mountain spotted fever presenting with, 175, 2088
- Acute musculoskeletal symptoms, guidelines for initial evaluation of adults with, 1, 1767
- Acute psychosis, antiribosomal P antibodies in pediatric SLE and, 671
- Acute rheumatic fever, 2078
- Adenocarcinoma, of lung, anti-topo I and, in SSc, 686
- Adenosine
 - collagenase and, 923
 - deaminase, MTX and, 1951
- Adenovirus, direct gene delivery to synovium and, 820
- Adenylate cyclase activator, collagenase, adenosine and, 923
- Adenylyl cyclase/cAMP/protein kinase A, T cells in lupus and, 23
- Adhesion, lymphocyte-fibroblast, inhibition of, 226
- Adhesion molecules
 - anti-endothelial antibodies in Wegener's granulomatosis and, 758
 - anti-TNF α in RA and, 1077, 1082
 - cellular, in adjuvant arthritis, 810
 - intercellular, 226, 467, 810, 1082, 1913
 - lymphocyte function-associated antigen 1, 810
 - synovial distribution of α_v /CD18 leukointegrin and, 1913
 - synovial endothelial cell, 467
 - vascular cell, 226, 467, 1077, 1082, 1781, 1913
- Adjuvant arthritis, in rats, 204, 504, 810, 1677
- Adjuvants, silicone breast implants and, 1615, 1619
- Adolescent medicine
 - glucocorticoid-induced osteoporosis and, 1791
 - recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
- Wegener's granulomatosis of the lung, 615
- Adverse reactions
 - amyloidosis after gold therapy, 1932
 - to antithymocyte globulin in SSc, 1132
 - in generalized Wegener's granulomatosis, 2052
 - in RA, 41, 257, 713, 996, 1016, 1092, 1102
 - to sulfasalazine, 2004, 2013, 2021
- Age
 - augmentation mammoplasty, SSc and, 1125
 - barriers to return to work due to arthritis, musculoskeletal diseases and, 101
 - in early undifferentiated connective tissue disease, 403
 - fibromyalgia and, 682
 - in JRA, 746, 1385
 - maternal-fetal immunology, autoimmune disease and, 191
 - mortality in rheumatoid vasculitis and, 266
 - in OA, 81, 648, 988
 - in RA, 463, 616, 629, 723, 1115
 - in Sjögren's syndrome, 297
 - in SLE, 657, 671
- Aggrecans
 - antibodies to, in SF, 1990
 - neopeptide markers of skeletal maturation, aging and, 1234
 - recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
- Aging
 - neopeptide markers of skeletal maturation and, 1234
 - protein metabolism in RA and, 1115
- Agonists, muscarinic type III cholinergic, in Sjögren's syndrome, 195
- Agranulocytosis, in RA, 723
- AKR/J-*lpr/lpr* mice, T cells in lupus and, 23
- Albright's hereditary osteodystrophy, 1921
- Albumin, serum, antiribosomal antibodies in neuropsychiatric SLE and, 1483
- Alcohol use
 - glucocorticoid-induced osteoporosis and, 1791
 - running, musculoskeletal pain, age and, 64
- Alkaline phosphatase, bone mineral metabolism in JRA and, 746
- Alleles
 - apolipoprotein E4 in RA and amyloidosis and, 1728
 - DRB, 868, 1733
 - HLA, 183, 931, 938, 943, 1151, 1355, 1362, 1733
 - human TAP, for HLA-B27 binding peptides, 1892
 - major histocompatibility complex class II, 1507, 1833
 - in RA, 1109, 1791
 - in SLE, 663, 1763, 1833, 2046
- Allergic reactions, to antithymocyte globulin in SSc, 1132
- Alloantigens, in SLE, 23, 600
- Allo-autoimmune disease, maternal-fetal immunology and, 191
- Allogeneic bone marrow transplantation, RA progression after, 1246
- Allografts, in revision total hip arthroplasty, 1939
- Alopecia, in RA, 723
- $\alpha 1(I)$ procollagen gene, in SSc dermal fibroblasts, 1347
- α_v /CD18 leukointegrin, synovial distribution of, 1913
- Alveolar hemorrhage, pulmonary, vascular injury in SLE and, 9
- American College of Rheumatology (ACR)
 - Ad Hoc Committee on Clinical Guidelines, 1, 713, 723
 - Audiovisual Aids Subcommittee, 2078
 - criteria, 657, 1055, 1161, 1208, 1385, 1643, 2080
 - guidelines, 1, 713, 723, 1767, 1791
 - documents about RA, 34, 535, 713, 723
 - pediatric rheumatology and, 1218
 - 1995 Presidential Address, 887
 - 1996 Slide Competition, 2078

American College of Rheumatology (ACR) (*cont'd*)

SLICC/ACR damage index, 363

Amerindian HLA haplotype, in SSc, 1362

Amino acids

anti-NOR 90 in rheumatic diseases and, 1313

centromere kinesin-like protein, CENP-E in SSc and, 1355

collagen degradation and, 1455

Ki antigen epitope homology and, 855

major epitope of PM-Scl autoantigen and, 1588

in SLE, 663, 1483, 1654, 1833

T cells in RA and, 446

Aminoacyl-transfer RNA, in myositis, 146, 292

Amitriptyline, fluoxetine and, in fibromyalgia, 1852

Amyloidosis

as adverse effect of gold therapy, 1952

giant cell arteritis and, 1073

Amyopathic DM, 1419

Anabolic steroid drugs, in glucocorticoid-induced osteoporosis, 1791

Ancillary tests, cost of, in RA, 177

Anemia

in gastric antral vascular ectasia in SSc, 341

microangiopathic hemolytic, vascular injury in SLE and, 9

in RA, 321, 723

Aneurysms, in IgA multiple myeloma presenting as Henoch-Schönlein

purpura/polyarteritis nodosa, 698

Angiogenesis

hepatocyte growth factor and, 1566

T cells in RA and, 914

Angiotensin-converting enzyme, in childhood-onset scleroderma, 1041

Animal studies

See also Bovine, Canine, Chicken, Gorilla, Guinea pig, Macaque,

Mouse, Pig, Primate, Rat, Rabbit, Rhesus monkey

antibiotics in reactive arthritis, 1238

collagen degradation, 1455

gamma-linolenic acid in RA and, 1808

HTLV-I in autoimmune disorders and, 1410

Sjögren's syndrome, 195

Ankle

antibiotics in reactive arthritis and, 1238

pain, acute musculoskeletal symptoms and, 1

Ankylosing spondylitis (AS)

cervical myelopathy from ossification of the posterior longitudinal

ligament in, 2074

HLA genes in, 943

HLA-B27 negative, HLA-B associations in, 1768

HLA-DR8 and acute anterior uveitis in, 351

pyoderma gangrenosum, spondylarthropathy and, 1062

sulfasalazine in, 1400, 2004

TAP alleles in, 1892

Annexins, antiphospholipid antibody syndrome and, 1441, 1444, 1466

Anorexia nervosa, systemic pseudovasculitis from scurvy in, 532

Anterior chamber uveitis, in macaque, 610

Anterior cruciate ligament

IL-1 receptor antagonist in canine OA and, 1535

nucleotide pyrophosphohydrolase in articular cartilage and, 245

Anterior uveitis, HLA-DR8 and, in AS, 351

Anti-A polypeptide antibodies, anti-U1 RNA antibodies in connective

tissue disease and, 1265

Anti-A/B, antibodies to heterogeneous nuclear RNP in SSc and, 1669

Anti-annexin V, antiphospholipid antibody syndrome and, 1441, 1444,

1466

Anti-apoptosis, TGF β and, in rheumatoid synovial cells, 1267

Anti- β_2 -glycoprotein I, antiphospholipid antibodies and, 1441, 1444,

1466

Antibiotics

corticosteroids and, in *Staphylococcus aureus* arthritis, 1596

in reactive arthritis, 1238

Antibiotics (*cont'd*)

revision total hip arthroplasty and, 1939

Antibodies

anti-A polypeptide, 1265

anti- β_2 -glycoprotein I, 1441, 1444, 1446, 1606

anti- β_2 -integrin, 1913

anti-CD3, 600, 1840, 1913

anti-CD4, 52, 1773

anti-CD14, 1913

anti-CD29, 1913

anti-CD68, 1913

anticardiolipin, 1441, 1444, 1466

anticentromere, 863, 1041

anti-chromatin, 894

anticytokine, 125

anti-denatured DNA, 894

anti-DNA, 894, 1980

anti-dsDNA, 522, 671, 894, 938

anti-endothelial cell, 758

antifibrillar, 1151

anti-glycyl-transfer RNA synthetase, 146

anti-heterogeneous nuclear RNP, 1669

anti-HTLV-I, 463

antiidiotypic, 1980

anti-IgG3, 894

anti-Jo-1, 292

anti-Ki, 855

anti-La/SS-B, 522, 783

anti-native DNA, 894

antineutrophil cytoplasmic, 1, 698, 1262

antinuclear, 1, 283, 1055, 1166, 1300, 1980

anti-nuclear matrix, 1300

anti-P, 1833

antiphospholipid, 9, 537, 1441, 1444, 1466

antiprotease, 1441, 1444, 1466

antiretroviral, 1654

antiribosomal, 671, 894, 1483

anti-RNA polymerase I, 894

anti-Ro/SS-A, 522, 894, 1427

anti-70K, 1265

anti-SS-A/SS-B, 1166

anti-ssDNA, 894

anti-TGF β , 1192

anti-TNF α , 1082

anti-topoisomerase I, 152, 686

anti-tRNA, 507

anti-U1 RNA, 1265

anti-U1 RNP, 507, 938, 1300

anti-WS, 1308

CD80/CD86, 1287

ENA, 1055

HTLV-I, 610

IgG, 1499, 1720, 1990

IgM, 1499

Mi-2, 868

mitotic spindle apparatus and, 1643

monoclonal, 52, 110, 115, 125, 181, 204, 287, 386, 537, 539, 583, 600,

767, 783, 792, 1077, 1199, 1277, 1371, 1576, 1613, 1685, 1703, 1747,

1913, 1980

polyclonal, 245, 583, 767, 792

reactivity of, 1355, 1654

serum, 1951

silicone breast implants and, 1615, 1619

Yersinia-specific, 1238

Anticardiolipin

antibodies, antiphospholipid antibodies in SLE and, 1441, 1444,

1466

Anticardiolipin (*cont'd*)

- immunoassay, compared with ELISA for anti- β_2 -glycoprotein I, 1606
- Anti-CD3
 - in RA, 1277, 1499
 - monoclonal antibody, in SLE, 600, 1840
 - synovial distribution of α_4 /CD18 leukointegrin and, 1913
- Anti-CD4, in RA, 52, 1102, 1773
- Anti-CD14, synovial distribution of α_4 /CD18 leukointegrin and, 1913
- Anti-CD28, CD69 activation in RA and, 1277
- Anti-CD29, synovial distribution of α_4 /CD18 leukointegrin and, 1913
- Anti-CD36, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Anti-CD45 autoantibodies, in SLE, 592
- Anti-CD68, synovial distribution of α_4 /CD18 leukointegrin and, 1913
- Anti-CD69, CD69 activation in RA and, 1277
- Anti-CENP-E, in SSc, 1355
- Anticentromere antibodies
 - in childhood-onset scleroderma, 1041
 - recombinant human CENP-A protein and, 863
- Anti-chromatin antibodies, nephritogenic autoantibodies in lupus and, 894
- Anti-collagen antibodies, in early RA, 1720
- Anticytokine antibodies, T cells, bacterial superantigens and, in RA synoviocytes, 125
- Anticytokine therapy, for collagen arthritis in DBA/1 mice, 797
- Anti-DNA
 - antiidiotypic antibodies in SLE and, 1980
 - nephritogenic autoantibodies in lupus and, 894
 - topoisomerase I autoantibody, lung cancer and, in SSc, 686
- Anti-dsDNA
 - antibodies, 894, 938, 1178
 - antiidiotypes, anti-Ro, anti-La and, 522
 - in SLE, 671, 1055, 1980
- Anti-EJ, major histocompatibility complex class II alleles in myositis and, 507
- Anti-ENA, in RA in Native Americans, 283
- Anti-endothelial cell antibodies, in Wegener's granulomatosis, 758
- Anti-Fc receptor monoclonal antibody, antigen-presenting cell function in SLE and, 600
- Anti-Fce receptor I, human synovial mast cells and, 1222
- Antifibrillar antibodies, in SSc, 1151
- Antifolate drugs, in RA, 723
- Antigens
 - anti-PCNA in chronic intestinal pseudoobstruction and, 877
 - antiphospholipid antibody syndrome and, 1441, 1444, 1466
 - anti-Ro and anti-La anti-dsDNA antiidiotypes and, 522
 - anti-topoisomerase I, lung cancer and, in SSc, 686
 - autoantibodies and, 1308, 1860
 - B7-cross-reactive group, reactive arthritis, sexually transmitted diseases and, 1172
 - CD80/CD86 in chronic arthritis and, 1287
 - cryptic, 195
 - cutaneous lymphocyte, T cells and, in psoriatic arthritis, 137
 - DM-specific Mi-2 autoantigen and, 1769
 - Fas, TGF β , apoptosis and, in rheumatoid synovial cells, 1267
 - HLA, in shoulder synovitis in polymyalgia rheumatica, 1199
 - HLA genes and, in AS and reactive arthritis, 943
 - hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 - Ki antigen epitope homology and, 855
 - Mi-2 autoantibodies, HLA-DR and, in DM, 868
 - nuclear, 894
 - nuclear matrix, antinuclear antibodies, anti-nuclear matrix antibody and, 1300
 - in RA, 125, 183, 283, 446, 454, 629, 829, 844, 1371, 1781
 - silicone breast implants and, 1615, 1619
 - in SLE, 9, 23, 600, 792, 894, 1483, 1635, 1664
 - streptococcal, penicillin in Behçet's disease and, 2062

Antigens (*cont'd*)

- T cells and, 23, 844
- Anti-glycyl-transfer RNA synthetase antibody, in myositis, 146
- Anti-HGH, hepatocyte growth factor and, 1566
- Anti-HIV-1, hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
- Anti-heterogeneous nuclear RNP, in SSc, 1669
- Anti-HsEg5 (spindle kinesin-like protein), in SLE, 1635
- Anti-HTLV-I antibody, in RA, 463
- Antihyperuricemic drugs, in gout, 1406
- Anti-I, antibodies to heterogeneous nuclear RNP in SSc and, 1669
- Antiidiotypic antibody, in SLE, anti-dsDNA, anti-Ro, anti-La and, 522, 1980
- Anti-IgE, human synovial mast cells and, 1222
- Anti-IgG3 antibodies, nephritogenic autoantibodies in lupus and, 894
- Anti-IL-1 α/β , anticytokine therapy for collagen arthritis in DBA/1 mice and, 797
- Anti-IL-2, T cells, bacterial superantigens and, in RA, 125
- Antiinflammatory cytokines, IL-10 in RA, 386
- Antiinflammatory drugs
 - collagen degradation and, 1455
 - mitochondrial uncoupling and, 1998
- Anti-Jo-1
 - antibodies, 292
 - autoantibodies, 692, 1254
 - in myositis, 292, 1507
- Anti-Ki, Ki antigen epitope homology and, 855
- Antikininogen, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Anti-KJ, major histocompatibility complex class II alleles in myositis and, 507
- Anti-La/SS-B
 - anti-dsDNA antiidiotypes in, 522
 - detection of, by ELISA, in SLE, 1055
 - in Sjögren's syndrome, 783, 1733
- Anti-lymphocyte autoantibodies, anti-CD45 autoantibodies in SLE and, 592
- Anti-native collagen, in early RA, 1720
- Anti-native DNA antibodies, nephritogenic autoantibodies in lupus and, 894
- Anti-native G1 domain, aggrecan in SF and, 1990
- Antineutrophil cytoplasmic antibodies
 - acute musculoskeletal symptoms and, 1
 - in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 - ii, Wegener's granulomatosis, 1262
- Anti-NOR 90, in rheumatic diseases, 1313
- Antinuclear antibodies
 - acute musculoskeletal symptoms and, 1
 - antiidiotypic antibodies in SLE and, 1980
 - in hepatitis C virus in sicca syndrome, 1166
 - matrix, 1300
 - in RA in Native Americans, 283
- Antinucleosomes, nephritogenic autoantibodies in lupus and, 894
- Anti-NUMA-2, mitotic spindle apparatus and, 1643
- Anti-OJ
 - autoantibody, in antisyndetase syndrome, 692
 - major histocompatibility complex class II alleles in myositis and, 507
- Antioxidants
 - free radical injury in scleroderma and, 1146
 - micronutrients in, in knee OA, 648
 - transcription factor NF- κ B, TNF α and, 197
- Anti-P, in SLE, 1483, 1833
- Antiphospholipase A₂, antiphospholipid antibody syndrome and, 1441, 1444, 1466

- Antiphospholipid antibodies
 circulating, vascular injury in SLE and, 9
 monoclonal, germline V_H genes and, 537
 new complexities and new assays, 1441, 1444, 1466
- Antiphospholipid antibody syndrome
 familial primary, 705
 immunology of, 1441, 1444, 1466
- Antiphospholipid syndrome, splinter hemorrhage after arterial puncture in, 169
- Anti-PL-7, Anti-PL-12, major histocompatibility complex class II alleles in myositis and, 1507
- Anti-PM-Scl antibodies, major epitope of PM-Scl autoantigen and, 1588
- Antiproliferating cell nuclear antigen (Anti-PCNA), in chronic intestinal pseudoobstruction, 877
- Antiprotease, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Anti-protrusion rings, in revision total hip arthroplasty, 1939
- Anti-Rel-A nuclear location sequences, transcription factor nuclear factor- κ B and, 583
- Antiretroviral antibodies, in SLE, 1654
- Antirheumatic drugs, in RA, 723, 1006
- Antiribosomal antibodies, in SLE, 671, 894, 1483
- Antiribosomal P autoantibodies, in SLE, 1664, 2035
- Anti-RNA polymerase I antibodies, nephritogenic autoantibodies in lupus and, 894
- Anti-RNP, detection of, by ELISA, in SLE, 1055
- Anti-Ro/SS-A
 anti-dsDNA antiidiotypes and, 522
 autoantibodies, in complete heart block in Sjögren's syndrome, 1427
 circulating T cell receptor γ/δ cells in Sjögren's syndrome and, 1733
 detection of, by ELISA, in SLE, 1055
 major histocompatibility complex class II alleles in myositis and, 507
 nephritogenic autoantibodies in SLE and, 894
 in RA in Native Americans, 283
- Antiserum, polyclonal, procollagenase, doxycycline and, 235
- Anti-70K antibodies, anti-U1 RNA antibodies in connective tissue disease and, 1265
- Anti-signal recognition particle, major histocompatibility complex class II alleles in myositis and, 507
- Anti-Sm, detection of, by ELISA, in SLE, 1055
- Anti-SS-A/Ro
 anti-dsDNA antiidiotypes and, 522
 autoantibodies, in complete heart block in Sjögren's syndrome, 1427
 circulating T cell receptor γ/δ cells in Sjögren's syndrome and, 1733
 detection of, by ELISA, in SLE, 1055
 major histocompatibility complex class II alleles in myositis and, 507
 nephritogenic autoantibodies in SLE and, 894
 in RA in Native Americans, 283
- Anti-SS-A/SS-B antibodies, in hepatitis C virus and sicca syndrome, 1166
- Anti-SS-B/La
 anti-dsDNA antiidiotypes in, 522
 detection of, by ELISA, in SLE, 1055
 in Sjögren's syndrome, 783, 1733
- Anti-ssDNA, nephritogenic autoantibodies in lupus and, 894
- Antisynthetase syndrome, 692
- Anti-T cell receptor γ/δ monoclonal antibody V65, γ/δ T cells in rat adjuvant arthritis and, 204
- Anti-T helper cell therapy, in RA, 1773
- Anti-TGF β antibodies, MSU crystal-induced inflammation and, 1192
- Antithymocyte globulin, in SSc, 1132
- Anti-TNF α
 anticytokine therapy of collagen arthritis in DBA/1 mice and, 797
 in RA, 1077, 1082
- Anti-topoisomerase I antibodies, in SSc and RA, 152, 686
- Anti-tRNA, major histocompatibility complex class II alleles in myositis and, 507
- Anti-U1 RNA antibodies, in connective tissue disease, 1265
- Anti-U1 RNP
 antibodies, HLA type and, in connective tissue disease, 938
 major histocompatibility complex class II alleles in myositis and, 507
- Antivascular heparan sulfate proteoglycan antiheparin, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Antral vascular ectasia, gastric, in SSc, 341
- Anxiety, psychiatric diagnosis in fibromyalgia and, 2086
- Apatite ceramics, inflammatory properties of basic calcium phosphate crystals and, 1319
- Aplasia, gold-induced marrow, RA after bone marrow transplantation and, 1246
- Aplastic anemia, in RA, 723
- Apolipoprotein E4, in RA and amyloidosis, 1729
- Apoptosis
 fibroblast-like synoviocytes in RA and, 1781
 lymphocyte, in Sjögren's syndrome, 1875
 in lupus, 23, 1432
 TGF β and, in rheumatoid synovial cells, 1267
- Appetite, drug therapy in RA and, 723
- Arachidonic acid, free radical injury in scleroderma and, 1146
- Arg amino acid, hereditary C1q deficiency in SLE and, 663
- Arginine, N^G -monomethyl, effect of nitric oxide on chondrocytes and, 1905
- Arm
 bone mass, pamidronate and, in RA, 397
 in glucocorticoid-induced osteoporosis, 1791
 intravenous immunoglobulins in SLE and, 704
- Arrhythmia, thallium, cardiac dysfunction and, in SSc, 677
- Arterial hypertension, cardiac involvement in SSc and, 1138
- Arterial puncture, splinter hemorrhage after, 169
- Arteries
 Behçet-type vasculopathy without Behçet's disease and, 1926
 coronary lesions in Kawasaki disease and, L-selectin in, 534
 in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 radial, puncture of, splinter hemorrhage after, 169
 in renal vascular damage in SSc, 1030
 small, in systemic vasculopathy in multiple myeloma, 330
 temporal, matrix metalloproteinase 9 in giant cell arteritis and, 1747
- Arteritis
 giant cell, 1073, 1199, 1747
 temporal, glucocorticoid-induced osteoporosis and, 1791
- Arthralgia
 acute musculoskeletal symptoms and, 1
 in lupus nephritis after cyclophosphamide, 2028
 rubella vaccine and, 1529
- Arthritides
 chronic, in pediatric rheumatology in adult practices, 1218
 hepatocyte growth factor and, 1566
- Arthritis
 acute, 1238
 adjuvant, 204, 504, 810
 barriers to return to work due to, 101
 chronic, 1287, 1410
 collagen, 495, 515, 1545
 experimental, 1596
 gonococcal, 950
 IL-1 α -induced, 1292
 inflammatory, 1, 157, 950, 1566, 1576
 insulin-like growth factor in joints in, 1556
 large joint (in gorilla), 891
 in lupus nephritis after cyclophosphamide, 2028
 Lyme, 736

Arthritis (cont'd)

- in the macaque with HTLV-I, 610
- Mediterranean spotted fever and, 175, 2088
- monarticular, 175
- monoclonal cryo-antifibrinogenemia and, 1066
- peripheral, 2004
- poly-, 1
- psoriatic, 137, 711, 904, 1519, 2013
- reactive, 943, 950, 1172, 1740
- rubella vaccine and, 1529
- running, musculoskeletal pain, age and, 64
- septic, 1, 881, 1596
- seronegative, 1519
- Staphylococcus aureus*, 959, 1596
- venereal, 950
- Arthritis and Rheumatism Council Twin Study, cigarette smoking, risk of RA and, 732
- Arthritis Foundation, ACR and, 887
- Arthritis Impact Measurement Scales (AIMS2), in OA and RA, 1391
- Arthrodesis
 - pain and, in RA and OA, 357
 - in revision total hip arthroplasty, 1939
- Arthropathy
 - chronic inflammatory, cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
 - collagen degradation in, 1455
 - detection of *Chlamydia trachomatis* by polymerase chain reaction and, 1740
 - erosive, cryocrystalglobulinemia, systemic vasculopathy and, 335
 - HTLV-I in, 1410
- Arthroplasty, revision total hip, 1939
- Arthroscopic biopsy, effects of methylprednisolone on, in RA, 1970
- Arthroscopy
 - HTLV-I in autoimmune disorders and, 1410
 - in shoulder synovitis in polymyalgia rheumatica, 1199
- Arthus reaction, vascular injury in SLE and, 9
- Articular cartilage
 - antibodies to aggrecan in SF and, 1990
 - anticytokine therapy for collagen arthritis in DBA/1 mice and, 797
 - fibroblast adhesion to, 1072
 - fibronectin in, 567
 - hyaline, 245
 - IL-1 and, 478
 - IL-4, IL-10 and, in RA, 829
 - nucleotide pyrophosphohydrolase in, 245, 252
 - silicone breast implants and, 1615, 1619
 - TIMP-1 and oncostatin M in, 560
- Articular chondrocytes
 - human, integrins, in inflammatory SF, 1430
 - osteonectin in calcium and, 539
 - recombinant human osteogenic protein 1 and, 1896
 - TSG-6 in, 552
- Articular disease, antibodies to aggrecan in SF in, 1990
- Articular involvement
 - guidelines for evaluation of acute musculoskeletal symptoms and, 1
 - HTLV-I in autoimmune disorders and, 1410
- Articular tissue, nucleotide pyrophosphohydrolase in, 245, 252
- Aseptic loosening, after revision total hip arthroplasty, 1939
- Aseptic monarticular arthritis, Rocky Mountain spotted fever and, 175
- Atherosclerosis, drug therapy in RA and, 723
- Atrioventricular node, in complete heart block in Sjögren's syndrome, 1427
- Attention deficit, in SLE without central nervous system disease, 2035
- Augmentation mammoplasty, SSc and, 1125
- Auranofin, in RA, 616, 723
- Aurothioglucose, in RA, 723
- Aurothiomalate, in RA, 723

- Auto-alloimmune disease, maternal-fetal immunology and, 191
- Autoantibodies
 - anti-La/SS-B, 522, 767
 - anti-NOR 90 in rheumatic diseases and, 1313
 - anti-PCNA in chronic intestinal pseudoobstruction, 877
 - antiphospholipid antibody syndrome and, 1441, 1444, 1466
 - anti-Ro/SS-A, 522, 767, 1427
 - antisynthetase, in antisynthetase syndrome, 692
 - in HTLV-I in autoimmune disorders, 1410
 - Ki antigen epitope homology and, 855
 - in MCTD, 1254
 - Mi-2, HLA-DR and, in DM, 868
 - mitotic spindle apparatus and, 1643
 - in myositis, 146, 1254, 1507, 1860
 - in SLE, 9, 23, 592, 894, 1635, 1669, 1763, 1833, 2035
 - in SSc, 686, 1151, 1362
 - tRNA in interstitial lung disease and, 1308
- Autoantigen-based assays, anti-NOR 90 in rheumatic diseases and, 1313
- Autoantigens
 - centromere kinesin-like protein, CENP-E, in SSc, 1355
 - in Sjögren's syndrome, 195
 - spindle kinesin-like protein, HsEg5, in SLE, 1635
- Autoimmune diseases
 - anti-Jo-1 in myositis and, 292
 - circulating T cell receptor γ/δ cells in Sjögren's syndrome and, 1733
 - HTLV-I in, 1410
 - idiopathic, T cells in lupus and, 23
 - mitotic spindle apparatus and, 1643
 - sex hormones in, 1766
 - silicone breast implants and, 1615, 1619
 - Sjögren's syndrome and, 297, 1376
 - RA and, 183, 1027
- Autoimmune response
 - antibodies to heterogeneous nRNP in SSc and, 1669
 - autoimmunity to RNA polymerase II and, 1875
 - Mi-2 autoantibodies, HLA-DR and, in DM, 868
 - mitotic spindle apparatus and, 1643
- Autoimmunity
 - anti-NOR 90 in rheumatic diseases and, 1313
 - immunodeficiency and, 179
 - lupus, T cells and, 23
 - to RNA polymerase II, 1886
- Autoreactive T cells, self peptides, dendritic cells and, in RA, 183
- Autoreactivity, to human heat-shock protein 60 in oligoarticular JRA, 1826
- Avascular necrosis, drug therapy in RA and, 723
- Axial arthropathy, cryocrystalglobulinemia and, 335
- Axial vein thrombosis, antithymocyte globulin in SSc and, 1132
- Azathioprine, in RA, 616, 723, 1016, 1435, 1436

B

- B cells
 - corticosteroids, antibiotics and, in *Staphylococcus aureus* arthritis, 1596
 - in RA, 325, 638, 1499
 - shoulder synovitis in polymyalgia rheumatica and, 1199
 - in Sjögren's syndrome, 773, 1376, 1875
 - in SLE, 23, 592
- B-chain genes, hereditary C1q deficiency in SLE and, 663
- B7-cross-reactive group antigens, reactive arthritis, sexually transmitted diseases and, 1172
- B7-1 (CD80) costimulatory molecule, antigen-presenting cell function in SLE and, 600
- B19 infection, human parvovirus, in Henoch-Schönlein purpura, 880
- B27, HLA-B associations in HLA-B27 negative AS, 1768

- B27-positive psoriatic spondylarthropathy, pyoderma gangrenosum in, 1062
- Back pain
acute musculoskeletal symptoms and, 1
sulfasalazine in AS and, 2004
- Bacteria
antibiotics in arthritis and, 1238, 1596
detection of *Chlamydia trachomatis* by polymerase chain reaction and, 1740
major epitope of PM-Scl autoantigen and, 1588
- Bacterial DNA, molecular diagnosis of venereal arthritis and, 950
- Bacterial superantigens, in RA, 125, 1499
- Baculovirus, anticomplement antibodies, recombinant human CENP-A protein and, 863
- Basement membrane, nephritogenic autoantibodies in lupus and, 894
- Basic calcium phosphate crystals, inflammatory properties of, 1319
- Basic fibroblast growth factor, osteonectin in cartilage and, 539
- bax, apoptosis in Sjögren's syndrome and, 1875
- Bay x 1005, Bay y 1015, in inflammation, 515
- bcl-2, apoptosis and, 1267, 1875
- bcl-x, apoptosis in Sjögren's syndrome and, 1875
- Beck Depression Inventory
fluoxetine, amitriptyline and, in fibromyalgia, 1852
in scleroderma, 1035
- Behçet's disease, penicillin in, 2062
- Behçet-type vasculopathy, without Behçet's disease, 1926
- Beta carotene, antioxidant micronutrients in knee OA and, 648
- β gene polymorphism, T cell receptor, HLA-DR4 and, in RA, 931
- β_2 -glycoprotein I, antiphospholipid antibodies and, in SLE, 1441, 1444, 1466
- β_2 -integrin, synovial distribution of α_5 /CD18 leukointegrin and, 1913
- β_2 -microglobulin, soluble HLA class I antigens in SLE and, 792
- Biconal gammopathy, all-trans-retinoic acid in POEMS syndrome and, 1423
- Biochemistry
collagen degradation in arthritis and, 1455
IL-1, articular cartilage and, 478
T cells in lupus and, 23
- Biopsy
arthroscopic, 1199, 1970
lacrimal gland, 195
in lupus nephritis after cyclophosphamide, 2028
muscle and nerve, in rheumatoid vasculitis, 1937
prostate tissue, molecular diagnosis of venereal arthritis and, 950
in RA, 325, 1021, 1077, 1491, 1970
salivary gland, 195, 297, 783, 1609
in SLE, 704, 2066
in SSc, 341, 1161
synovial, 1, 181, 1061, 1077
temporal artery, in giant cell arteritis, 1747
- Biopsychosocial models of disease, disability in fibromyalgia and, 1627
- Bisphosphonates
bone mass and pamidronate in RA, 397
in glucocorticoid-induced osteoporosis, 1791
- Black patients
HLA-DRB1 genes, disease severity and, in RA, 1802
major histocompatibility complex class II alleles in myositis, 1507
SLE in, 1833, 2046
- Bladder
carcinoma, autoantibodies against muscle-cell membrane proteins in myositis and, 1860
nucleotide pyrophosphohydrolase in articular cartilage and, 245
- Blood
mononuclear cells, autoreactivity to human heat-shock protein 60 in oligoarticular JRA and, 1826
peripheral, 23, 52, 125, 137, 204, 257, 600, 773, 829, 844, 904, 914, 1277, 1499, 1566, 1875, 1951, 1961
- Blood (cont'd)
in RA, 216, 463, 829, 844, 1802
in renal vascular damage in SSc, 1030
silicone breast implants and, 1615, 1619
tests, acute musculoskeletal symptoms and, 1
transfusions, maternal-fetal immunology, autoimmune disease and, 191
vascular injury in SLE and, 9
vessels, 1199, 1926
- Body composition, progressive resistance training in RA and, 415
- Body mass index, antioxidant micronutrients in knee OA and, 648
- Bone
acute musculoskeletal symptoms and, 1
cells, 245, 489
collagen degradation and, 1455
density, effect of MTX on mouse bone cells and, 489
genetic protein 2, osteonectin in cartilage and, 539
in glucocorticoid-induced osteoporosis, 1791
loss, 81, 397, 1791
marrow, 629, 836
mineral density, 81, 397, 504, 746, 1791
mineral metabolism, in JRA, 746
morphogenic protein-7, in human articular chondrocytes, 1896
in OA, 81
pathology, in degenerative joint disease in the guinea pig, 1327
in RA, 162, 277, 397, 629, 836, 1246
resorption, 277, 489, 1791
in revision total hip arthroplasty, 1939
- Book reviews
Arthritis (Thompson), 1772
Friendly Fire: Explaining Autoimmune Disease (Isenberg and Morrow), 1938
Science on Trial (Angell), 1771
Systemic Sclerosis (Clements and Furst, eds), 1440
Treatment of the Rheumatic Diseases: Companion to the Textbook of Rheumatology (Weissman and Weinblatt, eds), 355
- Borrelia burgdorferi* DNA, in synovium, 736
- Bovine studies
antiphospholipid antibody syndrome and, 1441, 1444, 1466
collagen arthritis, 495, 1545
fibronectin in articular cartilage, 567
- Bowel disease, inflammatory, pyoderma gangrenosum, spondylarthropathy and, 1062
- Bowel infarction, vascular injury in SLE and, 9
- Brain
nucleotide pyrophosphohydrolase in articular cartilage and, 245
in RA and OA, 357
in SLE, 9, 1483
- Breast
milk, colchicine in, in familial Mediterranean fever, 1213
silicone implants, 1615, 1619
- Bursitis, acute musculoskeletal symptoms and, 1

C

- C3H-lpr/lpr mice, T cells in lupus and, 23
- Calcific constrictive pericarditis, CREST syndrome and, 347
- Calcinosis, centromere kinesin-like protein, CENP-E in SSc and, 1355
- Calcitonin, salmon, nasal spray, in glucocorticoid-induced osteoporosis, 1791
- Calcitriol, in glucocorticoid-induced osteoporosis, 1791
- Calcium
antiphospholipid antibody syndrome and, 1441, 1444, 1466
basic phosphate crystals, inflammatory properties of, 1319
bone mineral metabolism in JRA and, 746
effect of MTX on mouse bone cells and, 489
exogenous, procollagenase, doxycycline and, 235
in glucocorticoid-induced osteoporosis, 1791

Calcium (*cont'd*)

- T cells in lupus and, 23
- TSG-6 in articular chondrocytes and, 552
- Canadian health care costs for SLE, US health care costs and, 979
- Cancellous bone in glucocorticoid-induced osteoporosis, 1791
- Cancer in SLE, 1050
- Canine studies, IL-1 receptor antagonist in OA, 1535
- Capillaries
 - naïfold, in early pathologic analysis of SSc, 1161
 - self peptides, dendritic cells and, in RA, 183
- Capillaritis, microvascular angiitis in SLE and, 9
- Carbonate apatite crystals, inflammatory properties of basic calcium phosphate crystals and, 1319
- Carboxyl terminal domain, autoimmunity to RNA polymerase II and, 1875
- Carcinoma, autoantibodies against muscle-cell membrane proteins in myositis and, 1860
- Cardiac catheterization in calcific constrictive pericarditis in CREST syndrome, 347
- Cardiac involvement in SSc, 677, 1138, 1151
- Cardiolipin, antiphospholipid antibodies and, 1441, 1444, 1466
- Cardiomyopathy, autoantibodies against muscle-cell membrane proteins in, 1860
- Cardiovascular disease
 - drug therapy in RA and, 723
 - mortality in rheumatoid vasculitis and, 266
- Carnitine in inflammatory myopathy, 1869
- Cartilage
 - articular, 245, 252, 478, 560, 567, 797, 1072, 1990
 - chondrocytes and, 552, 1430, 1905
 - collagen degradation and, 1455
 - degradation, 495, 539, 552, 797, 829, 1535, 1720
 - elastic, 245
 - fibroblast-like synoviocytes in RA and, 1781
 - IL-1 and, 478, 1535
 - loss, 648
 - manoalide in IL-1 α -induced arthritis and, 1292
 - neopeptide markers of skeletal maturation, aging and, 1234
 - in OA, 308, 648, 1535
 - osteonection in, 539
 - proteoglycan, recombinant human osteogenic protein 1 and, 1896
 - synovial cell adhesion on EDA-containing fibronectin and, 1685
- Catabolism
 - IL-1 receptor antagonist in canine OA and, 1535
 - manoalide in IL-1 α -induced arthritis and, 1292
 - in RA, protein metabolism, aging and, 1115
- C-chain genes, hereditary C1q deficiency in SLE and, 663
- CD2, in RA synoviocytes, T cells, bacterial superantigens and, 125
- CD3
 - CD69 activation in RA and, 1277
 - cells, 23, 1951
- CD4 cells, 23, 183, 844, 904, 914, 1951
- CD4:CD8 ratio after photopheresis in psoriatic arthritis, 1519
- CD5 immunoconjugate in RA, 1102
- CD11a/CD18
 - cellular adhesion molecules in adjuvant arthritis and, 810
 - synovial distribution of α_d /CD18 leukointegrin and, 1913
 - T cells, bacterial superantigens and, in RA synoviocytes, 125
- CD11b/CD18, synovial distribution of α_d /CD18 leukointegrin and, 1913
- CD11bc/CD18, cellular adhesion molecules in adjuvant arthritis and, 810
- CD11c/CD18, synovial distribution of α_d /CD18 leukointegrin and, 1913
- CD14 in RA, 110, 115, 836
- CD16 in RA, 386, 1693
- CD23, IL-13 in RA and, 1693

- CD25 in RA, 1277
- CD27 cells in RA, enrichment of, 844
- CD28 in RA synovium, 110
- CD29, synovial distribution of α_d /CD18 leukointegrin and, 1913
- CD31, effects of methylprednisolone on adhesion molecules in RA and, 1970
- CD44
 - cells in RA, enrichment of, 844
 - cellular adhesion molecules in adjuvant arthritis and, 810
- CD45
 - anti-CD45 autoantibodies in SLE and, 592
 - cells, 844, 1199
- CD54, effects of methylprednisolone on adhesion molecules in RA and, 1970
- CD56 cells in SLE, 1840
- CD62E, CD62P, effects of methylprednisolone on adhesion molecules in RA and, 1970
- CD64 in RA, 386, 1693
- CD68
 - macrophages, in RA, articular damage and, 115
 - synovial distribution of α_d /CD18 leukointegrin and, 1913
- CD69 in RA, 844, 1277
- CD80
 - antigen-presenting cell function in SLE and, 600
 - CD86 and, in chronic arthritis, 1287
- CD86
 - CD80 and, in chronic arthritis, 1287
 - in RA synovium, 110
- CDR3, antiidiotypic antibodies in SLE and, 1980
- Cell activation, anti-CD45 autoantibodies in SLE and, 592
- Cell adhesion
 - fibronectin in articular cartilage and, 567
 - molecules in RA, effects of methylprednisolone on, 1970
- Cell counts, manoalide in IL-1 α -induced arthritis and, 1292
- Cell division
 - direct gene delivery to synovium and, 820
 - MTX and, 1951
- Cell function, antigen-presenting, in SLE, 600
- Cell lines, T cells in RA synoviocytes and, 125
- Cell membrane, anti-endothelial cell antibodies in Wegener's granulomatosis and, 758
- Cell migration in psoriatic arthritis, cutaneous lymphocyte antigen, T cells and, 137
- Cell proliferation
 - in articular cartilage, TIMP-1, oncostatin M and, 560
 - fibroblast-like synoviocytes in RA and, 1781
 - HTLV-I in autoimmune disorders and, 1410
 - synovial, transcription factor NF- κ B, TNF α and, 197
 - T cells and, 23, 125
- Cell surface
 - antigen-presenting cell function in SLE and, 600
 - HTLV-I in autoimmune disorders and, 1410
 - MTX and, 1951
 - in RA, recombinant human IL-1 receptor I and, 257
- Cellular adhesion molecules in adjuvant arthritis, 810
- Cellular cytotoxicity, anti-endothelial cell antibodies in Wegener's granulomatosis and, 758
- Cellular heterogeneous nuclear RNP, in SSc, antibodies to, 1669
- Cellular immune response, T cells in lupus and, 23
- Cellular immunity
 - in HTLV-I in autoimmune disorders, 1410
 - MTX and, 1951
- Cellular infiltration
 - leukotriene synthesis inhibitors in inflammation and, 515
 - in shoulder synovitis in polymyalgia rheumatica, 1199
- Cement in revision total hip arthroplasty, 1939

- CENP-A, recombinant human, to detect anticentromere antibodies, 863
- CENP-E, centromere kinesin-like protein, in SSc, 1355
- Center for Epidemiological Studies Depression Scale
in fibromyalgia, psychiatric diagnosis, health care-seeking and, 436
in RA, gender, work, emotional distress and, 427
- Central nervous system involvement
disability in fibromyalgia and, 1627
MTX and, 1951
in SLE, 9, 370, 1483, 2035
- Centromere kinesin-like protein, CENP-E, in SSc, 1355
- Centrosomes, mitotic spindle apparatus and, 1643
- Cerebral ischemia, vascular injury in SLE and, 9
- Cerebrospinal fluid, antiribosomal P protein antibodies in neuropsychiatric SLE and, 1483
- Cervical myelopathy in AS, 2074
- c-fos*, in HTLV-I in autoimmune disorders, 1410
- CH50, soluble HLA class I antigens in SLE and, 792
- Chemotaxis
hepatocyte growth factor and, 1566
macrophages in synovial lining in collagen arthritis and, 1545
- Chemotherapy, MTX-associated lymphoma in RA and, 325
- Chest radiography in Wegener's granulomatosis of the lungs, 615
- Chicken studies, oral type II collagen in JRA, 623
- Childhood-onset scleroderma, 1041
- Chimeric anti-CD4 monoclonal antibody, cM-T412 in RA, 52
- Chimeric anti-TNF α in RA, 1077, 1082
- Chimerism, RA progression after bone marrow transplantation and, 1246
- Chinese herbs in rheumatology, 354
- Chinese patients, mannose-binding protein in SLE, 706
- Chiropractors in RA and OA, 357
- Chlamydia trachomatis*
detection of, by polymerase chain reaction, 1740
reactive arthritis, sexually transmitted diseases and, 1172
- Chlorambucil in RA, 723
- Chloramphenicol acetyltransferase
reporter gene, $\alpha 1(I)$ procollagen gene in SSc fibroblasts and, 1347
transcription factor NF- κ B, TNF α and, 197
- Choctaw Indian patients, Amerindian HLA haplotype in SSc, 1362
- Cholinergic agonists, muscarinic type III, in Sjögren's syndrome, 195
- Chondrocytes
anticytokine therapy of collagen arthritis in DBA/1 mice and, 797
articular, 539, 552, 560, 1896
cartilage and, 478, 539, 567
effect of nitric oxide on, 1905
fibroblast-like synoviocytes in RA and, 1781
human, integrins, in inflammatory SF, 1430
insulin-like growth factor receptor and binding protein in, in OA, 968
metalloproteinase, IL-1 and, 709
- Chondroitin sulfate, antibodies to aggrecan in SF and, 1990
- Chondrosarcoma, autoantibodies against muscle-cell membrane proteins in myositis and, 1860
- Chromatin, nephritogenic autoantibodies in lupus and, 894
- Chromosomal flagellin gene, *Borrelia burgdorferi* in synovium and, 736
- Chromosomes, detection of *Chlamydia trachomatis* by polymerase chain reaction and, 1740
- Chronic anemia in RA, NSAIDs and, 321
- Chronic arthritides, in pediatric rheumatology in adult practices, 1218
- Chronic arthritis
HTLV-I in autoimmune disorders and, 1410
reactive, antibiotics in, 1238
- Chronic inflammation, leukotriene synthesis inhibitors in, 515
- Chronic inflammatory arthropathy
cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
glucocorticoid-induced osteoporosis and, 1791
- Chronic inflammatory arthropathy (cont'd)
HTLV-I in, 1410
- Chronic intestinal pseudoobstruction, anti-PCNA and, 877
- Chronic myalgia, psychiatric diagnosis in fibromyalgia and, 2086
- Chronic pain
barriers to return to work due to arthritis and musculoskeletal diseases and, 101
disability in fibromyalgia and, 1627
in RA and OA, 357
- Chronic RA
guidelines for management of, 713
synovitis in, fibroblast-like synoviocytes and, 1781
- Chymase, in human synovial mast cells, 1222
- Cigarette smoking, RA and, 732, 1711
- Ciprofloxacin, in reactive arthritis, 1238
- Circulating autoantibodies, nephritogenic autoantibodies in lupus and, 894
- Circulating blood neutrophils in RA, methylprednisolone, joint inflammation and, 216
- Circulating dendritic cells in RA, self peptides and, 183
- Circulating gelatinase in giant cell arteritis, 1747
- Circulating immune complexes in SLE, 9, 894
- Circulating inflammatory cells, recombinant human IL-1 receptor I in active RA and, 257
- Circulating leukocytes, anti-TNF α in RA and, 1082
- Circulating T cell receptor γ/δ cells in Sjögren's syndrome, 1733
- Circulation
MTX and, 1951
nephritogenic autoantibodies in lupus and, 894
in RA, 183
- Circulatory involvement, vascular injury in SLE and, 9
- Cirrhosis in RA, 723
- c-jun*, HTLV-I in autoimmune disorders and, 1410
- Clinical Images
Albright's hereditary osteodystrophy, 1921
drummer's finger, 1258
influence of ballet season on radiology reports, 1069
Mees' lines, 151
MRI in pyomyositis, 1760
vitamin C deficiency, 1422
Wegener's granulomatosis of the lungs, 615
- Clodrate, macrophages in synovial lining in collagen arthritis and, 1545
- Clonal proliferation, oligoclonal T cells in RA and, 904
- Clonality, EBV, in lymphomas in RA, 638
- Cloning, $\alpha 1(I)$ procollagen gene in SSc fibroblasts and, 1347
- Clonotypes, T cell, in RA, 446
- c-myc*
apoptosis in Sjögren's syndrome and, 1875
in HTLV-I in autoimmune disorders, 1410
- Coagulation
abnormalities, vascular injury in SLE and, 9
antiphospholipid antibody syndrome and, 1441, 1444, 1466
in SSc, 341, 1041
- Coagulation-fibrinolysis system, disease activity in SLE and, 287
- Cognitive-behavioral interventions in RA and OA, 357
- Cognitive dysfunction
disability in fibromyalgia and, 1627
MTX and, 1951
in SLE without central nervous system disease, 2035
- Colchicine, in breast milk in familial Mediterranean fever, 1213
- Cold-induced leukocytoclastic vasculitis in monoclonal cryo-antifibrinogenemia, 1066
- Cold-stress test in cardiac involvement in SSc, 1138
- Collagen
antibodies to, in RA, 1720
arthritis, 495, 515, 797, 1545, 1677

- Collagen (cont'd)**
in childhood-onset scleroderma, 1041
degradation of, 1455
epitopes, fibroblast adhesion to articular cartilage and, 1072
fibers, procollagenase, doxycycline and, 235
in glucocorticoid-induced osteoporosis, 1791
heterogeneity, in SSc fibroblasts, 1338
matrix, effect of nitric oxide on chondrocytes and, 1905
recombinant human osteogenic protein 1 and, 1896
type II, 41, 623, 1896
- Collagenase**
adenosine and, 923
collagen degradation and, 1455
fibronectin and, in articular cartilage, 567
IL-1 receptor antagonist in experimental OA and, 1535
matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
N[4-hydroxyphenyl] retinamide in RA and, 1021
nephritogenic autoantibodies in lupus and, 894
92-kd type IV, in giant cell arteritis, 1747
procollagenase, doxycycline and, 235
- Comorbidity**
depression in scleroderma and, 1035
mortality in rheumatoid vasculitis and, 266
in RA, 713
- Complement**
activation of, 1178
anti-endothelial cell antibodies in Wegener's granulomatosis and, 758
in SLE, 9, 706, 894, 1178
- Complement C1q, in SLE, 370, 663, 894**
- Complement C5a, in human synovial mast cells, 1222**
- Complementary DNA, anti-NOR 90 in rheumatic diseases and, 1313**
- Complete heart block, in Sjögren's syndrome, 1472**
- Computed tomography (CT)**
in glucocorticoid-induced osteoporosis, 1791
of the knee in gout, 1406
- Computerized Diagnostic Interview Schedule in fibromyalgia, psychiatric diagnosis, health care-seeking and, 436**
- Concanavalin A, silicone breast implants and, 1615, 1619**
- Condylar cartilage, mannoalide in IL-1 α -induced arthritis and, 1292**
- Congestive heart failure in SSc, thallium, cardiac dysfunction and, 677**
- Connective tissue**
collagen degradation in, 1455
matrix metalloproteinase 9 in RA and, 1576
ultrasound of, in shoulder pain, 1435
- Connective tissue cells, lymphocyte-fibroblast adhesion and, 226**
- Connective tissue disease**
antibodies to heterogeneous nuclear RNP in SSc and, 1669
anti-Jo-1 antibodies in myositis and, 292
anti-U1 RNA antibodies in, 1265
early undifferentiated, 403
hair dye use in SLE and, 657
HLA type and anti-U1 RNP in, 938
mixed, 1254, 1259, 1669
- Constrictive pericarditis, calcific, CREST syndrome and, 347**
- Continuing medical education about pediatric rheumatology in adult practices, 1218**
- Copper-dependent enzymes, collagen degradation and, 1455**
- Core protein, aggrecan, antibodies to, in SF, 1990**
- Cortical bone in glucocorticoid-induced osteoporosis, 1791**
- Corticosteroid drugs**
in focal myositis in MCTD, 1254
intraarticular, 277
MTX in fibroblastic rheumatism and, 2070
in polymyalgia rheumatica, 73, 1199
in RA, 277, 723, 1773
- Corticosteroid drugs (cont'd)**
in Sjögren's syndrome, 297
in SLE, 704, 1475
- Counseling, health outcome of, in OA and RA, 1391**
- Cranial neuropathy, in hepatitis C virus infection, polymyositis, lung fibrosis and, 1074**
- C-reactive protein**
collagen degradation and, 1455
insulin-like growth factor in arthritic joints and, 1556
in RA, 216, 629, 1021, 1092
- Creatine kinase, in focal myositis in MCTD, 1254**
- Creatinine**
in RA, 643, 723
in SSc, 1030, 1146
- CREST syndrome**
calcific constrictive pericarditis in, 347
centromere kinesin-like protein, CENP-E in SSc and, 1355
- Cross-linking**
collagen degradation and, 1455
in human synovial mast cells, 1222
- Cross-reactivity**
antibodies in SLE and, 1654, 1980
B7 group antigen, reactive arthritis, sexually transmitted diseases and, 1172
in mixed monoclonal cryoglobulinemia in primary Sjögren's syndrome, 767
nephritogenic autoantibodies in lupus and, 894
- Cruciate ligament**
anterior, 245, 1535
in degenerative joint disease in the guinea pig, 1327
- Cryo-antifibrinogenemia, monoclonal, 1066**
- Cryocryoglobulinemia, systemic vasculopathy, erosive arthropathy and, 335**
- Cryoglobulinemia, mixed monoclonal, in primary Sjögren's syndrome, 767**
- Cryoglobulins in hepatitis C virus and sicca syndrome, 1166**
- Cryptic antigens in Sjögren's syndrome, 195**
- Crystalglobulin in systemic vasculopathy in multiple myeloma due to, 330**
- Crystal-induced inflammation**
acute musculoskeletal symptoms and, 1
transforming growth factor β 1 and, 1192
- Crystals**
basic calcium phosphate, inflammatory properties of, 1319
in cryocryoglobulinemia, 335
in human synovial mast cells, 1222
MSU, acute musculoskeletal symptoms and, 1, 1192
needle-shaped, in CT of the knee in gout, 1406
- CTD7, CTD18 synthetic peptides, autoimmunity to RNA polymerase II and, 1875**
- Cushingoid facies, drug therapy in RA and, 723**
- Cutaneous involvement, antithymocyte globulin in SSc and, 1132**
- Cutaneous lymphocyte antigen-positive T cells in psoriatic arthritis, 137**
- Cutaneous nodules, MTX in fibroblastic rheumatism and, 2070**
- Cutaneous SSc**
diffuse, childhood-onset scleroderma and, 1041
limited, 347, 1439
- Cutaneous telangiectasia in gastric antral vascular ectasia in SSc, 341**
- Cyclic AMP**
collagenase, adenosine and, 923
dibutyl, osteonectin in cartilage and, 539
T cells in lupus and, 23
- Cyclooxygenase**
free radical injury in scleroderma and, 1146
leukotriene synthesis inhibitors in inflammation and, 515
NSAID, mitochondrial uncoupling and, 1998

Cyclophosphamide
 in lupus nephritis, 2028
 in RA, 723
 in SLE, 1475
 steroids, MTX and, in multicentric reticulohistiocytosis, 171
 Cyclosporine in RA, 723, 1006, 1491
 Cysteine, osteonectin in cartilage and, 539
 Cysts, subchondral, in OA of the finger joints, 308
 Cytokines
 anticytokine therapy of collagen arthritis in DBA/1 mice and, 797
 anti-endothelial antibodies in Wegener's granulomatosis and, 758
 in cartilage, 539, 560, 567
 chondrocytes and, 552, 1905
 hepatocyte growth factor and, 1566
 in JRA and juvenile spondylarthropathy, 1703
 lymphocyte-fibroblast adhesion and, 226
 mRNA, 959, 1376
 MTX and, 1951
 in polymyalgia rheumatica, 1264
 proinflammatory, all-*trans*-retinoic acid in POEMS syndrome and, 1423
 in RA, 125, 183, 386, 829, 1077, 1115, 1371, 1693, 1781, 1961
 in SLE, 9, 379
 Cytolysis, CD56 cells in SLE and, 1840
 Cytomegalovirus
 human, direct gene delivery to synovium and, 820
 MTX in RA and, 1608
 Cytoplasm
 autoantibodies directed against tRNA in interstitial lung disease and, 1308
 in human synovial mast cells, 1222
 matrix metalloproteinase 9 in giant cell arteritis and, 1747
 SS-B/La antigen in labial salivary glands in Sjögren's syndrome and, 783
 Cytoplasmic antibodies, antineutrophil, 698, 1262
 Cytoplasmic staining, mitotic spindle apparatus and, 1643
 Cytostatic drugs, mortality in rheumatoid vasculitis and, 266
 Cytotoxicity
 direct gene delivery to synovium and, 820
 infection after cyclophosphamide in SLE and, 1475
 MTX and, 1951

D

D dimer fragments, disease activity in SLE and, 287
 Dactylitis in seronegative spondylarthropathy, 1524
 Dark Agouti rats, nitric oxide in adjuvant arthritis and collagen arthritis in, 1677
 Daudi target cells, CD56 cells in SLE and, 1840
 DBA/1 mice, collagen arthritis in, 495, 1545
 Debridement in revision total hip arthroplasty, 1939
 Degenerative joint disease
 in the guinea pig, 1327
 revision total hip arthroplasty in, 1939
 Delayed-type hypersensitivity
 in psoriatic arthritis, 137
 silicone breast implants and, 1615, 1619
 Demographic studies
 barriers to return to work due to arthritis and musculoskeletal diseases, 101
 early undifferentiated connective tissue disease, 403
 ESR in polymyalgia rheumatica, 304
 gastric antral vascular ectasia in SSc, 341
 lupus nephritis after cyclophosphamide, 2028
 mortality in rheumatoid vasculitis, 266
 oral type II collagen in JRA, 623
 psychiatric diagnosis and health care-seeking in fibromyalgia, 436
 in RA, 257, 397, 427

Demographic studies (*cont'd*)
 Spanish-language outcome questionnaire and, 93
 in SSc, 341, 1035
 Denatured collagen, in early RA, antibodies to, 1720
 Dendritic cells, in RA, self peptides and, 183
 Deoxyypyridinoline
 bone mineral metabolism in JRA and, 746
 collagen degradation and, 1455
 Depression
 psychiatric diagnosis in fibromyalgia and, 2086
 in scleroderma, 1035
 in SLE, 671, 1833
 Dermal fibroblasts in SSc, 1339, 1347
 Dermatologic vignette
 amyopathic DM, 1419
 secondary erythema, 1761
 Dermatomyositis (DM)
 anti-glycyl-transfer RNA synthetase antibodies in, 146
 anti-Jo-1 antibodies in, 292
 autoantibodies against muscle-cell membrane proteins in, 1860
 HTLV-I DNA in, 535
 major histocompatibility complex class II alleles in, 507
 Mi-2 in, 868, 1769
 Destructive arthropathy
 collagen degradation in, 1455
 matrix metalloproteinase 9 in RA and, 1576
 Dexamethasone
 lymphocyte-fibroblast adhesion and, 226
 osteonectin in cartilage and, 539
 TSG-6 in articular chondrocytes and, 552
 Diabetes, drug therapy in RA and, 723
 Diarrhea, sulfasalazine in psoriatic arthritis and, 2013
 Diarthrodial joints, T cells in RA and, 914
 Diathesis, hemorrhagic, antiphospholipid antibody syndrome and, 1441, 1444, 1466
 Dibutyl cyclic AMP, osteonectin in cartilage and, 539
 Diet
 in OA, 357, 648
 in RA, 357, 643
 Diffuse SSc
 $\alpha 1(I)$ procollagen gene in, 1347
 Amerindian HLA haplotype in, 1362
 antibodies to heterogeneous nuclear RNP in, 1669
 cutaneous, childhood-onset scleroderma and, 1041
 free radical injury in, 1146
 Digestive system in watermelon stomach in SSc, 1439
 Digital ulcers in scleroderma, 1035, 1146
 Digoxigenin, V_{α} and V_{β} transcripts in RA and, 454
 Dimero-flurbiprofen, mitochondrial uncoupling and, 1998
 Diphosphoglucose dehydrogenase, uridine, fibroblast-like synoviocytes in RA and, 1781
 Disability
 in fibromyalgia, 682, 1627
 Index, Health Assessment Questionnaire, 64, 616
 in OA, 81
 pain and, 357
 in RA, 616, 713, 723
 running, musculoskeletal pain, age and, 64
 Discoid lesions in SLE, 2078
 Disease activity
 autoreactivity to human heat-shock protein 60 in oligoarticular JRA and, 1826
 early undifferentiated connective tissue disease and, 403
 insulin-like growth factor in arthritic joints and, 1556
 matrix metalloproteinase 9 in giant cell arteritis and, 1747
 nuclear factor- κB transcription factor and, 583

Disease activity (cont'd)

- in RA, 34, 115, 257, 357, 397, 415, 713, 1027, 1092, 1102, 1371, 1711, 1720, 1808, 1818
- SK&F 106615 in rat adjuvant arthritis and, 504
- in SLE, 287, 370, 671, 792, 1178, 1441, 1444, 1466, 1654, 1840, 2035
- SLICC/ACR damage index and, 363
- in SSc, 1146, 1362
- subglottic stenosis in Wegener's granulomatosis and, 1754
- sulfasalazine in AS and, 1400
- TNF receptor p75 in JRA and, 883

Disease duration

- CT of the knee in gout and, 1406
- in early undifferentiated connective tissue disease, 403
- in fibromyalgia, 682
- penicillin in Behçet's disease and, 2062
- in polymyalgia rheumatica, 304
- in RA, 41, 616
- in renal vascular damage in SSc, 1030
- in Sjögren's syndrome, 297

Disease exacerbation

- antibiotics in reactive arthritis and, 1238
- epidemiology of Wegener's granulomatosis and, 87
- progressive resistance training and, in RA, 415
- in SLE, 9, 370, 2083

Disease flares

- acute musculoskeletal symptoms and, 1
- in generalized Wegener's granulomatosis, 2052
- of lupus nephritis after cyclophosphamide, 2028
- maternal-fetal immunology, autoimmune disease and, 191
- in RA, 713, 1016, 1021, 1970

Disease-modifying antirheumatic drugs (DMARDs), in RA, 115, 162, 616, 713, 723, 1006, 1016

Disease onset

- $\alpha 1(I)$ procollagen gene in SSc fibroblasts and, 1347
- anticytokine therapy of collagen arthritis in DBA/1 mice and, 797
- in antisynthetase syndrome, 692
- in chronic arthropathy after rubella vaccine, 1529
- in collagen arthritis, 495, 797, 1545
- corticosteroids, antibiotics and, in *Staphylococcus aureus* arthritis, 1596
- in fibromyalgia, 682
- in lupus nephritis after cyclophosphamide, 2028
- in RA, 713
- in SLE, 23, 1840

Disease outcome, in early undifferentiated connective tissue disease, 403

Disease progression

- antibodies to heterogeneous nuclear RNP in SSc and, 1669
- cytokine mRNA in Sjögren's syndrome and, 1376
- IL-10 in collagen arthritis and, 495
- in OA of the finger joints, 308
- penicillin in Behçet's disease and, 2062
- in RA, 616, 1006, 1246, 1802

Disease remission

- antiribosomal P antibodies and, in SLE, 671
- autoreactivity to human heat-shock protein 60 in oligoarticular JRA and, 1826
- early undifferentiated connective tissue disease and, 403
- in generalized Wegener's granulomatosis, 2052
- in RA, 191, 713, 996, 1246

Disease severity

- acute musculoskeletal symptoms and, 1
- corticosteroids, antibiotics and, in *Staphylococcus aureus* arthritis, 1596
- $\gamma\delta$ T cells in rat adjuvant arthritis and, 204
- in JRA, 623, 746
- penicillin in Behçet's disease and, 2062

Disease severity (cont'd)

- in RA, 266, 629, 713, 1711, 1720, 1802
- in SLE, 379, 979
- in SSc, 1035, 1151

Distal extremities, swelling of, pitting edema and, in polymyalgia rheumatica, 73

Distal interphalangeal joints, in OA, 308

Dizygotic twins, cigarette smoking, risk of RA in, 732

DNA

- antibodies, 522, 894, 938
- anti-topo I, lung cancer and, in SSc, 686
- bacterial, molecular diagnosis of venereal arthritis and, 950
- Borrelia burgdorferi*, in synovium, 736
- complementary, anti-NOR 90 in rheumatic diseases and, 1313
- detection of *Chlamydia trachomatis* by polymerase chain reaction and, 1740
- HTLV-I and, 535, 1410
- in lymphocyte apoptosis in Sjögren's syndrome, 1875
- oligotyping, 1362, 1507, 1833
- plasmid, direct gene delivery to synovium and, 820
- in RA, 1781, 2080
- in SLE, 9, 370, 663, 1833
- thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773
- typing, 938, 1151, 1246

Dorsal forearm skin, intravenous immunoglobulins and, in SLE, 704

Dorsal patella, knee pain and, 1244

Doxycycline, procollagenase and, 235

DQA1

- haplotypes, ribosomal P autoantibodies in SLE and, 1833
- in SSc and RA, 152

DQA1*0501 alleles, in Sjögren's syndrome, 1733

DQB1

- haplotypes, ribosomal P autoantibodies in SLE and, 1833
- in SSc and RA, 152

DQB1*0201, DQB1*0301 alleles, in Sjögren's syndrome, 1733

DR3, in myositis, 507

DR4, T cell receptor β gene polymorphism and, in RA, 931

DRB1

- collagen antibodies in early RA and, 1720
- haplotypes, ribosomal P autoantibodies in SLE and, 1833

DRB1*0301 alleles, in Sjögren's syndrome, 1733

DRB1*1302, DQB1*0604 haplotype, antifibrillar in SSc and, 1151

Drug interactions, acute febrile toxicity after MTX and azathioprine in RA, 1016

Drugs

- acidic prodrugs, 1998
- all-trans-retinoic acid, 1423
- 5-aminosalicylic acid, 1400
- amitriptyline, 1852
- antibiotic, 1238, 1596, 1939
- anti-CD4 monoclonal antibody-coated lymphocytes (cM-T412), 52
- antifolate, 723
- antihyperuricemic, 1406
- antiinflammatory, 1455, 1998
- antioxidant, 1146
- antirheumatic, 1006
- antithymocyte globulin, 1132
- anti-TNF α , 1077
- aspirin, 1818
- auranofin, 616, 723
- aurothioglucose, 723
- aurothiomalate, 723
- azathioprine, 616, 723, 1016, 1435, 1436
- benzathine penicillin, 2062
- bisphosphonate, 397, 1791
- calcitriol, 1791
- chlorambucil, 723

Drugs (cont'd)

chloroquine, 1818
 ciprofloxacin, 1238
 colchicine, 1213, 2062
 collagen, oral type II, 41
 corticosteroids, 73, 277, 297, 704, 723, 1199, 1254, 1475, 1773, 1818, 2070
 cyclophosphamide, 171, 723, 1475, 2028, 2052
 cyclosporine, 723, 1006, 1491
 cytostatic, 266
 deflazacort, 1818
 dexamethasone, 226, 539, 552
 DMARD, 115, 162, 616, 713, 723, 1006, 1016
 doxycycline, 235
 etidronate, 1791
 fluoride, 1791
 fluoxetine, 1852
 flurbiprofen, 1998
 folinic acid, 2052
 γ -linolenic acid, 1808
 glucocorticoid, 216, 226, 552, 713, 723, 1754, 1791
 gold, 616, 713, 723, 1932, 1951
 hormone replacement, 1791
 hydroxychloroquine, 34, 157, 616, 723, 1055
N-[4-hydroxyphenyl] retinamide, 1021
 immunosuppressive, 1, 157, 266, 325, 638, 704, 1016, 1754
 indomethacin, 321
 intravenous immunoglobulin, 1027
 methotrexate (MTX), 171, 272, 325, 489, 616, 713, 723, 1016, 1115, 1435, 1436, 1608, 1951, 2052, 2070
 methylprednisolone, 216, 1970
 metronidazole, 321
 muscarinic type III cholinergic agonists, 195
 nabumetone, 1998
 naproxen, 321, 515, 891
 NSAID, 73, 321, 357, 515, 616, 713, 723, 1998, 2004
 opioid, 357
 pamidronate, 397
 penicillamine, 616, 713, 723, 1951
 penicillin, 2062
 pilocarpine, 195
 pravastatin, 1259
 prednisolone, 216
 prednisone, 304, 616, 713, 723, 1791, 2052
 recombinant human IL-1 receptor I, 257
 retinoic acid, 1423
 retinoid, 1021
 SAARD, 996
 salsalate, 321
 second-line, 1773, 1818
 salmon calcitonin nasal spray, 1791
 SK&F 106615, 504
 steroid, 1, 171, 610, 1199, 1264, 1791
 sulfamethoxazole, 2052
 sulfapyridine, 1400
 sulfasalazine, 34, 616, 711, 723, 1400, 2004, 2013, 2021
 sulfonamide, 1400
 tenidap, 1263
 thiazide diuretics, 1791
 topical tretinoin, 1070
 triamcinolone, 277
 trimethoprim, 723, 2052
 xylocaine, 277
 zileuton, 515
 zymosan, 515
 Drummer's finger, 1258
 Dry eyes, in Sjögren's syndrome, 297

Dry mouth, in Sjögren's syndrome, 57, 195
 Dual-energy x-ray absorptiometry, in glucocorticoid-induced osteoporosis, 1791
 Dyscrasia, all-*trans*-retinoic acid in POEMS syndrome and, 1423
 Dysmotility, esophageal, centromere kinesin-like protein, CENP-E in SSc and, 1355
 Dyspepsia, sulfasalazine in psoriatic arthritis and, 2013
 Dyspnea
 in drug therapy in RA, 723
 in Wegener's granulomatosis of the lungs, 615

E

Ear, in child with SLE, 2078
 Early RA
 collagen antibodies in, 1720
 N-[4-hydroxyphenyl] retinamide in, 1021
 oral type II collagen in, 41
 sawtooth strategy in, 996
 V α and V β transcripts in, 454
 Early SSc, pathologic analysis of, 1161
 Early undifferentiated connective tissue disease, 403
 Economic factors
 disability in fibromyalgia and, 1627
 in social and psychological impact of musculoskeletal conditions, 1931
 Ectasia, gastric antral vascular, in SSc, 341
 Ectoenzymes, soluble bone marrow stromal cell antigen 1 in RA, 629
 EDA-containing fibronectin, synovial cell adherence on, 1685
 Edema
 acute musculoskeletal symptoms and, 1
 pitting, 73, 1931
 Education level
 barriers to return to work due to arthritis and musculoskeletal disease and, 101
 running, musculoskeletal pain, age and, 64
 Effector cells
 CD56 cells in SLE and, 1840
 self peptides, dendritic cells and, in RA, 183
 Effusions
 acute musculoskeletal symptoms and, 1
 pericardial, in SSc, 1138
 synovial, matrix metalloproteinase 9 in RA and, 1576
 Elastic cartilage, nucleotide pyrophosphohydrolase in articular cartilage and, 245
 Elderly
 OA in, 81, 357
 RA in, 357, 415, 1115
 Emergency room visits for SLE, health care costs and, 979
 Emotional factors
 depression in scleroderma and, 1035
 in RA, 427
 Endocarditis, Libman-Sacks, vascular injury in SLE and, 9
 Endocrinopathy, all-*trans*-retinoic acid in POEMS syndrome and, 1423
 Endoglycosidase H, osteonectin in cartilage and, 539
 Endoscopy, in gastric antral vascular ectasia in SSc, 341
 Endothelial activation, imaging of, in RA, 1371
 Endothelial cells
 adhesion molecules and, 467, 810, 1970
 hepatocyte growth factor and, 1566
 in RA, 1082, 1576
 vascular, in JRA and juvenile spondylarthropathy, 1703
 Endothelial E-selectin, in SSc, 1161
 Endothelial migration, hepatocyte growth factor and, 1566
 Endothelin-1, in childhood-onset scleroderma, 1041
 Endothelium
 in RA, 1576, 1970
 in shoulder synovitis in polymyalgia rheumatica, 1199

- Endothelium (*cont'd*)
 vascular, 583, 1082, 1441, 1444, 1466
- End-stage hip disease, revision total hip arthroplasty in, 1939
- End-stage joint disease, acute musculoskeletal symptoms and, 1
- Enteropathy, NSAIDs and, in RA, 321
- Enterotoxin A, staphylococcal, T cells, bacterial superantigens and, in RA synovocytes, 125
- Enterotoxin D, RF-producing B cells in RA and, 1499
- env* gene
 antibodies to peptides in SLE and, 1654
 HTLV-I in autoimmune disorders and, 1410
- Environmental factors
 Amerindian HLA haplotype in SSc and, 1362
 hair dye use and SLE, 657
 in JRA, 1385
- Enzyme-linked immunosorbent assay (ELISA)
 compared with anticardiolipin immunoassay for anti- β_2 -glycoprotein I, 1606
 detection of ENA by, in SLE, 1055
- Enzymes
 angiotensin-converting, in childhood-onset scleroderma, 1041
 in antisyndetase syndrome, 692
 copper-dependent, collagen degradation and, 1455
 ecto-, 629
 glycyl-transfer RNA synthetase in myositis and, 146
 nucleotide pyrophosphohydrolase in human serum and, 252
 procollagenase, doxycycline and, 235
 in RA, 629, 1576, 1781
- Epidemiologic studies
 anti-HTLV-I antibody in RA, 463
 augmentation mammoplasty and SSc, 1125
 JRA, 1385
 Sjögren's syndrome, 195
 Wegener's granulomatosis, 87
- Epidermal necrolysis, toxic, after sulfasalazine in psoriatic arthritis, 711
- Epidermal skin blisters, cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
- Epithelial cells, thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773
- Epitopes
 antibodies to aggrecan in SF in, 1990
 antibodies to peptides in SLE and, 1654
 anti-topo I, lung cancer and, in SSc, 686
 autoantigen, anti-NOR 90 in rheumatic diseases and, 1313
 collagen, fibroblast adhesion to articular cartilage and, 1072
 glycyl-transfer RNA synthetase in myositis and, 146
 HLA-DRB1 genes, disease severity and, in RA, 1802
 Ki antigen homology and, 855
 nephritogenic autoantibodies in lupus and, 894
 of PM-Scl antigen, 1588
- Epstein-Barr virus (EBV)
 lymphomas in RA and, 325, 638
 thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773
- Erosions
 in OA of the finger joints, 308
 in RA, 162, 1006, 1802, 1934
 silicone breast implants and, 1615, 1619
- Erosive arthropathy, cryocrystalglobulinemia, systemic vasculopathy and, 335
- Erosive RA, collagen antibodies in, 1720
- Erosive synovitis, in RA, 713
- Erythralgia, secondary, painful, swollen and erythematous hands and feet in, 1761
- Erythrocyte sedimentation rate (ESR)
 in focal myositis in MCTD, 1254
- Erythrocyte sedimentation rate (ESR) (*cont'd*)
 in polymyalgia rheumatica, 304
 as predictor of disease exacerbations in SLE, 370
- Erythrocytes, silicone breast implants and, 1615, 1619
- Escherichia coli*, autoantibodies directed against tRNA in interstitial lung disease and, 1308
- E-selectin
 anti-endothelial cell antibodies in Wegener's granulomatosis and, 758
 in RA, 1077, 1082, 1371, 1970
 in SSc, 1041, 1161
 synovial endothelial cells and, 467
 T cells and, in psoriatic arthritis, 137
- Esophageal dysmotility, centromere kinesin-like protein, CENP-E in SSc and, 1355
- Etidronate, in glucocorticoid-induced osteoporosis, 1791
- Ethnic studies
 major histocompatibility complex class II alleles in myositis, 1507
 of SLE, 663, 1833
- European criteria for Sjögren's syndrome, in hepatitis C virus and sicca syndrome, 1166
- European League Against Rheumatism (EULAR), response criteria for RA, 34
- Exercise
 OA, sports and, 988
 pain and, 357
 in RA, 357, 415
 running, musculoskeletal pain, age and, 64
- Expectation bias, in RA clinical trials, 1773
- Experimental OA, IL-1 receptor antagonist in, 1535
- Experimental serum sickness, acute, vascular injury in SLE and, 9
- Experimental *Staphylococcus aureus*, corticosteroids and antibiotics in, 1596
- Extraarticular features
 of HTLV-I in autoimmune disorders, 1410
 of RA, 183, 713
- Extracellular matrix
 effect of nitric oxide on chondrocytes and, 1905
 fibroblast-like synovocytes in RA and, 1781
- Extracellular space, MTX and, 1951
- Extracorporeal photochemotherapy, in psoriatic arthritis, 1519
- Extractable nuclear antigens (ENA)
 detection of, by ELISA, in SLE, 1055
 in RA in Native Americans, 283
- Extraglandular features of Sjögren's syndrome
 long-term followup of, 297
 mixed monoclonal cryoglobulinemia and, 767
- Extremities
 acute musculoskeletal symptoms and, 1
 distal, swelling of, pitting edema and, in polymyalgia rheumatica, 73
 ischemia and gangrene of, vascular injury in SLE and, 9
- Eyes
 in Behçet-type vasculopathy without Behçet's disease, 1926
 dry, in Sjögren's syndrome, 297
 HTLV-I in autoimmune disorders and, 1410

F

- Fab fragments, risk of lymphoma in primary Sjögren's syndrome and, 767
- Face
 in Kawasaki disease, 2078
 photosensitive pruritic rash on, in amyopathic DM, 1419
- Factors
 anti-tumor necrosis, in RA, 1077, 1082
 granulocyte-macrophage colony-stimulating, 386, 836, 1287
 growth, 195, 539, 552, 560, 829, 914, 959, 968, 1192, 1267, 1376, 1556, 1566, 1896

Factors (cont'd)

- leukemia inhibitory, TIMP-1, oncostatin M and, in cartilage, 560
- nuclear factor- κ B, 1410
- nucleolar transcription NOR 90/hUBF, 1313
- recombinant human stem cell, human synovial mast cells and, 1222
- scatter, 1566
- thioredoxin/adult T cell leukemia-derived, in Sjögren's syndrome, 773
- tumor necrosis, 9, 125, 183, 195, 197, 226, 386, 467, 495, 539, 552, 797, 959, 1109, 1115, 1161, 1410, 1545, 1693, 1703, 1781
- von Willebrand, in childhood-onset scleroderma, 1041
- Familial Mediterranean fever, colchicine in breast milk in, 1213
- Familial primary antiphospholipid antibody syndrome, 705
- Fas
 - molecules, autoimmune disorders, HTLV-I and, 1410
 - soluble, in SLE, 1611, 1612
- Fat necrosis, subcutaneous, polyarthritis, pancreatic disease and, 1922
- Fatal opportunistic infection, after cyclophosphamide and corticosteroids in SLE, 1475
- Fatal postpartum vasculitis, in SLE, 352
- Fatigue
 - in fibromyalgia, 682, 2086
 - in RA, 415, 713
- Fatty acids, γ -linolenic acid in RA, 1808
- Fc receptors, IgG, antigen-presenting cell function in SLE and, 600
- Fcy receptors, IL-10 in RA and, 386
- Feet
 - cyclosporine in early RA and, 1006
 - in secondary erythema, 1761
- Femoral condyle, IL-1 and, 478, 1535
- Femoral neck
 - bone mass, pamidronate and, in RA, 397
 - bone mineral density, bone loss, age and, in OA, 81
- Femoral osteophytes, sports, risk of OA and, 988
- Femur
 - glucocorticoid-induced osteoporosis and, 1791
 - manoalide in IL-1 α arthritis and, 1292
 - in revision total hip arthroplasty, 1939
- Fertility, drug therapy in RA and, 723
- Fetus
 - loss of, 9, 1441, 1444, 1466
 - maternal-fetal immunology and autoimmune disease, 191
- Fever
 - acute musculoskeletal symptoms and, 1
 - in acute toxic reaction in RA after MTX and azathioprine, 1016
 - in focal myositis and MCTD, 1254
 - HLA, anti-U1 RNP and, in connective tissue disease, 938
 - revision total hip arthroplasty and, 1939
 - Rocky Mountain spotted, acute monarticular arthritis in, 175, 2088
 - vascular injury in SLE and, 9
 - in Wegener's granulomatosis of the lungs, 615
- Fibers, elastic, matrix metalloproteinase 9 in giant cell arteritis and, 1747
- Fibrillar, autoantibodies to, in SSc, 1151
- Fibrinolysis, disease activity in SLE and, 287
- Fibroblast growth factor
 - basic, osteonectin in cartilage and, 539
 - receptor, T cells in RA and, 914
- Fibroblastic rheumatism, low-dose MTX in, 2070
- Fibroblast-like synoviocytes
 - collagenase, adenosine and, 923
 - in RA, 1781
- Fibroblasts
 - adhesion of, to articular cartilage, 1072
 - autoantibodies against muscle-cell membrane proteins in myositis and, 1860
 - hepatocyte growth factor and, 1566

Fibroblasts (cont'd)

- matrix metalloproteinase 9 in giant cell arteritis and, 1747
- in SSc, 1338, 1347
- synovial, 226, 574, 820, 1576
- T cells in RA synoviocytes and, 125
- Fibromyalgia
 - disability and, 1627
 - fluoxetine and amitriptyline in, 1852
 - long-term followup of, 682
 - multi-organ dysesthesia and, 180
 - psychiatric diagnosis and health care-seeking in, 436, 2086
 - rubella vaccine and, 1529
 - Spanish-language outcome questionnaire in, 93
- Fibronectin
 - adhesion of nitric acid on chondrocytes and, 1905
 - EDA-containing, synovial cell adhesion and, 1685
 - nephritogenic autoantibodies in lupus and, 894
 - synthesis of, in articular cartilage, 567
- Fibroproliferation, hepatocyte growth factor and, 1566
- Fibrosis
 - hepatic, drug therapy in RA and, 723
 - lung, 152, 692, 1074, 1308, 1362
- Fingers
 - dactylitis of, in seronegative spondylarthropathy, 1524
 - drummer's, 1258
 - joints of, 308, 325
 - splinter hemorrhage after arterial puncture in, 169
- Fitness, progressive resistance training in RA and, 415
- Flagellin gene, *Borrelia burgdorferi* DNA in synovium and, 736
- Fluency, neuropsychological deficits in SLE without central nervous system disease, 2035
- Fluid retention, drug therapy in RA and, 723
- Fluoride, glucocorticoid-induced osteoporosis and, 1791
- Fluoxetine, amitriptyline and, in fibromyalgia, 1852
- Flurbiprofen, mitochondrial uncoupling and, 1998
- Focal bone lesion irradiation, all-*trans*-retinoic acid in POEMS syndrome and, 1423
- Focal lymphocytic infiltrates, in Sjögren's syndrome, 195
- Focal myositis, in MCTD, 1254
- Focal segmental necrotizing glomerulonephritis, vascular injury in SLE and, 9
- Folate
 - antioxidant micronutrients in knee OA and, 648
 - deficiency, drug therapy and, 723, 1951
- Folinic acid, disease remission in generalized Wegener's granulomatosis and, 2052
- Followup studies
 - antioxidant micronutrients in knee OA, 648
 - antisynthetase syndrome, 692
 - barriers to return to work due to arthritis and musculoskeletal diseases, 101
 - CT of the knee in gout, 1406
 - fibromyalgia, 682
 - focal myositis and MCTD, 1254
 - JRA, 1385
 - OA of the finger joints, 308
 - RA, 34, 115, 415, 1246, 1491
 - Sjögren's syndrome, 297
 - SSc, 677, 1132
- Food and Drug Administration (FDA), drug therapy in RA and, 723
- Forced vital capacity in interstitial lung disease in RA, 1711
- Foreign antigens, silicone breast implants and, 1615, 1619
- Forskolin, collagenase, adenosine and, 923
- Fractures
 - acute musculoskeletal symptoms and, 1
 - glucocorticoid-induced osteoporosis and, 1791

Framingham OA Study, antioxidant micronutrients in knee OA and, 648

Free fatty acids, γ -linolenic acid in RA, 1808

Free radical injury, in scleroderma, 1146

Freund's adjuvant

complete, phagocytes, inflammation and, in collagen arthritis, 1545
in silicone immunology, 1615, 1619

Functional ability

acute musculoskeletal symptoms and, 1

depression in scleroderma and, 1035

in fibromyalgia, 1627

in OA, 357

pain and, 357

in RA, 34, 357, 415, 427, 616, 713, 996

Spanish-language outcome questionnaire and, 93

Fusion proteins

PM-Scl autoantigen and, 1588

recombinant, autoimmunity to RNA polymerase II and, 1886

G

G1 domain, native, antibodies to, in aggrecan in SF, 1990

gag gene

autoimmune disorders, HTLV-I and, 1410

peptides in SLE and, 1654

Gait, progressive resistance training in RA and, 415

γ/δ T cells

in rat adjuvant arthritis, 204

in shoulder synovitis in polymyalgia rheumatica, 1199

in Sjögren's syndrome, 1733

Gamma-linolenic acid, in RA, 1808

Gammopathy

biclonal, all-*trans*-retinoic acid in POEMS syndrome and, 1423

monoclonal, cryoglobulinemia and, 335

Gangrene

limb, vascular injury in SLE and, 9

systemic vasculopathy in multiple myeloma and, 330

Gastric antral vascular ectasia, in SSc, 341

Gastroenteritis, infectious, nitric oxide in RA and, 643

Gastrointestinal involvement

hemorrhage, in gastric antral vascular ectasia in SSc, 341

NSAID, mitochondrial uncoupling and, 1998

in RA, 713, 723

sulfasalazine and, 2004, 2013, 2021

vascular injury in SLE and, 9

Gelatinase B

in giant cell arteritis, 1747

in RA, 1576

Gender

antifibrillar in SSc and, 1151

antiribosomal P antibodies and, in SLE, 671

effect of MTX on mouse bone cells and, 489

ESR in polymyalgia rheumatica and, 304

in JRA, 1385

maternal-fetal immunology and autoimmune disease, 191

mortality in rheumatoid vasculitis and, 266

in OA, 81, 648, 988

pyoderma gangrenosum, spondylarthropathy and, 1062

in RA, 723, 1246

in silicone immunology, 1615, 1619

Generalized lymphadenopathy in hypercalcemia and SLE, 2066

Generalized Wegener's granulomatosis, disease remission in, 2052

Genes

$\alpha 1(I)$ procollagen, 1347

α_v /CD18 leukointegrin and, 1913

American HLA haplotype, SSc and, 1362

apoptosis-associated, lymphocyte apoptosis and, in Sjögren's syndrome, 1875

Genes (*cont'd*)

collagenase, 574, 923

direct delivery of, to synovium, 820

germline, V_H , monoclonal antiphospholipid antibodies and, 537

HTLV-I DNA in PM/DM and, 535

luciferase reporter, matrix metalloproteinase 1 activation by tyrosine kinases and, 574

lymphocyte-fibroblast adhesion and, 226

mapping of, in myositis, 1507

maternal-fetal immunology, autoimmune disease and, 191

in RA, 446, 454, 638, 1021

in SLE, 23, 663, 1654

transcription factor NF- κ B, TNF α and, 197

TSG-6 in articular chondrocytes, 552

Genetics

C1q deficiency in SLE and, 663

HLA genes and, in AS and reactive arthritis, 943

major histocompatibility complex alleles in myositis and, 1507

osteonectin in cartilage and, 539

primary Raynaud's disease and, 1189

in SSc, 1166, 1362

T cell receptor β genes, HLA-DR4 and, in RA, 931

Genital infection, reactive arthritis and, 1172

Genomes

EBV, clonality of, in lymphomas in RA, 638

hereditary C1q deficiency in SLE and, 663

Genotypes, HLA, in SSc and RA, 152

Geographic factors, epidemiology of Wegener's granulomatosis and, 87

Germline genes, V_H , monoclonal antiphospholipid antibodies and, 537

Germline mutations, T cells in lupus and, 23

Germline polymorphisms, T cell receptor β genes, HLA-DR4 and, in RA, 931

Gestation, maternal-fetal immunology, autoimmune disease and, 191

Giant cell arteritis

amyloidosis and, 1073

matrix metalloproteinase 9 in, 1747

in polymyalgia rheumatica, 73, 1199

Glands

salivary, 1161, 1376, 1410, 1609

in Sjögren's syndrome, 195, 773, 783, 1376, 1609

Glaucoma, drug therapy in RA and, 723

Global assessment

intravenous immunoglobulin in refractory RA and, 1027

oral type II collagen in JRA and, 623

sulfasalazine and, 1400, 2004, 2013, 2021

Globulin, antithymocyte, in SSc, 1132

Glomeruli

in IgA multiple myeloma, Henoch-Schönlein purpura/polyarteritis nodosa and, 698

nephritogenic autoantibodies in lupus and, 894

Glomerulonephritis, in SLE, 9, 894

Glucagon, protein metabolism, aging and, in RA, 1115

Glucocorticoid drugs

injectable, in subglottic stenosis in Wegener's granulomatosis, 1754

lymphocyte-fibroblast adhesion and, 226

osteoporosis induced by, 1791

in RA, 216, 713, 723

TSG-6 in articular chondrocytes and, 552

Glutathione-S-transferase GSTM1 null alleles, in SLE, 1763

Gly amino acid, hereditary C1q deficiency in SLE and, 663

Glycoforms, anti-CD45 autoantibodies in SLE and, 592

Glycoprotein, antiphospholipid antibody syndrome and, 1441, 1444, 1466

Glycosyl phosphatidylinositol, soluble bone marrow stromal cell antigen 1 in RA and, 629

Glycosylation

- human TAP alleles for HLA-B27 binding peptides and, 1892
- osteonectin in cartilage and, 539

Glycyl-transfer RNA synthetase, autoantibodies to, in myositis, 146

Gold

- amyloidosis as side effect of, 1932
- intramuscular, 616
- MTX and, 1951
- in RA, 616, 723, 1246

Gonococcal arthritis, molecular diagnosis of, 950

Gorilla studies, arthritis, 891

Gout

- acute musculoskeletal symptoms and, 1
- CT of the knee in, 1406
- TGF β in MSU crystal-induced inflammation and, 1192

gp70/anti-gp70, retroviral, nephritogenic autoantibodies in lupus and, 894

gp150/95, α_4 /CD18 leukointegrin and, 1913

Graft-versus-host disease, maternal-fetal immunology, autoimmune disease and, 191

Granules, human synovial mast cells and, 1222

Granulocyte-macrophage colony-stimulating factor

- CD80/CD86 in chronic arthritis and, 1287
- in RA, 386, 836

Granulomatosis, Wegener's, 87, 615, 758, 1262, 1754, 2052

Granulomatous microcrystalline synovial inflammation, in cryocrystal-globulinemia, 335

Greek studies, ribosomal P autoantibodies in SLE, 1833

Grip strength

- oral type II collagen in JRA and, 623
- on Spanish-language outcome questionnaire, 93

Group A streptococcal infection, musculoskeletal manifestations of, 1260

Growth factors

- cartilage and, 539, 829
- fibroblast, 539, 914
- hepatocyte, in arthritis, 1566
- insulin-like, 968, 1556
- platelet-derived AA, 552, 1267
- TIMP-1, oncostatin M and, in articular cartilage, 560
- transforming, 195, 552, 560, 959, 1192, 1267, 1376, 1896

Growth hormones, protein metabolism, aging and, in RA, 1115

Guidelines

- for the initial evaluation of adults with acute musculoskeletal symptoms, 1
- for OA of the hip and knee, 887, 2083
- for RA, 713, 723

Guinea pig studies

- degenerative joint disease, 1327
- silicone immunology, 1615, 1619

Gut, MTX and, 1951

H

³H-proline, recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896

³H-thymidine

- IL-13 in RA and, 1693
- TIMP-1, oncostatin M and, in articular cartilage, 560
- transcription factor NF- κ B, TNF α and, 197

Hair dye use, SLE and, 657

Hand

- in cryocrystalglobulinemia, 335
- hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
- OA of the finger joints, 308
- in polyarteritis nodosa, 2078
- in RA, 325, 1006
- in secondary erythralgia, 1761

Haplotypes

- HLA-DR3, circulating T cell receptor γ/δ cells in Sjögren's syndrome and, 1733

major histocompatibility complex class II alleles in myositis and, 1507

mannose-binding protein polymorphisms in black patients with SLE and, 2046

silicone breast implants and, 1615, 1619

in SSc, 152, 1362

Headache, MTX and, 1951

Healing phenomena in RA, 162, 1934

Health Assessment Questionnaire

- depression in scleroderma and, 1035

Modified, Spanish-language, 93

in OA, 81

in RA, 216, 616, 1711

in study of running, musculoskeletal pain and age, 64

Health care costs in SLE in the US and Canada, 979

Health care-seeking, psychiatric diagnosis in fibromyalgia and, 436

Health outcome of telephone intervention in OA and RA, 1391

Health status, antioxidant micronutrients in knee OA and, 648

Heart

- calcific constrictive pericarditis in CREST syndrome, 347

human synovial mast cells and, 1222

thallium perfusion and cardiac dysfunction in SSc, 677

Heat-shock protein

- nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
- 60, autoreactivity to, disease remission and, in oligoarticular JRA, 1826

HeLa cells

- anti-Jo-1 antibodies in myositis and, 292

autoantibodies against tRNA and, 1308

Helper cells in RA, 1499, 1773

Hematology

- disease exacerbation and hematocrit in SLE, 370

disorders, cyclophosphamide in lupus nephritis and, 2028

hemoglobin

- adhesion of nitric oxide on chondrocytes and, 1905

ESR in polymyalgia rheumatica and, 304

in NSAID enteropathy and chronic anemia in RA, 321

hemolytic anemia, microangiopathic, vascular injury in SLE and, 9

malignancy in SLE and, 1050

toxicity, drug therapy in RA and, 723

Hemispherical cups in revision total hip arthroplasty, 1939

Hemochromatosis, in adults with acute musculoskeletal symptoms, 1767

Hemorrhage

- in gastric antral vascular ectasia in SSc, 341

pulmonary alveolar, vascular injury in SLE and, 9

in RA, 321, 723

splinter, after arterial puncture, 169

Hemorrhagic diathesis, antiphospholipid antibody syndrome and, 1441, 1444, 1466

Hemostasis, molecular markers of, in SLE, 287

Henoch-Schönlein purpura

- human parvovirus B19 infection in, 880

polyarteritis nodosa overlap, IgA multiple myeloma presenting as, 698

rash and arthritis in, 2078

Heparan sulfate

- proteoglycan, antivasular, antiphospholipid antibody syndrome and, 1441, 1444, 1466

in synovial cell adhesion on EDA-containing fibronectin, 1685

Heparinase, heparitinase, in synovial cell adhesion on EDA-containing fibronectin, 1685

Hepatic infarction, vascular injury in SLE and, 9

- Hepatitis C
in porphyria cutanea tarda and SLE, 352
virus, 1027, 1074, 1166
- Hepatocyte growth factor in inflammatory arthritis, 1566
- Herbimycin A, matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
- Hereditary osteodystrophy, Albright's 1921
- Herpes simplex virus, direct gene delivery to synovium and, 820
- Heterogeneity
antiphospholipid antibodies and, 1441, 1444, 1466
autoantibodies to glycyl-transfer RNA synthetase in myositis and, 146
in fibroblasts in SSc, 1338
V α and V β transcripts in early RA and, 454
- Heterogeneous nRNP in SSc, 1669
- High-dose corticosteroids
infection after cyclophosphamide and, in SLE, 1475
intravenous, in focal myositis and MCTD, 1254
- High-dose intravenous immunoglobulins, in SLE, 704
- Hip
arthritis in, in gorilla, 891
glucocorticoid-induced osteoporosis and, 1791
in OA, 81, 357, 988, 2083
in RA, 357
total replacement of, 357, 1939
- Hispanic studies
major histocompatibility complex class II alleles in myositis, 1507
ribosomal P autoantibodies in SLE and, 1833
- Histamine, human synovial mast cells and, 1222
- Histidyl-transfer RNA
in antisynthetase syndrome, 692
major histocompatibility complex class II alleles in myositis and, 1507
- Histology
antibiotics in reactive arthritis and, 1238
autoimmune disorders, HTLV-I and, 1410
collagen arthritis and, 495, 797
degenerative joint disease in the guinea pig and, 1327
IL-1 receptor antagonist in experimental OA and, 1535
low-dose MTX in fibroblastic rheumatism and, 2070
in progression of RA after bone marrow transplantation, 1246
SK&F 106615 in rat adjuvant arthritis and, 504
transcription factor NF- κ B and, 583
- Histones, nephritogenic autoantibodies in lupus and, 894
- Histopathology in systemic vasculopathy in multiple myeloma, 330
- HLA
alleles, 1355, 1362, 1733
antigens, in shoulder synovitis in polymyalgia rheumatica, 1199
genes, 943
haplotypes, silicone breast implants and, 1615, 1619
maternal-fetal immunology, autoimmune disease and, 191
in RA, 152, 1109
sexually transmitted diseases, reactive arthritis and, 1172
in SLE, 23, 792
in SSc, 152, 1151, 1362
typing, 868, 931, 939, 1166
- HLA-B associations of HLA-B27 negative AS, 1768
- HLA-B27
acute musculoskeletal symptoms and, 1
in AS, 943, 1768
binding peptides, human TAP alleles for, 1892
HLA genes and, in reactive arthritis, 943
- HLA-DQ alleles in myositis, 1507
- HLA-DQ8, ribosomal P autoantibodies in SLE and, 1833
- HLA-DQB1
alleles, 1151, 1355, 1833
HLA-DRB1 genes, disease severity and, in RA, 1802
- HLA-DR in RA, 183, 386, 454, 836
- HLA-DR2 alleles in myositis, 1507
- HLA-DR2, DQ6 haplotype, ribosomal P autoantibodies in SLE and, 1833
- HLA-DR3 haplotype, circulating T cell receptor γ/δ cells in Sjögren's syndrome and, 1733
- HLA-DR4
alleles, in myositis, 1507
in RA, 931, 1802
- HLA-DR7, Mi-2 autoantibodies in DM and, 868
- HLA-DR8 in acute anterior uveitis in AS, 351
- HLA-DR β chain Mi-2 autoantibodies in DM, 868
- HLA-DRB1 in RA, 1109, 1802
- Homocysteine, MTX and, 1951
- Homeostasis
calcium, glucocorticoid-induced osteoporosis and, 1791
T cells and, 904
- Homogeneity, Amerindian HLA haplotype, SSc and, 1362
- Homology, Ki antigen epitope, 855
- Homozygosity
Mi-2 autoantibodies in DM and, 868
in SLE, 663, 1763
TNF microsatellite polymorphisms, HLA and, in RA, 1109
- Hormones
osteonectin in cartilage and, 539
parathyroid, bone mineral metabolism in JRA and, 746
protein metabolism, aging and, in RA, 1115
replacement therapy, glucocorticoid-induced osteoporosis and, 1791
sex, 1766, 1791
- Hospital health care costs of SLE in the US and Canada, 979
- Hospitalization
antithymocyte globulin in SSc and, 1132
epidemiology of Wegener's granulomatosis and, 87
- HTLV-I
autoimmune disorders and, 1410
DNA, in PM/DM, 535
in the macaque, 610
- Human IL-1 receptor antagonist in RA, 1092
- Human immunodeficiency virus (HIV)
infection, hydroxychloroquine and, in AIDS and arthritis, 157
transcription factor NF- κ B, TNF α and, 197
- Human parvovirus B19 infection in Henoch-Schönlein purpura, 880
- Human studies
antibodies to aggrecan in SF, 1990
articular cartilage, 478, 560, 567
chondrocytes, 1430, 1896
detection of anticentromere antibodies using recombinant human CENP-I protein, 863
doxycycline and procollagenase, 235
inflammation and basic calcium phosphate crystals, 1319
lymphocyte-fibroblast adhesion, 226
manoalide in IL-1 α arthritis and, 1292
nucleotide pyrophosphohydrolase in serum, 252
recombinant osteogenic protein 1, 1896
silicone immunology and, 1615, 1619
synovial endothelial cell adhesion molecules, 467
synovial mast cells, 1222
T cells in lupus, 23
TAP alleles for HLA-B27 binding peptides, 1892
TGF β 1 in crystal-induced inflammation, 1192
transcription factor NF- κ B, 197, 583
TSG-6 in articular chondrocytes, 552
- Human T lymphotropic virus I (HTLV-I)
autoimmune disorders and, 1410
DNA in PM/DM, 535
macaque infected with, 610
peptides in SLE and, 1654

Human T lymphotropic virus I (HTLV-I) (*cont'd*)
tax gene in Sjögren's syndrome, 1609
 Humoral immune response, T cells in lupus and, 23
 Humoral immunity, MTX and, 1951
 Hyaline articular cartilage, nucleotide pyrophosphohydrolase in, 245
 Hyaluronan, TSG-6 in articular chondrocytes and, 552
 Hybridoma cells, nephritogenic autoantibodies in lupus and, 894
 Hydroxyapatite
 glucocorticoid-induced osteoporosis and, 1791
 inflammation, basic calcium phosphate crystals and, 1319
 Hydroxychloroquine
 in AIDS and arthritis, 157
 anti-ENA in SLE and, 1055
 in RA, 34, 616, 723
 Hydroxyproline
 recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
 urinary, bone mass, pamidronate and, in RA, 397
 Hypercalcemia, SLE and, 2066
 Hypergammaglobulinemia, autoimmune disorders, HTLV-I and, 1410
 Hyperplasia, α_v /CD18 leukointegrin and, 1913
 Hypersensitivity, delayed-type, 137, 1615, 1619
 Hypertension
 arterial, cardiac involvement in limited SSc and, 1138
 drug therapy in RA and, 723
 malignant, in cryocrystalglobulinemia, 335
 pulmonary, free radical injury in scleroderma and, 1146
 renovascular, vascular injury in SLE and, 9
 systemic vasculopathy in multiple myeloma and, 330
 Hypoalbuminemia, pancytopenia, MTX and, in RA, 272
 Hypocomplementemia, HLA, anti-U1 RNP and, in connective tissue disease, 938
 Hypogonadism, glucocorticoid-induced osteoporosis and, 1791
 Hypoprotection, antiphospholipid antibody syndrome and, 1441, 1444, 1466
 Hyporesponsiveness, CD69 in RA and, 1277
 Hypoxemia, acute reversible, vascular injury in SLE and, 9

I

Idiopathic autoimmune disease
 HTLV-I in, 1410
 T cells in lupus and, 23
 Idiopathic inflammatory myopathy, carnitine in muscle in, 1869
 Idiopathic Sjögren's syndrome, HTLV-I in, 1410
 Idiotype
 antiidiotypic antibodies in SLE and, 1980
 anti-Ro and anti-La anti-dsDNA antiidiotypes and, 522
 cross-reactive, risk of lymphoma in primary Sjögren's syndrome and, 767
 IgA
 antibodies, anti-topo I, lung cancer and, in SSc, 686
 multiple myeloma, presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 sulfasalazine in AS and, 1400
 IgE, human synovial mast cells and, 1222
 IgG
 anti-Ro and anti-La anti-dsDNA antiidiotypes and, 522
 antibodies, 686, 758, 1441, 1444, 1466, 1499, 1720, 1990
 in familial primary antiphospholipid antibody syndrome, 705
 MTX and, 1951
 RF-producing B cells and, in RA, 1499
 silicone immunology and, 1615, 1619
 in Sjögren's syndrome, 195
 in SLE, 9, 600, 1441, 1444, 1466, 1664, 1980
 sulfasalazine in AS and, 1400
 3, nephritogenic autoantibodies in lupus and, 894

IgM
 antibodies, 1441, 1444, 1466, 1499
 κ , risk of lymphoma in primary Sjögren's syndrome and, 767
 RF-producing B cells and, in RA, 1499
 in SLE, 592, 600, 1441, 1444, 1664, 1466, 1980
 sulfasalazine in AS and, 1400
 Imaging studies of endothelial activation in RA, 1371
 Immune complexes in SLE, 9, 894
 Immune response
 in antiphospholipid antibody syndrome, 1441, 1444, 1466
 in autoimmune disorders and HTLV-I, 1410
 MTX and, 1951
 in RA, 110, 125, 446, 454
 silicone immunology and, 1615, 1619
 in SLE, 9, 23, 1664
 Immunity, cellular and humoral, MTX and, 1951
 Immunization, vascular injury in SLE and, 9
 Immunoassay, anticardiolipin, ELISA and, for anti- β_2 -glycoprotein I, 1606
 Immunoconjugates, anti-CD5, in RA, 1102
 Immunodeficiency, autoimmunity and, 179
 Immunofluorescence, intravenous immunoglobulins in SLE and, 704
 Immunogenetics
 anti-U1 RNA antibodies in connective tissue disease and, 1265
 Mi-2 autoantibodies, HLA-DR and, in DM, 868
 RA and, 152
 ribosomal P autoantibodies in SLE and, 1833
 SSc and, 152, 1151
 Immunoglobulins
 α_v /CD18 leukointegrin and, 1913
 antiphospholipid antibody syndrome and, 1441, 1444, 1466
 in IgA multiple myeloma, Henoch-Schönlein purpura/polyarteritis nodosa, 698
 intravenous, 704, 1027
 in RA, 638, 1371, 1499
 risk of lymphoma in primary Sjögren's syndrome and, 767
 Immunohistology in hypercalcemia and SLE, 2066
 Immunology
 of antiphospholipid antibody syndrome, 1441, 1444, 1466
 autoantibodies to glycyl-transfer RNA synthetase in myositis and, 146
 autoimmune disorders, HTLV-I and, 1410
 hepatitis C virus in sicca syndrome and, 1166
 HLA alleles in Sjögren's syndrome and, 1733
 human synovial mast cells and, 1222
 IL-1, articular cartilage and, 478
 maternal-fetal, autoimmune disease and, 191
 of MTX, 1951
 of shoulder synovitis in polymyalgia rheumatica, 1199
 silicone breast implants and, 1615, 1619
 Immunopathology, neuropsychological deficits in SLE without central nervous system disease and, 2035
 Immunoreactivity
 hepatocyte growth factor and, 1566
 nucleotide pyrophosphohydrolase in human serum and, 252
 Immunoregulation, IL-10 in RA and, 386
 Immunosuppressive drugs
 acute musculoskeletal symptoms and, 1
 hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 mortality in rheumatoid vasculitis and, 266
 in RA, 325, 1016
 in SLE, 704, 1840
 Implant removal, revision total hip arthroplasty and, 1939
 Impotence, glucocorticoid-induced osteoporosis and, 1791
 In situ hybridization, to study cytokine mRNA in *Staphylococcus aureus* arthritis, 959
 Indian Health Services, SSc, Amerindian HLA haplotype and, 1362

Indomethacin, enteropathy and chronic anemia in RA induced by, 321
Inducible lymphocyte antigen, fibroblast-like synoviocytes in RA and, 1781

Infection

acute musculoskeletal symptoms and, 1
Amerindian HLA haplotype, SSc and, 1362
after cyclophosphamide and corticosteroids in SLE, 1475
cytokine mRNA in *Staphylococcus aureus* arthritis and, 959
genital, reactive arthritis and, 1172
group A streptococcal, musculoskeletal manifestations of, 1260
hepatitis C virus, 1074, 1166
HIV, 1437
HTLV-I, 610, 1410
molecular diagnosis of venereal arthritis and, 950
mortality in rheumatoid vasculitis and, 266
opportunistic, hydroxychloroquine and, in AIDS and arthritis, 157
in RA, 272, 463, 638, 723, 1016, 1027, 1437
revision total hip arthroplasty and, 1939
thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773

Infectious gastroenteritis, nitric oxide in RA and, 643

Infertility, glucocorticoid-induced osteoporosis and, 1791

Inflammation

acute, MTX and, 1951
anti-endothelial antibodies in Wegener's granulomatosis and, 758
autoimmune disorders, HTLV-I and, 1410
in Behçet-type vasculopathy without Behçet's disease, 1926
in collagen arthritis, 495, 797, 1545
crystal-induced, 1, 1192, 1319
cytokines and, 959, 1703
direct gene delivery to synovium and, 820
fibronectin in articular cartilage and, 567
glomerular, nephritogenic autoantibodies in lupus and, 894
human chondrocyte integrins in SF and, 1430
hydroxychloroquine and, in AIDS and arthritis, 157
joint, 125, 216, 552, 713, 1371, 1961, 1970
lymphocyte-fibroblast adhesion and, 226
manoalide in IL-1 α arthritis and, 1292
matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
matrix metalloproteinase 9 in giant cell arteritis and, 1747
in OA, 357
pain and, 357
in RA, 183, 257, 321, 643, 713, 829, 844, 904, 914, 1077, 1693, 1781, 1808, 1934, 1970
in rat adjuvant arthritis, 504, 810
revision total hip arthroplasty and, 1939
sexually transmitted diseases, reactive arthritis and, 1172
silicone breast implants and, 1615, 1619
synovial, 183, 335, 904, 1077
T cells and, in psoriatic arthritis, 137
thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773
transcription factor NF- κ B in, 583

Inflammatory arthritis

AIDS and, hydroxychloroquine in, 157
matrix metalloproteinase 9 in RA and, 1576
molecular diagnosis of venereal arthritis and, 950
primary, acute musculoskeletal symptoms and, 1

Inflammatory arthropathy, chronic, 137, 1410

Inflammatory bowel disease, pyoderma gangrenosum, spondylarthropathy and, 1062

Inflammatory cells, MTX and, 1951

Inflammatory infiltrates, α_v /CD18 leukointegrin and, 1913

Inflammatory joint disease, acute musculoskeletal symptoms and, 1

Inflammatory myopathy

autoantibodies against muscle-cell membrane proteins in, 1860

Inflammatory myopathy (cont'd)

idiopathic, carnitine in muscle in, 1869

Inflammatory vasculopathy, vascular injury in SLE and, 9

Injectable IL-1 receptor antagonist, human, 1092, 1535

Injectable IL-1 α , human recombinant, manoalide and, 1292

Insulin-like growth factor

in the arthritic joint, 1556

in OA chondrocytes, 968

Integrins

α_v /CD18, 1913

human chondrocyte, in inflammatory SF, 1430

Inter- α -inhibitor, TSG-6 in articular chondrocytes and, 552

Intercellular adhesion molecule 1 (ICAM-1)

α_v /CD18 leukointegrin and, 1913

anti-endothelial antibodies in Wegener's granulomatosis and, 758

lymphocyte-fibroblast adhesion and, 226

in RA, 1082, 1970

in rat adjuvant arthritis, 810

synovial endothelial cells and, 467

Intercellular adhesion molecule 2 (ICAM-2), synovial endothelial cells and, 467

Intercellular adhesion molecule 3 (ICAM-3), α_v /CD18 leukointegrin and, 1913

Intercellular matrix, matrix metalloproteinase 9 in giant cell arteritis and, 1747

Interferon- γ (IFN- γ)

CD80/CD86 in chronic arthritis and, 1287

corticosteroids, antibiotics and, in *Staphylococcus aureus* arthritis, 1596

cytokine mRNA and, 959, 1376

lymphocyte-fibroblast adhesion and, 226

in RA, 125, 1961

in SLE, 379, 600

Interleukin-1 (IL-1)

cartilage and, 478, 829

chondrocytes, metalloproteinase activation and, 709

in collagen arthritis, 495, 1545

collagenase, adenosine and, 923

matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574

MTX and, 1951

in RA, 257, 1781

receptor antagonist, 478, 797, 820, 1092

in Sjögren's syndrome, 195

vascular injury in SLE and, 9

Interleukin-1 α (IL-1 α)

arthritis induced by, manoalide and, 1292

cartilage and, 478, 539

in collagen arthritis, 797

recombinant human IL-1 receptor I in active RA and, 257

Interleukin-1 β (IL-1 β)

all-*trans*-retinoic acid in POEMS syndrome and, 1423

anti-endothelial antibodies in Wegener's granulomatosis and, 758

autoimmune disorders, HTLV-I and, 1410

cartilage and, 478, 539

in collagen arthritis, 797

cytokine mRNA in *Staphylococcus aureus* arthritis and, 959

hepatocyte growth factor in inflammatory arthritis and, 1566

lymphocyte-fibroblast adhesion and, 226

MTX and, 1951

in RA, 125, 386, 1693

TSG-6 in articular chondrocytes and, 552

Interleukin-2 (IL-2)

IL-10 and, 379, 386

mRNA and, in Sjögren's syndrome, 1376

in RA, 1277, 1961

receptors, in childhood-onset scleroderma, 1041

- Interleukin-2 (IL-2) (*cont'd*)
in SLE, 600, 1840
- Interleukin-4 (IL-4)
cytokine mRNA and, 959, 1376
IL-10:IFN γ -secreting cells in SLE and, 379
in RA, 829, 1693, 1961
- Interleukin-5 (IL-5) mRNA in Sjögren's syndrome and, 1376
- Interleukin-6 (IL-6)
all-*trans*-retinoic acid in POEMS syndrome and, 1423
anti-endothelial antibodies in Wegener's granulomatosis and, 758
hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
IL-10:IFN γ -secreting cells in SLE and, 379
in polymyalgia rheumatica, 1264
serum, SK&F 106615 in rat adjuvant arthritis and, 504
in Sjögren's syndrome, 195, 1376
T cells, bacterial superantigens and, in RA synoviocytes, 125
TIMP-1, oncostatin M and, in articular cartilage, 560
- Interleukin-8 (IL-8)
anti-endothelial antibodies in Wegener's granulomatosis and, 758
T cells, bacterial superantigens and, in RA synoviocytes, 125
- Interleukin-10 (IL-10)
in collagen arthritis, 495
cytokine mRNA and, 959, 1376
in RA, 386, 829
in Sjögren's syndrome, 195
- Interleukin-11 (IL-11), TIMP-1, oncostatin M and, in articular cartilage, 560
- Interleukin-12 (IL-12), cytokine mRNA and, 959, 1376
- Interleukin-13 (IL-13) in RA, 1693
- Interlobar artery, renal vascular damage in SSc and, 1030
- International Kidney Biopsy Registry, renal effects of cyclosporine in RA, 1491
- International League Against Rheumatism (ILAR), response criteria for RA, 34
- International Symposium on Sjögren's Syndrome (Fifth), 195
- Interphalangeal joints
distal, OA in, 308
proximal, 162, 308
- Interphase cells, mitotic spindle apparatus and, 1643
- Interstitial collagenase, matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
- Interstitial lung disease
in RA, 1711
tRNA and, 146, 1308
- Interstitial nephritis, drug therapy in RA and, 723
- Intestinal pseudoobstruction, chronic, anti-PCNA in, 877
- Intimal lining, fibroblast-like synoviocytes in RA and, 1781
- Intraarticular corticosteroids, bone and, in RA, 277
- Intraarticular IL-1 receptor antagonist in experimental OA, 1535
- Intraarticular IL-1 α , human recombinant, manolide and, 1292
- Intraarticular tophi in the knee in gout, CT of, 1406
- Intracellular proteins, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Intramuscular gold in RA, 616
- Intratracheal dilation in subglottic stenosis in Wegener's granulomatosis, 1754
- Intravenous antithymocyte globulin in SSc, 1132
- Intravenous corticosteroids, high-dose, in focal myositis and MCTD, 1254
- Intravenous cyclophosphamide, corticosteroids, infection and, in SLE, 1475
- Intravenous immunoglobulins
in RA, 1027
in SLE, 704
- Intravenous MTX, disease remission in generalized Wegener's granulomatosis and, 2052
- Intravenous pulse methylprednisolone, in RA, 216, 1970
- Intronic sequences, $\alpha 1(I)$ procollagen gene in SSc dermal fibroblasts and, 1347
- Iritis, acute musculoskeletal symptoms and, 1
- Iron overload, in ACR guidelines for adults with acute musculoskeletal symptoms, 1767
- Irradiation
focal bone lesion, all-*trans* retinoic acid in POEMS syndrome and, 1423
ultraviolet A, in photopheresis of psoriatic arthritis, 1519
- Ischemia
cardiac involvement in limited SSc and, 1138
vascular injury in SLE and, 9
- Isoforms
anti-CD45 autoantibodies in SLE and, 592
anticytokine treatment of collagen arthritis and, 797
- Isometric exercise, pain and, in RA and OA, 357
- Isoprostane, free radical injury in scleroderma and, 1146
- Isoprotein, serum apolipoprotein E4, in RA and amyloidosis, 1728
- Isotypes in SLE, 9
- Isozymes, T cells in lupus and, 23

J

- J $\beta 2.1$ gene, T cells in RA and, 446
- Joints
acute musculoskeletal symptoms and, 1
ankle, antibiotics in reactive arthritis and, 1238
anticytokine treatment of collagen arthritis in DBA/1 mice and, 797
counts of, 357, 403, 623, 1006, 1773
damage to, 713, 1006
destruction of, 162, 183, 204, 1566, 1703, 1781, 2070
detection of *Chlamydia trachomatis* in, by polymerase chain reaction, 1740
diarthrodial, 914
direct gene delivery to synovium and, 820
diseases of, 1, 357, 988, 1327, 1990
erosion of, 1006
fibronectin in articular cartilage and, 567
finger, 308, 325, 1524
hip, 988, 1939
inflammation of, 125, 216, 552, 713, 1319, 1371, 1566, 1677, 1970
insulin-like growth factor and, 1556
interphalangeal, 162, 308
knee, 820, 1406, 1545
metacarpophalangeal, 162, 308
metatarsophalangeal, 162
MTX in fibroblastic rheumatism and, 2070
in OA, 308, 357, 539, 648, 988
pain in, 711, 713, 1027, 1435, 2013, 2021
patellofemoral, 988
peripheral, sulfasalazine in AS and, 2004
in psoriatic arthritis, 137, 1519
in RA, 53, 125, 162, 183, 216, 357, 397, 454, 539, 713, 904, 914, 1006, 1027, 1077, 1082, 1092, 1781, 1808, 1818, 1970
in rat adjuvant arthritis, 504, 810
rheumatoid, IL-10 and, 386
shoulder, 1435
in silicone immunology, 1615, 1619
small, in early undifferentiated connective tissue disease, 403
space, 308, 648, 988
stifle, 1234, 1327
swelling of, 257, 415, 623, 1027, 1071, 1092, 1818, 2013, 2021
synovial, 1082
tenderness of, 216, 623, 1027, 2013, 2021
TGF β in MSU crystal-induced inflammation and, 1192
tibiofemoral, 988
- Jugular vein in focal myositis and MCTD, 1254

Juvenile rheumatoid arthritis (JRA)
 bone mineral metabolism in, 746
 cytokines in, 1703
 oligoarticular, autoreactivity to heat-shock protein 60 in, 1826
 oral type II collagen in, 623
 pain and, 357
 pauciarticular, 1703
 in Rochester, Minnesota, 1385
 Juvenile spondylarthropathy, cytokines in, 1703

K

Kawasaki disease
 face in, 2078
 L-selectin and coronary artery lesions in, 534
 pediatric, in adult rheumatology practices, 1218
 Kellgren score, bone mineral density, bone loss, age and, in OA, 81
 Keratan sulfate, antibodies to aggrecan in SF and, 1990
 Keratoconjunctivitis sicca in Sjögren's syndrome, 297
 Ki antigen epitope homology, SV40 large T antigen nuclear localization signal and, 855
 Kidney
 in cryoglobulinemia, 335
 nucleotide pyrophosphohydrolase in articular cartilage and, 245
 in renal vascular damage in SSc, 1030
 vascular injury in SLE and, 9
 Kinase
 creatine, in focal myositis and MCTD, 1254
 protein, 23, 552
 nucleotide pyrophosphohydrolase in human serum and, 252
 src-related tyrosine, matrix metalloproteinase 1 activation by, 574
 synovial endothelial cell adhesion molecules and, 467
 Kinesin-like protein
 centromere, CENP-E, in SSc, 1355
 spindle, HsEg5, in SLE, 1635
 Knee
 calcific constrictive pericarditis in CREST syndrome and, 347
 CT of, in gout, 1406
 joint, 216, 820, 1545
Mycobacterium kansasii septic arthritis in, in AIDS, 881
 OA, 81, 648, 887, 988
 pain, 1, 1244
 replacement, 357
 Rocky Mountain spotted fever with monarticular arthritis in, 175

L

Labial salivary gland in Sjögren's syndrome, 783, 1376
 Laboratory tests, disease flares in SLE and, 370, 2083
 lac Z marker gene, direct gene delivery to synovium and, 820
 Lacrimal gland, biopsy of, in Sjögren's syndrome, 195
 Lactation
 colchicine in breast milk in familial Mediterranean fever and, 1213
 drug therapy in RA and, 723
 Lamina media, matrix metalloproteinase 9 in giant cell arteritis and, 1747
 Laminin, nephritogenic autoantibodies in lupus and, 894
 Large cell lymphoma in RA
 EBV clonality in, 638
 MTX and, 325
 Large joint arthritis in lowland gorilla, 891
 Large vessel thrombosis, vascular injury in SLE and, 9
 Large vessel vasculitis in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 Laser coagulation in gastric antral vascular ectasia in SSc, 341
 La/SS-B
 anti-dsDNA anti-idiotypes and, 522
 GSTM1 null alleles in SLE and, 1763

La/SS-B (cont'd)

mixed monoclonal cryoglobulinemia in primary Sjögren's syndrome and, 767
 in Sjögren's syndrome, 783
 Lavage fluid, manolide in IL-1 α -induced arthritis and, 1292
 Learning, neuropsychological deficits in SLE without central nervous system disease and, 2035
 Lectins
 concanavalin A, in silicone immunology, 1615, 1619
 T cells, bacterial superantigens and, in RA synoviocytes, 125
 Lentiviruses, HTLV-I, autoimmune disorders and, 1410
 Lesions
 antral vascular, in gastric antral vascular ectasia in SSc, 341
 bone, 1327, 1423
 cartilage, 1535
 coronary artery, L-selectin and, in Kawasaki disease, 534
 IL-1 receptor antagonist in experimental OA and, 1535
 skin, cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
 in SLE, 9, 663, 2078
 Leucine, ribosomal P autoantibodies in SLE and, 1833
 Leukemia
 HTLV-I, 535, 1410
 thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome, 773
 Leukemia inhibitory factor, TIMP-1, oncostatin M and, in articular cartilage, 560
 Leukocytes
 anti-endothelial antibodies in Wegener's granulomatosis and, 758
 mononuclear, T cells in lupus and, 23
 MTX and, 1951
 in RA, 1082, 1576
 in shoulder synovitis in polymyalgia rheumatica, 1199
 synovial endothelial cell adhesion molecules and, 467
 Leukocytoclastic vasculitis
 cold-induced, in monoclonal cryo-antifibrinogenemia, 1066
 cutaneous, after MTX and azathioprine in RA, 1016
 Leukocytosis after MTX and azathioprine in RA, 1016
 Leukointegrins, α_4 /CD18, synovial distribution of, 1913
 Leukonychia, transverse, 151
 Leukopenia, drug therapy in RA and, 723
 Leukosequestration, pulmonary, vascular injury in SLE and, 9
 Leukotriene
 B₄, 515, 1951
 C₄, in human synovial mast cells, 1222
 MTX and, 1951
 Lewis rats
 antibiotics in reactive arthritis in, 1238
 SK&F 106615 in adjuvant arthritis in, 504
 LFA-1, adhesion molecules and, in adjuvant arthritis, 810
 Libman-Sacks endocarditis, vascular injury in SLE and, 9
 Ligaments, cruciate, 245, 1327, 1535
 Ligands
 α_4 /CD18 leukointegrin and, 1913
 T cells and, 23, 125, 137
 Light-headedness, from MTX, 1951
 Limited scleroderma
 cardiac involvement in, 1138
 cutaneous, 347, 1439
 free radical injury in, 1146
 nRNP in, 1669
 Linear SSc and linear morphea, childhood-onset scleroderma and, 1041
 Lip biopsy
 in early pathologic analysis in SSc, 1161
 human autoantibodies to the mitotic apparatus and, 1643

Lipids

- carnitine in muscle in idiopathic inflammatory myopathy and, 1869
- free radical injury in scleroderma and, 1146
- human synovial mast cells and, 1222
- MTX and, 1951

Lipopolysaccharides

- macrophage depletion in collagen arthritis and, 1545
- osteonectin in cartilage and, 539

Liposomes

- direct gene delivery to synovium and, 820
- macrophage depletion in collagen arthritis and, 1545

Livedo reticularis, systemic vasculopathy in multiple myeloma and, 330

Liver

- acute musculoskeletal symptoms and, 1
- in adjuvant arthritis and collagen arthritis, 1677
- antibiotics in reactive arthritis and, 1238
- drug therapy in RA and, 723
- NSAIDs, mitochondrial uncoupling and, 1998
- nucleotide pyrophosphohydrolase in articular cartilage and, 245

Localized scleroderma, childhood-onset, 1041

Loosening, aseptic, revision total hip arthroplasty and, 1939

Low-dose corticosteroids in RA, 1808

Low-dose cyclosporine in early RA, 1006

Low-dose glucocorticoids in RA, 713, 723

Low-dose intravenous immunoglobulin in refractory RA, 1027

Low-dose MTX

- effect of, on mouse bone cells, 489
- in fibroblastic rheumatism, 2070
- intravenous, disease remission in generalized Wegener's granulomatosis and, 2052
- molecular therapeutics and, 1951
- pulse, 171, 272

Lower extremities

- distal swelling of, pitting edema and, in polymyalgia rheumatica, 73
- in revision total hip arthroplasty, 1939

L-selectin, in Kawasaki disease with coronary artery lesions, 534

Luciferase reporter gene, matrix metalloproteinase 1 activation by src-related tyrosine kinases and, 574

Lumbar spine

- bone mass, pamidronate and, in RA, 397
- glucocorticoid-induced osteoporosis and, 1791
- revision total hip arthroplasty and, 1939

Lung

- antibiotics in reactive arthritis and, 1238
- cancer, anti-topo I and, in SSc, 686
- fibrosis of, 692, 1074
- human synovial mast cells in, 1222
- interstitial disease of, 146, 1308, 1711
- Mi-2 autoantibodies, HLA-DR and, in DM, 868
- nucleotide pyrophosphohydrolase in articular cartilage and, 245
- scleroderma lung disease, 180
- vascular injury in SLE and, 9
- Wegener's granulomatosis of, 615

Lupus

- See also Systemic lupus erythematosus
- antigen-presenting cell function in, 600
- complement split products and disease activity in, 1178
- HLA type, anti-U1 RNP and, 939
- Ki antigen epitope homology in, 855
- monocyte apoptosis in, 1432
- nephritogenic autoantibodies in, 894
- neuropsychological deficits in, without central nervous system disease, 1035
- T cells in, 23
- Lupus anticoagulant, immunology of antiphospholipid antibody syndrome and, 1441, 1444, 1466

Lupus nephritis

- complement split products, disease activity and, 1178
- cyclophosphamide and, 2028
- nephritogenic autoantibodies in, 894

Lupus psychosis, anti-P and, 1483

Lupus vasculitis, vascular injury in SLE and, 9

Lyme arthritis, *Borrelia burgdorferi* DNA in synovium and, 736

Lymph nodes

- acute musculoskeletal symptoms and, 1
- in adjuvant arthritis, 204, 1677
- in collagen arthritis, 1677
- hypercalcemia, SLE and, 2066
- mesenteric, antibiotics in reactive arthritis and, 1238
- in RA, 183, 325

Lymphadenopathy, generalized, hypercalcemia, SLE and, 2066

Lymphocyte antigens, inducible, fibroblast-like synoviocytes in RA and, 1781

Lymphocytes

- adhesion of, synovial fibroblasts and, 226
- adhesion molecules in adjuvant arthritis and, 810
- α_v /CD18 leukointegrin in, 1913
- apoptosis, apoptosis-associated genes and, in Sjögren's syndrome, 1875
- B. See B cells
- cytokines and, in JRA and juvenile spondylarthropathy, 1703
- HTLV-I DNA in PM/DM and, 535
- MTX and, 1951
- in psoriatic arthritis, 137
- in RA, 52, 115, 844, 1082
- silicone immunology and, 1615, 1619
- in Sjögren's syndrome, 783, 1376
- in SLE, 370, 592
- T. See T cells

Lymphocytic infiltrates

- focal, in Sjögren's syndrome, 195
- HTLV-I, autoimmune disorders and, 1410

Lymphoid aggregates

- CD86, CD28 and, in RA synovium, 110
- transcription factor nuclear factor- κ B and, 583

Lymphoid tissue, hypercalcemia, SLE and, 2066

Lymphoma

- HTLV-I in PM/DM, 535
- in RA, 325, 638, 723
- in Sjögren's syndrome, 297
- in SLE, 1050

Lymphoproliferation, T cells in RA and, 904

Lymphoproliferative disorders, MTX-associated lymphoma in RA and, 325

Lysozymes, tear fluid and, in Sjögren's syndrome, 297

Lysyl oxidase, collagen degradation and, 1455

Lysylpyridinoline, collagen degradation and, 1455

Lysyl-transfer RNA, in antisynthetase syndrome, 692

M

Mac-1

- adhesion molecules and, in adjuvant arthritis, 810
- α_v /CD18 leukointegrin in, 1913

Macaque studies, rheumatic diseases and HTLV-I, 610

Macrophage-like cells, fibroblast-like synoviocytes in RA and, 1781

Macrophages

- adhesion molecules in adjuvant arthritis and, 810
- α_v /CD18 leukointegrin in, 1913
- CD80/CD86 in chronic arthritis and, 1287
- cytokines in *Staphylococcus aureus* arthritis and, 959
- hepatocyte growth factor in inflammatory arthritis and, 1566
- in RA, 110, 115, 183, 386, 836, 1576, 1693
- in shoulder synovitis in polymyalgia rheumatica, 1199

- Macrophages (cont'd)**
in *Staphylococcus aureus* arthritis in mice, 1596
T cells in lupus and, 23
- Macropinocytosis, self peptides, dendritic cells and, in RA, 183**
- Magnetic resonance imaging**
acute musculoskeletal symptoms and, 1
in dactylitis in seronegative spondylarthropathy, 1524
in degenerative joint disease in the guinea pig, 1327
in pyomyositis, 1760
- Major histocompatibility complex**
antifibrillarin in SSc and, 1151
class II, 125, 195, 1507
molecules, self peptides, dendritic cells and, in RA, 183
in Sjögren's syndrome, 195
in SLE, 23, 1833
- Malaise**
acute musculoskeletal symptoms and, 1
in Wegener's granulomatosis of the lungs, 615
- Malar rash, HLA type, anti-U1 RNP and, 939**
- Malignancy**
acute musculoskeletal symptoms and, 1
in SLE, 1050, 2066
- Malignant B cells, EBV clonality in lymphomas in RA and, 638**
- Malignant hypertension, acute, in cryocryoglobulinemia, 335**
- Malignant lymphoma, in Sjögren's syndrome, 297**
- Mammoplasty, augmentation, 1125, 1615, 1619, 1771, 1765**
- Mannose-binding protein, in SLE, 706, 2046**
- Manoalide, in IL-1 α -induced arthritis, 1292**
- Marrow**
nucleotide pyrophosphohydrolase in articular cartilage and, 245
suppression, MTX and, 1951
- Mast cells**
in early pathologic analysis in SSc, 1161
human synovial, 1222
- Mastocytoma cells, antigen-presenting cell function in SLE and, 600**
- Maternal-fetal immunology, autoimmune disease and, 191**
- Matrix**
antinuclear antibody, 1300
calcified, effect of MTX on mouse bone cells and, 489
collagen, effect of nitric oxide on chondrocytes and, 1905
extracellular, 1781, 1905
glucocorticoid-induced osteoporosis and, 1791
intercellular, 1747
metalloproteinase, 560, 884, 923, 1234, 1455, 1576, 1747, 1781
- Medical education, rheumatology in, 887, 1218**
- Mediterranean spotted fever, arthritis and, 2088**
- Mees' lines, 151**
- Memory T cells, in RA, 844**
- Meningococcal sepsis, vascular injury in SLE and, 9**
- Meniscus, nucleotide pyrophosphohydrolase in articular cartilage and, 245**
- Menstrual history, glucocorticoid-induced osteoporosis and, 1791**
- Mesenchymal cells, fibroblast-like synoviocytes in RA and, 1781**
- Mesenteric circulation, vascular injury in SLE and, 9**
- Mesenteric lymph nodes, antibiotics in reactive arthritis and, 1238**
- Messenger RNA**
in cartilage, 539, 560, 567
CD80/CD86 in chronic arthritis and, 1287
in collagen arthritis, 797, 1545
collagenase, adenosine and, 923
cytokines in *Staphylococcus aureus* arthritis and, 959
HTLV-I, autoimmune disorders and, 1410
lymphocyte-fibroblast adhesion and, 226
manoalide in IL-1 α -induced arthritis and, 1292
matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
matrix metalloproteinase 9 in giant cell arteritis and, 1747
- Messenger RNA (cont'd)**
nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
in OA, 968, 1535
in RA, 386, 1021, 1693
in Sjögren's syndrome, 773, 1376, 1875
in SSc fibroblasts, 1338, 1347
synovial endothelial cell adhesion molecules and, 467
transcription factor NF- κ B, TNF α and, 197
TSG-6 in articular chondrocytes and, 552
- met gene, hepatocyte growth factor in inflammatory arthritis and, 1566**
- Meta-analysis of low-dose corticosteroids in RA, 1808**
- Metabolic bone disease, collagen degradation and, 1455**
- Metabolism**
bone mineral, in JRA, 746
colchicine in breast milk in familial Mediterranean fever and, 1213
polyphosphoinositide, T cells in lupus and, 23
protein, aging and, in RA, 1115
- Metacarpophalangeal joints**
erosion healing, DMARDs and, in RA, 162
in OA, 308
- Metalloproteinase**
activation of, chondrocytes, IL-1 and, 709
N-[4-hydroxyphenyl] retinamide and, in RA, 1021
IL-1 receptor antagonist in experimental OA and, 1535
matrix, 560, 884, 923, 1234, 1747, 1781
TIMP-1, articular cartilage and, 478, 560
- Metatarsophalangeal joints, erosion healing, DMARDs and, in RA, 162**
- Methionine, MTX and, 1951**
- Methotrexate (MTX)**
disease remission in generalized Wegener's granulomatosis and, 2052
effect of, on mouse bone cells, 489
low-dose, 171, 272, 489, 1951, 2052, 2070
molecular therapeutics and, 1951
pulse, 171, 272
in RA, 272, 325, 616, 713, 723, 1016, 1115, 1435, 1436, 1608
- Methylation reaction, MTX and, 1951**
- Methylprednisolone in RA, 216, 1970**
- Metronidazole in NSAID enteropathy and chronic anemia in RA, 321**
- Mi-2 in DM, 868, 1769**
- Microangiopathic hemolytic anemia, vascular injury in SLE and, 9**
- Microchimerism, maternal-fetal immunology, autoimmune disease and, 191**
- Microcrystalline synovial inflammation, granulomatous, in cryocryoglobulinemia, 335**
- Micronutrients, antioxidant, in knee OA, 648**
- Microorganisms, molecular diagnosis of venereal arthritis and, 950**
- Microsatellite polymorphism, TNF, in RA, 1109**
- Microscopic polyangiitis, polyarteritis nodosa and, 1208**
- Minocycline, HLA-DRB1 genes, disease severity and, in RA, 1802**
- Minor salivary gland biopsy in Sjögren's syndrome, 195**
- Mitochondrial function, carnitine in muscle in idiopathic inflammatory myopathy and, 1869**
- Mitogens**
hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
matrix metalloprotein 1 collagenase gene, activation of, by *src*-related tyrosine kinases and, 574
T cells and, 23, 125
TGF β 1 and apoptosis in rheumatoid synovial cells, 1267
- Mitotic spindle apparatus**
human autoantibodies to, 1643
kinesin-like protein, HsEg5 in SLE and, 1635
- Mitral regurgitation in limited SSc, 1138**
- Mixed connective tissue disease (MCTD)**
focal myositis and, 1254
heterogeneous nuclear RNP in SSc and, 1669

- Mixed connective tissue disease (MCTD) (*cont'd*)
 pravastatin-induced rhabdomyolysis in, 1259
 Mixed monoclonal cryoglobulinemia in primary Sjögren's syndrome, 767
 Modified Health Assessment Questionnaire, Spanish-language, 93
 Molecular biology, T cells in lupus and, 23
 Molecular diagnosis of venereal arthritis, 950
 Molecular lesions, hereditary C1q deficiency in SLE and, 663
 Molecular markers in hemostasis in SLE, 287
 Molecular therapeutics, MTX and, 1951
 Monarthralgia, acute musculoskeletal symptoms and, 1
 Monarthritis
 molecular diagnosis of venereal arthritis and, 950
 in *Mycobacterium kansasii* septic arthritis in AIDS, 881
 Monarticular arthritis, Rocky Mountain spotted fever presenting with, 175
 Monoclonal antibodies
 α_v /CD18 leukointegrin and, 1913
 anti-CD3, 600, 1773, 1840
 anti-CD4, 52
 anti-Fc receptor, 600
 anti-IL-10, 386
 antiphospholipid, germline V_H genes and, 537
 anti-T cell receptor γ/δ V65 in rat adjuvant arthritis, 204
 cytokines and, in JRA and juvenile spondylarthropathy, 1703
 in matrix metalloproteinase 9 in giant cell arteritis, 1747
 osteonectin in cartilage and, 539
 in RA, 110, 115, 125, 181, 386, 1077, 1082, 1277, 1371, 1576
 in shoulder synovitis in polymyalgia rheumatica, 1199
 in Sjögren's syndrome, 767, 783
 in SLE, 287, 600, 792, 894, 1613, 1980
 in synovial cell adhesion on EDA-containing fibronectin, 1683
 transcription factor NF- κ B and, 583
 Monoclonal cryo-antifibrinogenemia, 1066
 Monoclonal cryoglobulinemia, mixed, in primary Sjögren's syndrome, 767
 Monoclonal gammopathy, cryocryoglobulinemia and, 335
 Monoclonal IgA κ , in multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 Monoclonal protein, all-*trans*-retinoic acid in POEMS syndrome and, 1423
 Monocytes
 anti-endothelial antibodies in Wegener's granulomatosis and, 758
 cytokines in *Staphylococcus aureus* arthritis and, 959
 in RA, 257, 836
 in SLE, 23, 379, 1432
 TGF β 1 in MSU crystal-induced inflammation and, 1192
 Mononeuritis multiplex, acute musculoskeletal symptoms and, 1
 Mononuclear cells
 autoreactivity to heat-shock protein 60, disease remission and, in oligoarticular JRA, 1826
 in RA, 110, 386, 829, 1277, 1693, 1961
 in SLE, 379, 600, 1840
 thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773
 Mononuclear leukocytes, T cells in lupus and, 23
 Monosodium urate crystals (MSU)
 acute musculoskeletal symptoms and, 1
 TGF β 1 in inflammation induced by, 1192
 Monozygotic twins
 CD56 cells in SLE and, 1840
 cigarette smoking, risk of RA and, 732
 Morbidity
 in depression in scleroderma, 1035
 mortality in rheumatoid vasculitis and, 266
 Morphogenetic protein-7, bone, on human articular chondrocytes, 1896
 Morphology
 CD86, CD28 and, in synovium in RA, 110
 vascular injury in SLE and, 9
 Mortality
 in epidemiology of Wegener's granulomatosis, 87
 in *Staphylococcus aureus* arthritis in mice, 1596
 in fibromyalgia, 682
 long-distance running, musculoskeletal pain, aging and, 64
 in RA, 272, 723
 in rheumatoid vasculitis, 266
 in SSc, 677, 686
 Mouse studies
 See also AKR/J-*lpr/lpr* mice, C3H-*lpr/lpr* mice, DBA/1 mice, MRL-*lpr* mice, MRL-*lpr/lpr* mice, Newborn mice, (NZB \times NZW)F $_1$ mice
 air pouch model, leukotriene synthesis inhibitors in inflammation and, 515
 macrophage depletion in collagen arthritis, 1545
 as a model for human Wegener's granulomatosis, 1262
 MTX and, 489, 1951
 of SLE, 23, 600, 894
 Staphylococcus aureus, 959, 1596
 MRL-*lpr* mice, nephritogenic autoantibodies in lupus and, 894
 MRL-*lpr/lpr* mice, T cells in lupus and, 23
 Mucosal damage, NSAID, mitochondrial uncoupling and, 1998
 Mucositis, drug therapy in RA and, 723
 Multicentric reticulohistiocytosis, steroids, cyclophosphamide and MTX in, 171
 Multi-organ dysesthesia, fibromyalgia and, 180
 Multiple myeloma, systemic vasculopathy in, 330
 Muscarinic type III cholinergic agonists in Sjögren's syndrome, 195
 Muscle
 acute musculoskeletal symptoms and, 1, 1767
 biopsy, in rheumatoid vasculitis, 1937
 carnitine in, in idiopathic inflammatory myopathy, 1869
 fibromyalgia, disability and, 1627
 HTLV-I, autoimmune disorders and, 1410
 papillary, in cardiac involvement in limited SSc, 1138
 smooth, matrix metalloproteinase 9 in giant cell arteritis and, 1747
 weakness, glucocorticoid-induced osteoporosis and, 1791
 Muscle-cell membrane proteins, autoantibodies and, in myositis, 1860
 Musculoskeletal conditions, economic cost and social and psychological impact of, 1931
 Musculoskeletal involvement
 barrier to return to work due to, 101
 disease exacerbations and, in SLE, 370
 in early undifferentiated connective tissue disease, 403
 in group A streptococcal infection, 1260
 management of RA and, 713
 pain, running, age and, 64
 in polymyalgia rheumatica, 73, 1199
 Musculoskeletal symptoms
 acute, guidelines for evaluation of in adults, 1, 1767
 in chronic arthropathy after rubella vaccine, 1529
 Mutations
 codon 54, mannose-binding protein in SLE in Chinese and, 706
 T cells in lupus and, 23
 Myalgia
 acute musculoskeletal symptoms and, 1
 chronic arthropathy after rubella vaccine and, 1529
 psychiatric diagnosis in fibromyalgia and, 2086
 Mycobacteria
 silicone immunology and, 1615, 1619
 in synovial tissue in RA, 2080
Mycobacterium bovis heat-shock protein, nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
Mycobacterium kansasii septic arthritis in AIDS, 881

Mycobacterium tuberculosis, γ/δ T cells and, in rat adjuvant arthritis, 204
 Myeloma, multiple, 330, 698
 Myelopathy
 acute, acute musculoskeletal symptoms and, 1
 caused by ossification of the posterior longitudinal ligament in AS, 2074
 Myelosuppression, drug therapy in RA and, 723
 Myopathy
 autoantibodies against muscle-cell membrane proteins in, 1860
 glucocorticoid-induced osteoporosis and, 1791
 idiopathic inflammatory, carnitine in muscle in, 1869
 Myositis
 anti-Jo-1 antibodies in, 292
 in antisynthetase syndrome, 692
 autoantibodies in, 146, 1860
 focal, MCTD and, 1254
 major histocompatibility complex class II alleles in, 1507

N

Nabumetone, mitochondrial uncoupling and, 1998
 N-acetyl-L-cysteine, transcription factor NF- κ B, TNF α and, 197
 Nailfold involvement
 in early pathologic analysis in SSc, 1161
 Mi-2 autoantibodies, HLA-DR and, in DM, 868
 Naproxen
 enteropathy and chronic anemia in RA induced by, 321
 leukotriene synthesis inhibitor in inflammation and, 515
 in OA in lowland gorilla, 891
 Nasal septum, in neopeptide marker of skeletal maturation and aging, 1234
 Nasal spray, salmon calcitonin, in glucocorticoid-induced osteoporosis, 1791
 Nasal ulcers, acute musculoskeletal symptoms and, 1
 National Vaccine Injury Compensation Program, chronic arthropathy, rubella vaccine and, 1529
 Native American studies
 Amerindian HLA haplotype in SSc, 1362
 serology in RA, 283
 Native CD45, anti-CD45 autoantibodies in SLE and, 592
 Native type II collagen, antibodies to, in early RA, 1720
 Natural killer cells
 in shoulder synovitis in polymyalgia rheumatica, 1199
 T cells in lupus and, 23
 Nausea, oral type II collagen in RA and, 41
 Neck, in focal myositis in MCTD, 1254
 Necrolysis, toxic epidermal, sulfasalazine in psoriatic arthritis and, 711
 Necrosis
 papillary, drug therapy in RA and, 723
 subcutaneous fat, polyarthritis, pancreatic disease and, 1922
 Necrotizing glomerulonephritis, focal segmental, vascular injury in SLE and, 9
 Necrotizing vasculitis
 in RA, 1937
 in systemic vasculopathy in multiple myeloma, 330
Neisseria gonorrhoeae, molecular diagnosis of venereal arthritis and, 950
 Neopeptide marker of skeletal maturation, aging and, 1234
 Neonatal fibroblasts, heterogeneity of, in SSc, 1338
 Neoplasms, EBV clonality in lymphomas in RA, 638
 Neovascularization, synovial, hepatocyte growth factor in inflammatory arthritis and, 1566
 Nephritis
 interstitial, drug therapy in RA and, 723
 lupus, 894, 1178, 2028
 Nephritogenic autoantibodies in lupus, 894

Nephropathy
 effects of cyclosporine in RA and, 1491
 in renal vascular damage in SSc, 1030
 Nerve biopsy in rheumatoid vasculitis, 1937
 Nerve growth factor, fibroblast-like synoviocytes in RA and, 1781
 Nerves, lumbar, in revision total hip arthroplasty, 1939
 Neurologic involvement
 acute musculoskeletal symptoms and, 1
 in hepatitis C virus infection and sicca syndrome, 1166
 vascular injury and, in SLE, 9
 Neuropathy
 cranial, in hepatitis C virus infection, lung fibrosis and PM, 1074
 peripheral, in rheumatoid vasculitis, 1937
 Neuropeptides, pain and, in RA and OA, 357
 Neuroplasticity, fibromyalgia, disability and, 1627
 Neuropsychiatric SLE, anti-P in, 1483, 1833
 Neuropsychological deficits in SLE without central nervous system disease, 2035
 Neuroticism-Extraversion-Openness Personality Inventory, in depression in scleroderma, 1035
 Neurovascular examination in revision total hip arthroplasty, 1939
 Neutrophils
 fibroblast adhesion to articular cartilage and, 1072
 in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 procollagenase, doxycycline and, 235
 in RA, 216, 1576, 1970
 in shoulder synovitis in polymyalgia rheumatica, 1199
 Newborn infants, synovial endothelial adhesion molecules and, 467
 Newborn mice, effect of MTX on bone cells in, 489
 Niacin, antioxidant micronutrients in knee OA and, 648
 92-kd type IV collagenase, in giant cell arteritis, 1747
 96-kd gelatinase B, in RA, 1576
 Nitric oxide
 in adjuvant arthritis and collagen arthritis, 1677
 effect of, on chondrocytes, 1905
 in RA, 643, 1781
 vasodilatation, joint swelling and, 1071
 Nitrobutyl-flurbiprofen, mitochondrial uncoupling and, 1998
 Nodules
 acute musculoskeletal symptoms and, 1
 low-dose MTX in fibroblastic rheumatism and, 2070
 subcutaneous, in acute rheumatic fever, 2078
 Non-Hodgkin's lymphoma, in SLE, 1050
 Nonsteroidal antiinflammatory drugs (NSAIDs)
 in distal extremity swelling with pitting edema in polymyalgia rheumatica, 73
 leukotriene synthesis inhibitors in inflammation and, 515
 mitochondrial uncoupling and, 1998
 in OA, 357
 in RA, 321, 357, 616, 713, 723
 sulfasalazine and, 2004, 2013, 2021
 Nontraditional remedies for pain in RA and OA, 357
 NOR 90/hUBF nucleolar transcription factor, in rheumatic diseases, 1313
 N-terminal
 antibodies to aggrecan in SF and, 1990
 major epitope of PM-Scl autoantigen and, 1588
 Nuclear antigens
 nephritogenic autoantibodies in lupus and, 894
 proliferating cell, in chronic intestinal pseudoobstruction, 877
 Nuclear factor- κ B, 197, 583, 1410
 Nuclear mitotic apparatus
 human autoantibodies and, 1643
 kinesin-like protein, HsEg5 in SLE and, 1635
 Nuclear RNP (nRNP), heterogeneous, in SSc, 1669

Nucleic acid, for detection of *Chlamydia trachomatis* by polymerase chain reaction, 1740
 Nucleolar autoantibodies, antifibrillar in SSc and, 1151
 Nucleolar transcription factor NOR 90/hUBF, in rheumatic diseases, 1313
 Nucleosomes, nephritogenic autoantibodies in lupus and, 894
 Nucleotide pyrophosphohydrolase
 in articular cartilage, 245
 in human serum, 252
 Nucleotides
 autoantibodies, tRNA and, 1308
 hereditary C1q deficiency in SLE and, 663
 matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
 T cells in RA and, 446
 Null alleles, glutathione-S-transferase GSTM1, in SLE, 1763
 Nursing mothers, colchicine in breast milk in familial Mediterranean fever and, 1213
 (NZB \times NZW)F₁ mice, T cells in lupus and, 23

O

Occlusive vasculopathy, cryoglobulinemia and, 335
 Occupational factors, Amerindian HLA haplotype in SSc and, 1362
 Occupational therapists, Spanish-language outcome questionnaire and, 93
 Octacalcium phosphate crystals, basic calcium phosphate crystals, inflammation and, 1319
 Octapeptides, major epitope of PM-Scl autoantigen and, 1588
 OKT3, antigen-presenting cell function in SLE and, 600
 Oligoarthritis, acute musculoskeletal symptoms and, 1
 Oligoarticular JRA
 autoreactivity to heat-shock protein 60 and disease remission in, 1826
 bone mineral metabolism in, 746
 Oligoclonal T cell proliferation, in RA, 904
 Oligonucleotides, hereditary C1q deficiency in SLE and, 663
 Oligotyping
 DNA, 1362, 1507, 1833
 HLA-DRB1 genes, disease severity and, in RA, 1802
 ribosomal P autoantibodies in SLE and, 1833
 Oncogenes, fibroblast-like synoviocytes in RA and, 1781
 Oncornaviruses, HTLV-I, autoimmune disorders and, 1410
 Ophthalmology, Sjögren's syndrome and, 297
 Opioid drugs, in RA and OA, 357
 Opportunistic infection
 after cyclophosphamide and corticosteroids in SLE, 1475
 hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 Oral colchicine in breast milk in familial Mediterranean fever, 1213
 Oral corticosteroids, bone and, in RA, 277
 Oral cyclophosphamide, corticosteroids, infection and, in SLE, 1475
 Oral glucocorticoids in RA, 216, 713
 Oral gold in RA, 723
 Oral MTX, lymphoma from, in RA, 325
 Oral pamidronate, bone mass in RA and, 397
 Oral prednisolone, pulse methylprednisolone, joint neutrophils and, in RA, 216
 Oral type II collagen
 in early RA, 41
 in JRA, 623
 Oral ulcers, HLA type, anti-U1 RNP and, 939
 Organ involvement
 cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
 in fibromyalgia, 180
 HTLV-I, autoimmune disorders and, 1410
 human autoantibodies to the mitotic spindle apparatus and, 1643
 management of RA and, 713
 mortality in rheumatoid vasculitis and, 266

Organ involvement (*cont'd*)
 in Sjögren's syndrome, 297
 in SLE, 9, 1475
 in subglottic stenosis in Wegener's granulomatosis, 1754
 Organic brain syndrome, anti-P in neuropsychiatric SLE and, 1483
 Organomegaly, all-*trans*-retinoic acid in POEMS syndrome and, 1423
 Orogenital ulcers, in Behçet-type vasculopathy without Behçet's disease, 1926
 Osteoarthritis
 acute musculoskeletal symptoms and, 1
 α_v /CD18 leukointegrin in, 1913
 bone mineral density, bone loss and age in, 81
 collagen degradation and, 1455
 experimental, IL-1 receptor antagonist in, 1535
 of the finger joints, 308
 in the guinea pig, 1327
 of the hip, 2083
 hepatocyte growth factor in, 1566
 hip, 81, 357, 988, 2083
 insulin-like growth factor in, 968, 1556
 knee, 81, 648, 887, 988, 2083
 osteonectin in cartilage in, 539
 osteophytes in, 308, 648, 988, 1535
 pain in, 357
 progressive, 648
 RA and, 110, 162, 629, 1576
 Spanish-language outcome questionnaire in, 93
 telephone interventions in, 1391
 transcription factor NF- κ B in, 583
 weight-bearing sports and, 988
 Osteocalcin
 bone mineral metabolism in JRA and, 746
 collagen degradation and, 1455
 serum, corticosteroids, bone and, in RA, 277
 Osteoclasts
 collagen degradation and, 1455
 glucocorticoid-induced osteoporosis and, 1791
 Osteodystrophy, Albright's hereditary, 1921
 Osteogenic protein 1, recombinant human, and human articular chondrocytes, 1896
 Osteolysis, silicone immunology and, 1615, 1619
 Osteonectin, in cartilage, 539
 Osteopenia
 bone mineral metabolism in JRA and, 746
 in degenerative joint disease in the guinea pig, 1327
 Osteophytes
 in degenerative joint disease in the guinea pig, 1327
 erosion healing, DMARDs and, in RA, 162
 in OA, 308, 648, 988, 1535
 Osteophytosis, weight-bearing sports, risk of OA and, 988
 Osteoporosis
 collagen degradation and, 1455
 glucocorticoid-induced, 1791
 in RA, 397, 723
 Osteotomy, pain and, in RA and OA, 357
 Outcome measures
 fluoxetine, amitriptyline and, in fibromyalgia, 1852
 in RA, 1711, 1773, 1808
 Outcome questionnaires, Spanish-language, 93
 Outcome studies
 early undifferentiated connective tissue disease, 403
 OA, 357, 1391
 RA, 357, 616, 996, 1391
 sulfasalazine in AS, 1400
 Outpatient care in RA, 177

Overlap syndromes

- IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa and, 698
- SSc and RA, 152
- Oxidation, protein metabolism, aging and, in RA, 1115
- Oxidative accumulations, carnitine in muscle in idiopathic inflammatory myopathy and, 1869
- Oxidative stress, free radical injury in scleroderma and, 1146
- Oxygen, reactive, antioxidant micronutrients in knee OA and, 648

P

- p65, transcription factor NF- κ B and, 583
- p75, TNF receptor, disease activity in JRA and, 883
- P815 cells, antigen-presenting cell function in SLE and, 600
- Paget's disease, collagen degradation and, 1455
- Pain
 - barriers to return to work due to arthritis and musculoskeletal diseases, 101
 - brain and, in OA and RA, 357
 - chronic, 101, 357
 - in early undifferentiated connective tissue disease, 403
 - in fibromyalgia, 682, 1627, 1852, 2086
 - joint, 711, 713, 1027, 2013, 2021
 - knee, 648, 1244
 - musculoskeletal, 1, 64
 - in OA, 357, 648, 988, 1027
 - in RA, 216, 357, 415, 427, 713, 1092, 1773
 - revision total hip arthroplasty and, 1939
 - scale, on Spanish-language outcome questionnaire, 93
 - in secondary erythema, 1761
 - shoulder, ultrasound of joints and connective tissue in, 1435
 - spinal, in sulfasalazine in AS, 1400
- Pamidronate, bone mass in RA and, 397
- Pancreas
 - carcinoma, autoantibodies against muscle-cell membrane proteins in myositis and, 1860
 - disease of, subcutaneous fat necrosis, polyarthritis and, 1922
 - nucleotide pyrophosphohydrolase in articular cartilage and, 245
- Pancytopenia, MTX in RA and, 272
- Pannocytes, fibroblast-like synoviocytes in RA and, 1781
- Pannus
 - fibronectin in articular cartilage and, 567
 - matrix metalloproteinase 9 in RA and, 1576
- Pannus-like lesions, HTLV-I, autoimmune disorders and, 1410
- Papillary muscles, cardiac involvement in limited SSc and, 1138
- Papillary necrosis, drug therapy in RA and, 723
- Paraffin oil, silicone immunology and, 1615, 1619
- Paraprotein in monoclonal cryo-antifibrinogenemia, 1066
- Parathyroid hormone, bone mineral metabolism in JRA and, 746
- Parathyroid hormone-related protein, hypercalcemia, SLE and, 2066
- Parenteral gold in RA, 723
- Parturition, maternal-fetal immunology, autoimmune disease and, 191
- Parvovirus B19 infection in Henoch-Schönlein purpura, 880
- Patella, dorsal defect of, knee pain and, 1244
- Patellofemoral joints, sports, OA and, 988
- Pathogenesis
 - antiphospholipid antibodies and, 1441, 1444, 1466
 - autoantibodies against muscle-cell membrane proteins in myositis and, 1860
 - collagen degradation and, 1455
 - of cryocrystalglobulinemia, 335
 - cytokines in *Staphylococcus aureus* arthritis and, 959
 - free radical injury in scleroderma and, 1146
 - of glucocorticoid-induced osteoporosis, 1791
 - heterogeneity in skin fibroblasts in SSc and, 1338
 - of HLA genes in AS and peripheral reactive arthritis, 943
 - of HTLV-I, 610, 1410

Pathogenesis (cont'd)

- IL-10 in collagen arthritis and, 495
- matrix metalloproteinase 9 in giant cell arteritis and, 1747
- penicillin in Behçet's disease and, 2062
- of RA, 125, 183, 454, 836, 1246, 1773, 1781, 1951, 1961
- of Sjögren's syndrome, 195
- of SLE, 9, 706, 894, 1441, 1444, 1466, 1980
- Pathogenetics
 - anti-endothelial antibodies in Wegener's granulomatosis and, 758
 - HTLV-I, autoimmune disorders and, 1410
 - V α and V β transcripts in early RA and, 454
- Pathology
 - antiphospholipid antibody syndrome and, 1441, 1444, 1466
 - bone, degenerative joint disease in the guinea pig and, 1327
 - neopeptide marker of skeletal maturation, aging and, 1234
 - of OA, 308, 968
 - in SLE, 9, 2035
- Pathophysiology
 - antiphospholipid antibody syndrome and, 1441, 1444, 1466
 - manoalide in IL-1 α -induced arthritis and, 1292
 - nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
 - soluble bone marrow stromal cell antigen 1 in RA and, 629
- Patient assessment
 - global, 623, 1027, 1852, 2004, 2013, 2021
 - in RA, 1027, 1092
- Patient education about glucocorticoid-induced osteoporosis, 1791
- Pauciarticular JRA
 - cytokines in, 1703
 - prevalence of, 1385
- Pediatric rheumatology
 - in adult rheumatology practices, 1218
 - antiribosomal P antibodies in SLE and psychosis, 671
 - bone mineral metabolism in JRA, 746
 - childhood-onset scleroderma, 1041
 - glucocorticoid-induced osteoporosis in, 1791
 - Wegener's granulomatosis of the lungs, 615
- Pelvis
 - hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 - revision total hip arthroplasty and, 1939
- Penicillamine
 - MTX and, 1951
 - in RA, 616, 713, 723
- Penicillin in Behçet's disease, 2062
- Peptic ulcers, drug therapy in RA and, 723
- Peptides
 - collagen degradation and, 1455
 - Ki antigen epitope homology and, 855
 - major epitope of PM-Scl autoantigen and, 1588
 - nucleotide pyrophosphohydrolase in human serum and, 252
 - self, 183, 195
 - in SLE, 1483, 1980
 - synovial cell adhesion on EDA-containing fibronectin and, 1685
 - synthetic, autoimmunity to RNA polymerase II and, 1886
- Perforin, *Staphylococcus aureus* arthritis and, 959
- Periarticular tissue, matrix metalloproteinase 9 in RA and, 1576
- Pericardial involvement
 - acute musculoskeletal symptoms and, 1
 - in limited SSc, 1138
- Pericarditis, calcific constrictive, CREST syndrome and, 347
- Peripheral arthritis, sulfasalazine in AS and, 2004
- Peripheral arthropathy in cryocrystalglobulinemia, 335
- Peripheral blood
 - cells, 125, 379, 773, 1277, 1826, 1840, 1875, 1951, 1961
 - cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
 - γ/δ T cells in rat adjuvant arthritis and, 204
 - hepatocyte growth factor and, 1566
 - lymphocytes, HTLV-1 in PM/DM and, 535

- Peripheral blood (*cont'd*)
 MTX and, 1951
 in RA, 52, 125, 257, 829, 844, 904, 914, 1499, 1961
 in SLE, 23, 379, 600
- Peripheral joints, sulfasalazine in AS and, 2004
- Peripheral reactive arthritis, HLA genes in, 943
- Peripheral T cells
 anti-CD45 autoantibodies in SLE and, 592
 in RA, 914
- Peripheral neuropathy, prognosis in rheumatoid vasculitis and, 1937
- Peritendinous soft tissue, in dactylitis in seronegative spondylarthropathy, 1524
- Perivascular CD4 cells, in RA, 914
- Personality, depression in scleroderma and, 1035
- Phagocytic lining cells, inflammation in collagen arthritis and, 1545
- Phenotypes
 B cell, 325
 HLA, 152
 human synovial mast cells and, 1222
 IL-10:IFN γ -secreting cells in SLE and, 379
 in RA, 152, 257, 325, 844, 1693
 recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
 TAP alleles, HLA-B27 binding peptides and, 1892
- Phlogiston, MTX and, 1951
- Phosphatase
 alkaline, 489, 746
 protein, T cells in lupus and, 23
- Phosphate
 crystals, basic calcium, inflammation and, 1319
 glucocorticoid-induced osteoporosis and, 1791
- Phosphatidylinositol, glycosyl, soluble bone marrow stromal cell antigen 1 in RA and, 629
- Phospholipase A₂
 manoolide in IL-1 α -induced arthritis and, 1292
 tenidap in RA and, 1263
- Phospholipids
 antiphospholipid antibodies and, in SLE, 1441, 1444, 1466
- Phosphoric acid, silicone immunology and, 1615, 1619
- Phosphorylation, mitochondrial oxidative, uncoupling of, NSAIDs and, 1998
- Photochemotherapy, extracorporeal, in psoriatic arthritis, 1519
- Photosensitive pruritic rash on face and trunk in amyopathic DM, 1419
- Physical activity
 antioxidant micronutrients in knee OA and, 648
 running, musculoskeletal pain, aging and, 64
- Physician assessment
 depression in scleroderma and, 1035
 global, 623, 1027, 1178, 1852, 2004, 2013, 2021
 in RA, 713, 1027, 1092
 SLICC/ACR damage index and, 363
 Spanish-language outcome questionnaire and, 93
- Physicians and surgeons
 cost of SLE and, 979
 rheumatology as a profession, 887
- Physiology
 antiphospholipid antibody syndrome and, 1441, 1444, 1466
 effect of MTX on mouse bone cells and, 489
 neoepitope marker of skeletal maturation, aging and, 1234
- Pig studies, nucleotide pyrophosphohydrolase, 245, 252
- Pilocarpine in Sjögren's syndrome, 195
- Pitting edema, polymyalgia rheumatica and, 73, 1931
- Placenta, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Plant seed oil-derived unsaturated fatty acid, γ -linolenic acid in RA, 1808
- Plasma
 antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Plasma (*cont'd*)
 autoantibodies against muscle-cell membrane proteins in myositis and, 1860
 cells, 783, 1423
 hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 in monoclonal cryo-antifibrinogenemia, 1066
 protein, 1441, 1444, 1466
 in RA, 1115, 1576
 in SLE, 287, 1178
 sulfasalazine in AS and, 1400
 synovial cell adhesion on EDA-containing fibronectin and, 1685
- Plasmacytoma, silicone breast implants and, 1615, 1619
- Plasmapheresis in monoclonal cryo-antifibrinogenemia, 1066
- Plasmids
 α 1(I) procollagen gene in SSc dermal fibroblasts and, 1347
 matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
- Plasmin, TSG-6 in articular chondrocytes and, 552
- Plasmin- α_2 -plasmin inhibitor complex, disease activity in SLE and, 287
- Platelet-derived growth factor AA
 apoptosis of rheumatoid synovial cells and, 1267
 TSG-6 in articular chondrocytes and, 552
- Platelet-endothelial cell adhesion molecule (PECAM)
 adhesion molecules, pulse methylprednisolone and, in RA, 1970
 synovial endothelial cells and, 467
- Platelets
 antiphospholipid antibody syndrome and, 1441, 1444, 1466
 counts of, 370, 1423
- Pleuritis
 ENA in SLE and, 1055
 HLA type, anti-U1 RNP and, 938
- PM-Scl autoantigen, major epitope of, 1588
- Pneumonitis, drug therapy in RA and, 723
- Point tenderness, acute musculoskeletal symptoms and, 1
- pol* gene, HTLV-I, autoimmune disorders and, 1410
- Polyamines, MTX and, 1951
- Polyangiitis, microscopic, polyarteritis nodosa and, 1208
- Polyarteritis nodosa
 hand in, 2078
 microscopic polyangiitis and, 1208
 multiple myeloma and, 330, 698
 pediatric, in adult rheumatology practices, 1218
- Polyarthritis
 autoantibodies directed against tRNA in, 1308
 early undifferentiated connective tissue disease and, 403
 seropositive, in SSc and RA, 152
 subcutaneous fat necrosis, pancreatic disease and, 1922
- Polyarticular JRA
 bone mineral metabolism in, 746
 heat-shock protein 60 and, 1826
 prevalence of, 1385
- Polyarticular RA, management of, 713
- Polycellular dysregulation, self peptides, dendritic cells and, in RA, 183
- Polyclonal antibodies
 nuclear factor- κ B and, 583
 nucleotide pyrophosphohydrolase in articular cartilage and, 245
 risk of lymphoma in primary Sjögren's syndrome and, 767
 soluble HLA class I antigens in SLE and, 792
- Polyclonal human immunoglobulin, endothelial activation in RA and, 1371
- Polyclonal T cells
 CD56 cells in SLE and, 1840
 receptors for, V α and V β transcripts in RA and, 454
- Polydimethylsiloxane, silicone immunology and, 1615, 1619
- Polyethylene, revision total hip arthroplasty and, 1939
- Polyglutamates, MTX and, 1951
- Polyhistidine, peptides in SLE and, 1654

- Polymerase chain reaction, to diagnosis venereal arthritis, 950
- Polymer-based saliva substitutes, xerostomia in Sjögren's syndrome and, 57
- Polymers, synthetic, silicone immunology and, 1615, 1619
- Polymorphisms
in RA, 446, 931, 1109
TAP alleles, HLA-B27 binding peptides and, 1892
- Polymyalgia rheumatica
cytokines in, 1264
ESR in, 304
pitting edema in, 73, 1931
shoulder synovitis in, 1199
- Polymyositis (PM)
anti-glycyl-transfer RNA synthetase antibodies in, 146
anti-Jo-1 antibodies in, 292
HTLV-1 in, 535, 1410
lung fibrosis, cranial neuropathy and, in hepatitis C virus infection, 1074
myositis and, 1254
- Polyneuropathy, all-*trans*-retinoic acid in POEMS syndrome and, 1423
- Polypeptides
anti-NOR 90 in rheumatic diseases and, 1313
autoimmunity to RNA polymerase II and, 1886
- Polyproline, peptides in SLE and, 1654
- Polypyrimidine, antibodies to heterogeneous nRNP in SSc and, 1669
- Porphyria cutanea tarda, hepatitis C and, in SLE, 352
- Postmenopausal women, glucocorticoid-induced osteoporosis in, 1791
- Postpartum mothers, acute musculoskeletal symptoms and, 1
- Postpartum vasculitis, fatal, in SLE, 352
- Potassium, protein metabolism, aging and, in RA, 1115
- Pravastatin-induced rhabdomyolysis, in MCTD, 1259
- Precursor cells, CD56 cells in SLE and, 1840
- Prednisolone, oral, pulse methylprednisolone, joint neutrophils and, in RA, 216
- Prednisone
disease remission in generalized Wegener's granulomatosis and, 2052
ESR in polymyalgia rheumatica and, 304
neuropsychological deficits in SLE without central nervous system disease and, 2035
osteoporosis induced by, 1791
in RA, 616, 713, 723, 1818
- Pregnancy
acute musculoskeletal symptoms and, 1
drug therapy in RA and, 723
fatal postpartum vasculitis in SLE and, 352
maternal-fetal immunology, autoimmune disease and, 191
- Prevalence studies
Amerindian HLA haplotype in SSc, 1362
JRA, 1385
Wegener's granulomatosis, 87
- Primary antiphospholipid antibody syndrome, familial, 705
- Primary AS, pyoderma gangrenosum, undifferentiated seronegative spondylarthropathy and, 1062
- Primary care physicians, guidelines and, 1, 713
- Primary hip arthroplasty, revision total hip arthroplasty and, 1939
- Primary psychosis, antiribosomal P antibodies in pediatric SLE and, 671
- Primary Raynaud's disease, familial aggregation of, 1189
- Primary Raynaud's phenomenon, cardiac involvement in limited SSc and, 1138
- Primary Sjögren's syndrome
circulating T cell receptor γ/δ cells in, 1733
long-term followup of, 297
risk of lymphoma in, 767
xerostomia and saliva substitutes in, 57
- Primate studies, HTLV-I in the macaque, 610
- Procoagulation, antiphospholipid antibody syndrome and, 1441, 1444, 1466
- Procollagen
bone mineral metabolism in JRA and, 746
fibroblasts in SSc and, 1338, 1347
- Procollagenase, recombinant human neutrophil, doxycycline and, 235
- Progressive OA, antioxidant micronutrients in, 648
- Progressive resistance training in RA, 415
- Proinflammatory cytokines
all-*trans*-retinoic acid in POEMS syndrome and, 1423
Staphylococcus aureus arthritis and, 959
- Proliferating cell nuclear antigen (PCNA), autoantibodies against, in chronic intestinal pseudoobstruction, 877
- Proline, major epitope of PM-Scl autoantigen and, 1588
- Propeptides, bone mineral metabolism in JRA and, 746
- Prostaglandin D₂, human synovial mast cells and, 1222
- Prostaglandin F₂-like components in free radical injury in scleroderma, 1146
- Prostate biopsy in molecular diagnosis of venereal arthritis, 950
- Protease
neutrophil, fibroblast adhesion to articular cartilage and, 1072
serine, TSG-6 in articular chondrocytes and, 552
- Protein
antibodies to aggrecan core, in SF, 1990
antibodies to heterogeneous nRNP in SSc and, 1669
antigenic, of the DM-specific Mi-2 autoantigen, 1769
anti-NOR 90 in rheumatic diseases and, 1313
antinuclear antibodies, anti-nuclear matrix antibody and, 1300
antiphospholipid antibody syndrome and, 1441, 1444, 1466
antiribosomal P, 1483
cartilage and, 478, 539, 560, 567
centromere kinesin-like, CENP-E, 1355
chondrocytes and, 552, 1896, 1905
C-reactive, 629, 1021, 1027
glucocorticoid-induced osteoporosis and, 1791
heat-shock, 1677, 1826
human autoantibodies to the mitotic spindle apparatus and, 1643
insulin-like growth factor and, 968, 1556
macrophage depletion in collagen arthritis and, 1545
major epitope of PM-Scl autoantigen and, 1588
monoclonal, all-*trans*-retinoic acid in POEMS syndrome and, 1423
monocyte chemotactic, anti-endothelial antibodies in Wegener's granulomatosis and, 758
muscle-cell membrane, autoantibodies against, in myositis, 1860
para-, in monoclonal cryo-antifibrinogenemia, 1066
plasma, 1441, 1444, 1466
procollagenase, doxycycline and, 235
in RA, 629, 1021, 1027, 1092, 1115
recombinant fusion, autoimmunity to RNA polymerase II and, 1886
recombinant human CENP-A, detection of anticentromere antibodies with, 863
recombinant human osteogenic protein 1, 1896
in Sjögren's syndrome, 1427, 1875
in SLE, 9, 23, 671, 706, 1483, 1635, 1980, 2066
tRNA and, 146, 1308
tuberculin purified, cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
- Proteinuria, drug therapy in RA and, 723
- Proteoglycans
cartilage and, 478, 829, 1896
fibroblast-like synoviocytes in RA and, 1781
manoalide in IL-1 α -induced arthritis and, 1292
- Proteolysis, insulin-like growth factor in arthritis and, 1556
- Prothrombin, antiphospholipid antibodies and, 1441, 1444, 1466
- Proto-oncogenes, HTLV-I, autoimmune disorders and, 1410
- Proximal interphalangeal joints
erosion healing, DMARD and, in RA, 162

Proximal interphalangeal joints (*cont'd*)
in OA, 308
Pruritic rash, photosensitive, on face and trunk in amyopathic DM, 1419
P-selectin
adhesion molecules, pulse methylprednisolone and, in RA, 1970
synovial endothelial cells and, 467
Pseudogout, acute musculoskeletal symptoms and, 1
Pseudoobstruction, chronic intestinal, anti-PCNA in, 877
Pseudothrombophlebitis, in focal myositis and MCTD, 1254
Pseudovasculitis, systemic, from scurvy in anorexia nervosa, 532
Psoralen-ultraviolet A irradiation, in psoriatic arthritis, 1519
Psoriatic arthritis
photopheresis in, 1519
sulfasalazine in, 711, 2013
T cells in, 137, 904
Psoriatic spondylarthropathy, pyoderma gangrenosum and, 1062
Psychiatric diagnosis, health care-seeking in fibromyalgia and, 436, 2086
Psychiatric pathology in SLE without central nervous system disease, 2035
Psychological factors
acute musculoskeletal symptoms and, 1
in fibromyalgia, 2086
in musculoskeletal conditions, 1931
pain and, in RA and OA, 357
in SLE without central nervous system disease, 2035
Psychosis in SLE, 671, 1483, 1833
Psychosocial Adjustment to Illness Scale, in depression in scleroderma, 1035
Pulmonary alveolar hemorrhage, vascular injury in SLE and, 9
Pulmonary fibrosis
autoantibodies directed against tRNA in, 1308
in RA, 152
in SSc, 152, 1362
Pulmonary function test in interstitial lung disease in RA, 1711
Pulmonary hypertension in SSc, 1138, 1146
Pulmonary involvement
acute musculoskeletal symptoms and, 1
antithymocyte globulin in SSc and, 1132
Mycobacterium kansasii septic arthritis in AIDS and, 881
in systemic pseudovasculitis from scurvy in anorexia nervosa, 532
Pulmonary leukosequestration, vascular injury in SLE and, 9
Pulse methylprednisolone, intravenous, in RA, 216, 1970
Pulse MTX, low-dose, 171, 272
Purine analogs, drug therapy in RA and, 723
Purpura
Henoch-Schönlein, 698, 880, 2078
skin, in cryocryoglobulinemia, 335
thrombotic thrombocytopenic, vascular injury in SLE and, 9
Pyoderma gangrenosum, spondylarthropathy and, 1062
Pyomyositis, MRI in, 1760
Pyridinium, collagen degradation and, 1455
Pyridinoline
collagen degradation and, 1455
urinary, corticosteroids, bone and, in RA, 277
Pyrimidine, MTX and, 1951
Pyrophosphate analogs in glucocorticoid-induced osteoporosis, 1791
Pyrophosphohydrolase, nucleotide, 245, 252

Q

Quality of life
pain and, in RA and OA, 357
revision total hip arthroplasty and, 1939
Quantitative CT, glucocorticoid-induced osteoporosis and, 1791
Questionnaires
AIMS2, 1391

Questionnaires (*cont'd*)
in augmentation mammoplasty and SSc, 1125
Beck Depression Inventory, 1035, 1852
Center for Epidemiology Studies Depression Scale, 427, 436
Computerized Diagnostic Interview Schedule, 436
to determine access to rheumatology services, 711
Fibromyalgia Impact, 1852
Food Frequency, 648
Health Assessment, 64, 81, 93, 216, 616, 1035, 1711
Neuroticism-Extraversion-Openness Personality Inventory, 1035
outcome, Spanish-language, 93
Psychosocial Adjustment to Illness Scale, 1035
in reactive arthritis and sexually transmitted diseases, 1172
self-assessment, 93
Trait Anxiety Inventory, 436

R

Rabbit studies
direct gene delivery to synovium and, 820
matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
neopeptide marker of skeletal maturation and aging, 1234
osteonectin in cartilage, 539
Racial factors
in reactive arthritis and sexually transmitted diseases, 1172
in ribosomal P autoantibodies in SLE, 1833
SSc and, 1125, 1151
Radial artery puncture, splinter hemorrhage after, 169
Radiography
acute musculoskeletal symptoms and, 1
anti-PCNA in chronic intestinal pseudoobstruction and, 877
collagen degradation and, 1455
in cryocryoglobulinemia, 335
CT of the knee in gout and, 1406
in degenerative joint disease in the guinea pig, 1327
hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
influence of ballet season in, 1069
of lowland gorilla, 891
in OA, 81, 308, 648, 988
in RA, 34, 115, 162, 397, 713, 1006, 1246
revision total hip arthroplasty and, 1939
in tracheostenosis, 1076
Wegener's granulomatosis of the lungs, 615, 2052
Radiologic Vignette
cervical myelopathy caused by ossification of the posterior longitudinal ligament in AS, 2074
dorsal defect of the patella and knee pain, 1244
Range of motion
acute musculoskeletal symptoms and, 1
pain and, in RA and OA, 357
Rash
acute musculoskeletal symptoms and, 1
HLA type, anti-U1 RNP and, 938
Mi-2 antibodies, HLA-DR and, in DM, 868
in RA, 257, 723
Rat studies
See also Dark Agouti rats, Lewis rats
adjuvant arthritis, 204, 504, 810, 1677
collagen degradation, 1455
nitric oxide production during collagen arthritis and, 1677
NSAID and mitochondrial uncoupling, 1998
TGF β 1 in MSU crystal-induced inflammation, 1192
Raynaud's disease
anti-Jo-1 antibodies in myositis and, 292
familial aggregation of, 1189
Raynaud's phenomenon
autoantibodies directed against tRNA in, 1308

- Raynaud's phenomenon (*cont'd*)
centromere kinesin like protein, CENP-E in, 1355
in SSc, 1138, 1161
- Reactive arthritis
antibiotics in, 1238
detection of *Chlamydia trachomatis* by polymerase chain reaction in, 1740
molecular diagnosis of venereal arthritis and, 950
peripheral, HLA genes in, 943
sexually transmitted diseases and, 1172
sulfasalazine in, 2021
- Reactive oxygen, antioxidant micronutrients in knee OA and, 648
- Reactivity
antibodies to aggrecan in SF and, 1990
antibodies to heterogeneous nRNP in SSc and, 1669
anti-CD45 autoantibodies in SLE and, 592
anticentromere antibodies, recombinant human CENP-A protein and, 863
antiphospholipid antibodies and, 1441, 1444, 1466
anti-Ro and anti-La anti-dsDNA antiidiotypes and, 552
centromere kinesin-like protein, CENP-E and, 1355
to heat-shock protein 60 in oligoarticular JRA, 1826
human autoantibodies to the mitotic spindle apparatus and, 1643
major epitope of PM-Scl autoantigen and, 1588
in SLE, 1635, 1654, 1980
- Recall antigens, antigen-presenting cell function in SLE and, 600
- Recombinant fusion protein, autoimmunity to RNA polymerase II and, 1886
- Recombinant heterogeneous nRNP, antibodies to, in SSc, 1669
- Recombinant human C5a, human synovial mast cells and, 1222
- Recombinant human neutrophil procollagenase, doxycycline and, 235
- Recombinant human osteogenic protein 1 in human articular chondrocytes, 1896
- Recombinant human stem cell factor, human synovial mast cells and, 1222
- Recombinant human TGF β 1 in MSU crystal-induced inflammation, 1192
- Recombinant Ki antigen epitope homology with SV40 large T antigen nuclear localization signal in lupus, 855
- Recombinant IL-1
human, receptor I, in RA, 257, 1092
receptor antagonist, in experimental OA, 1535
- Recombinant IL-1 α , manolide in arthritis induced by, 1292
- Recombinant IL-2, CD69 in RA and, 1277
- Recombinant IL-10
human, in RA, 386
murine, in collagen arthritis, 495
- Recombinant IL-13 in RA, 1693
- Recombinant ribosomal P protein in pediatric SLE, 671
- Recombinant spindle kinesin-like protein, HsEg5, in SLE, 1635
- Recurrent miscarriages, vascular injury in SLE and, 9
- Refractory RA
acute toxicity after azathioprine and MTX in, 1016
low-dose intravenous immunoglobulin in, 1027
management of, 713
NSAID-induced enteropathy and chronic anemia in, 321
- Reiter's syndrome
detection of *Chlamydia trachomatis* by polymerase chain reaction in, 1740
molecular diagnosis of venereal arthritis and, 950
sulfasalazine in, 2021
TAP alleles and HLA-B27 binding peptides in, 1892
- Rel-A, transcription factor NF- κ B and, 583
- Relapsing Henoch-Schönlein purpura/polyarteritis nodosa, IgA multiple myeloma presenting as, 698
- Remitting seronegative symmetrical synovitis with pitting edema, polymyalgia rheumatica and, 1931
- Renal biopsy
after cyclosporine in RA, 1491
disease flares of lupus nephritis after cyclophosphamide and, 2028
- Renal disease in SLE, 9, 671, 894, 1178
- Renal failure
drug therapy in RA and, 723
systemic vasculopathy in multiple myeloma and, 330
- Renal function
acute musculoskeletal symptoms and, 1
in RA, 272, 1491
- Renal involvement
drug therapy in RA and, 723
in SLE, 9, 370, 671
in SSc, 1030, 1151
in systemic pseudovasculitis from scurvy in anorexia nervosa, 532
- Renovascular hypertension, vascular injury in SLE and, 9
- Resistance training in RA, 415
- Respiration, mitochondrial uncoupling, NSAID and, 1990
- Respiratory chain enzyme complexes, carnitine in muscle in idiopathic inflammatory myopathy and, 1869
- Reticulohistiocytosis, multicentric, steroids, cyclophosphamide and MTX in, 171
- Retinal toxicity, drug therapy in RA and, 723
- Retinoic acid, all-*trans*, in POEMS syndrome, 1423
- Retinoids, *N*-[4-hydroxyphenyl] retinamide in RA, 1021
- Retroviral gp70/anti-gp70 complexes, nephritogenic autoantibodies in lupus and, 894
- Retroviruses
direct gene delivery to synovium and, 820
in HTLV-I and autoimmune disorders, 1410
infection from, HTLV-I in the macaque, 610
peptides in SLE and, 1654
- Revision total hip arthroplasty, 1939
- Rhabdomyolysis, pravastatin-induced, in MCTD, 1259
- Rhabdomyosarcoma cell line, autoantibodies against muscle-cell membrane, proteins in myositis and, 1860
- Rheumatic diseases
ACR Slide Collection on the, 2078
acute musculoskeletal symptoms and, 1
anti-glycyl-transfer RNA synthetase antibodies in myositis and, 146
anti-NOR 90 in, 1313
antiphospholipid antibodies and, 1441, 1444, 1466
autoantibodies against muscle-cell membrane proteins in myositis and, 1860
glucocorticoid-induced osteoporosis and, 1791
maternal-fetal immunology, autoimmune disease and, 191
MTX and, 1951
pain in, 357
rheumatology as a profession and, 887
- Rheumatic fever, acute, wrist and subcutaneous nodules in, 2078
- Rheumatism, fibroblastic, low-dose MTX and, 2070
- Rheumatoid arthritis (RA)
ACR preliminary definition of improvement in, 535
active, recombinant human IL-1 receptor I in, 257
acute musculoskeletal symptoms and, 1
adhesion molecules and, 810, 1970
AIDS and, 1437
 α_4 /CD18 leukointegrin in, 1913
amyloidosis in, 1728
antibodies to heterogeneous nRNP in SSc and, 1669
anti-CD4 monoclonal antibody-coated lymphocytes (cM-T412) in, 52
anti-CD5 immunoconjugate in, 1102
anti-HTLV-1 antibody in, 463
anti-IL-10 in, 386
anti-NOR 90 in, 1313
anti-TNF α in, 1077, 1082

Rheumatoid arthritis (RA) (cont'd)

- articular damage and synovial tissue macrophages in, 115
- azathioprine toxicity in, 1016, 1435, 1436
- bacterial superantigens in, 125
- bone marrow and, 629, 836
- CAMPATH-1H and synovial tissue in, 181
- cartilage in, 539, 829
- CD28 in, 110
- CD69 in, 1277
- CD86 in, 110
- cigarette smoking and, 732
- collagen in, 1455, 1720
- collagenase, adenosine and, 923
- corticosteroids in, 277, 1818
- cyclosporine in, 1006, 1491
- cytomegalovirus and, 1608
- dendritic cells and self peptides in, 183
- DMARD in, 162, 616
- early, 41, 454, 996, 1006, 1720
- early undifferentiated connective tissue disease and, 403
- EBV clonality in lymphomas in, 638
- emotional distress in, 427
- endothelial activation in, 1371
- erosions and DMARD in, 162
- erosive, 1720
- expectation bias in, 1773
- fibromyalgia, disability and, 1627
- γ -linolenic acid in, 1808
- gender in, 427
- guidelines for management of, 713
- guidelines for monitoring drug therapy in, 723
- healing phenomena in, 1934
- hepatocyte growth factor in, 1566
- HLA-DRB1 genes and disease severity in, 1802
- IL-4 in, 829
- IL-10 in, 386, 495, 829
- IL-13 in, 1693
- insulin-like growth factor in, 1556
- interstitial lung disease in, 1711
- leukotriene synthesis inhibitors in, 515
- low-dose intravenous immunoglobulin in, 1021
- maternal-fetal immunology and, 191
- matrix metalloproteinase 9 in, 1576
- methylprednisolone in, 216, 1970
- mortality in rheumatoid vasculitis and, 266
- MTX in, 272, 325, 1016, 1435, 1436, 1608, 1951
- myositis and, 292, 1860
- N*-[4-hydroxyphenyl] retinamide in, 1021
- nitric oxide in, 643
- NSAID-induced enteropathy and chronic anemia in, 321
- outpatient care costs in, 177
- pain in, 357
- pamidronate and bone mass in, 397
- pancytopenia in, 272
- progression of, 1246
- progressive resistance training in, 415
- protein metabolism and aging in, 1115
- in a public health hospital, 283
- recombinant human IL-1 receptor I in, 257, 1092
- refractory, 321, 713, 1016, 1027
- response criteria for, 34
- RF-producing B cells in, 1499
- "sawtooth" strategy in, 996
- self peptides and dendritic cells in, 183
- seronegative, 1499
- seropositive, 325, 1499
- serum apolipoprotein E4 isoprotein in, 1728

Rheumatoid arthritis (RA) (cont'd)

- SLE and, 1050, 2035
- Spanish-language outcome questionnaire in, 93
- synovial endothelial cell adhesion molecules in, 467
- synovial tissue in, 115, 2080
- synoviocytes in, 125, 1781
- synovium in, 110
- systemic sclerosis and, 152
- T cells in, 125, 446, 844, 904, 914, 931
- telephone interventions in, 1391
- tenidap in, 1263
- Th1 in, 1961
- TNF microsatellite polymorphisms in, 1109
- TNF α in, 197
- transcription factor NF- κ B in, 197, 583
- work status in, 101, 427
- Rheumatoid cartilage surface, synovial cell adhesion on EDA-containing fibronectin and, 1685
- Rheumatoid factor (RF)
 - MTX and, 1951
 - in primary Sjögren's syndrome, 767
 - in RA, 283, 616, 629, 713, 1027, 1499, 1802
 - serum, acute musculoskeletal symptoms and, 1
- Rheumatoid SF, hepatocyte growth factor and, 1566
- Rheumatoid synovial cells, apoptosis of, 1267
- Rheumatoid synoviocytes, HTLV-I, autoimmune disorders and, 1410
- Rheumatoid synovium
 - fibroblast-like synoviocytes in, 1781
 - IL-10 and, 386
 - IL-13 and, 1693
 - T cells in, 844, 914
- Rheumatoid synovitis
 - α_v /CD18 leukointegrin in, 1913
 - fibroblast-like synoviocytes in, 1781
- Rheumatoid vasculitis
 - mortality in, 266
 - prognosis in, 1937
- Rheumatology and rheumatologists
 - access to, 711
 - fibromyalgia, disability and, 1627
 - guidelines for management of RA and, 713
 - pediatric rheumatology in adult rheumatology practices, 1218
 - professionalism of, 887
 - recertification of, 2082
 - SLICC/ACR damage index and, 363
- Rhesus monkey studies, HTLV-I, 610
- Ribosomal mycobacterial DNA, synovial tissue in RA and, 2080
- Ribosomal P
 - autoantibodies in SLE, 1833
 - peptides in neuropsychiatric SLE, 1483
 - protein, cognitive and psychologic deficits in SLE without central nervous system disease and, 2035
- Ribosomal RNA
 - autoantibodies directed against tRNA and, 1308
 - detection of *Chlamydia trachomatis* by polymerase chain reaction and, 1740
- Ricin, anti-CD5 immunoconjugate in RA and, 1102
- RNA
 - anti-Ro and anti-La anti-dsDNA antiidiotypes and, 522
 - in antisynthetase syndrome, 692
 - hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 - messenger, 197, 226, 386, 467, 539, 552, 560, 567, 574, 773, 797, 923, 959, 968, 1021, 1287, 1292, 1338, 1347, 1410, 1535, 1677, 1693, 1747, 1875
 - polymerase II, autoimmunity to, 1886
 - sicca syndrome, hepatitis C virus and, 1166
 - synthetase, anti-Jo-1 antibodies in myositis and, 292

RNA (cont'd)
 transfer, 146, 292
 RNP
 anti-U1, HLA type and, 938
 heterogeneous nuclear, antibodies to, in SSc, 1669
 Ro, anti-Ro autoantibody in SLE and, 1654
 Ro
 proteins in complete heart block in Sjögren's syndrome, 1427
 RNP, anti-Ro autoantibody in SLE and, 1654
 Rocky mountain spotted fever presenting with acute monoarticular arthritis, 175, 2088
 Ro/La autoantibodies, glutathione-S-transferase GSTM1 null alleles in SLE and, 1763
 Ro/SS-A
 anti-dsDNA antiidiotypes and, 522
 risk of lymphoma in primary Sjögren's syndrome and, 767
 Rubella vaccine, chronic arthropathy and musculoskeletal symptoms after, 1529
 Running
 musculoskeletal pain, age and, 64
 OA and, 988
 Rupture, acute musculoskeletal symptoms and, 1

S

³⁵S-methionine, fibronectin and, in articular cartilage, 567
³⁵S-sulfate, recombinant human osteogenic protein 1 in human articular chondrocytes and, 1896
 S1 fragment, major epitope of PM-Scl autoantigen and, 1588
 S107 protein, antiidiotypic antibodies in SLE and, 1980
 Saliva
 sicca syndrome, hepatitis C virus and, 1166
 substitutes, xerostomia in Sjögren's syndrome and, 57
 Salivary gland
 biopsy in Sjögren's syndrome, 1609
 in early pathologic analysis of SSc, 1161
 HTLV-I, autoimmune disorders and, 1410
 labial, 783, 1376
 minor, 195
 sublabial, 297
 Salmon calcitonin nasal spray in glucocorticoid-induced osteoporosis, 1791
 Salsalate, after NSAID enteropathy and chronic anemia in RA, 321
 "Sausage-like" fingers in dactylitis in seronegative spondylarthropathy, 1524
 "Sawtooth" strategy in early RA, 996
 Scatter factor, hepatocyte growth factor and, 1566
 Sclerodactyly
 centromere kinesin-like protein, CENP-E in, 1355
 low-dose MTX in fibroblastic rheumatism and, 2070
 Scleroderma
 See also Systemic sclerosis (SSc)
 Amerindian HLA haplotype in, 1362
 antifibrillar in, 1151
 anti-PCNA in chronic intestinal pseudoobstruction and, 877
 augmentation mammaplasty and, 1125
 autoimmunity to RNA polymerase II in, 1886
 free radical injury in, 1146
 limited cutaneous, calcific constrictive pericarditis in, 347
 lung disease in, 180
 Mi-2 antibodies, HLA-DR and, in DM, 868
 Scleroderma-RA overlap syndrome, 152
 Sclerosis
 skin, in SSc and RA, 152
 subchondral, 308, 1327
 Scurvy, systemic vasculitis from, in anorexia nervosa, 532
 Secondary erythema, painful, swollen, and erythematous hands and feet in, 1761

Secondary Sjögren's syndrome
 long-term followup of, 297
 xerostomia and saliva substitutes in, 57
 Second-line drugs in RA, 1773, 1818
 Segmental necrotizing glomerulonephritis, focal, vascular injury in SLE and, 9
 Self-assessment
 depression in scleroderma and, 1035
 progressive resistance training and, in RA, 415
 questionnaires, Spanish-language, 93
 Self-esteem, fibromyalgia, disability and, 1627
 Self peptides
 dendritic cells and, in RA, 183
 endogenous, 183
 in Sjögren's syndrome, 195
 Sepsis, meningococcal, vascular injury in SLE and, 9
 Septic arthritis
 acute musculoskeletal symptoms and, 1
 corticosteroids and antibiotics in *Staphylococcus aureus* arthritis, 1596
Mycobacterium kansasii, in AIDS, 881
 Serine protease, TSG-6 in articular chondrocytes and, 552
 Seroimmunology, disease remission in generalized Wegener's granulomatosis and, 2052
 Serology
 disease exacerbation and, in SLE, 370
 in HTLV-I in the macaque, 610
 in RA, 283, 454
 in SSc, 1151, 1355, 1362
 Seronegative arthritis, photopheresis in, 1519
 Seronegative RA, RF-producing B cells in, 1499
 Seronegative spondylarthropathy
 dactylitis in, 1524
 undifferentiated, pyoderma gangrenosum and, 1062
 Seronegative SS-A/SS-B antibodies, sicca syndrome, hepatitis C virus and, 1166
 Seropositive polyarthritis in SSc and RA, 152
 Seropositive RA
 collagen degradation in, 1455
 MTX-associated lymphoma in, 325
 RF-producing B cells in, 1499
 T cells in, 904
 Serum
 all-trans-retinoic acid in POEMS syndrome and, 1423
 antibodies to aggrecan in SF and, 1990
 anti-NOR 90 in rheumatic diseases and, 1313
 antiphospholipid antibody syndrome and, 1441, 1444, 1466
 anti-Ro and anti-La anti-dsDNA antiidiotypes and, 522
 in antisyndetase syndrome, 692
 apolipoprotein E4 isoprotein, 1728
 autoantibodies and, 1308, 1643, 1860
 autoimmunity to RNA polymerase II and, 1886
 bone mineral metabolism in JRA and, 746
 colchicine in breast milk in familial Mediterranean fever and, 1213
 collagen degradation and, 1455
 complete heart block in Sjögren's syndrome and, 1427
 corticosteroids and antibiotics in *Staphylococcus aureus* arthritis and, 1596
 creatinine, 723
 cytokines, in polymyalgia rheumatica, 1264
 in early undifferentiated connective tissue disease, 403
 HLA type, anti-U1 RNP and, 938
 hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 IgGκ cryoglobulinemia, in cryocryoglobulinemia, 335
 IL-6, SK&F 106615 and, in rat adjuvant arthritis, 504
 major epitope of PM-Scl autoantigen and, 1588
 matrix metalloproteinase 9 in giant cell arteritis and, 1747

- Serum (cont'd)**
 in monoclonal cryo-antifibrinogenemia, 1066
 in myositis, 146, 292, 1254
 nucleotide pyrophosphohydrolase in, 252
 in RA, 277, 463, 629, 643, 723, 884, 1082, 1720, 1728, 1951
 RF, acute musculoskeletal symptoms and, 1
 sicca syndrome, hepatitis C virus and, 1166
 silicone immunology and, 1615, 1619
 in SLE, 9, 671, 792, 1055, 1178, 1483, 1635, 1654, 1980, 2035, 2046
 in SSc, 686, 1132, 1355, 1669
 sulfasalazine in AS and, 1391
 7-hydroxyl-MTX, 1951
- Sex hormones**
 autoimmune disease and, 191, 1766
 glucocorticoid-induced osteoporosis and, 1791
- Sexually transmitted diseases, reactive arthritis and, 1172**
- Shoulder**
 pain, ultrasound of joints and connective tissue in, 1435
 synovitis, in polymyalgia rheumatica, 1199
- Shunts, silastic ventriculoperitoneal, silicone immunology and, 1615, 1619**
- Sialadenitis, Sjögren's syndrome and, 195**
- Sicca symptoms in Sjögren's syndrome, 297**
- Sicca syndrome, hepatitis C virus and, 1166**
- Silicone breast implants**
 ACR statement on, 1765
 controversy about, 1615, 1619, 1771
 rheumatology profession and, 887
 and SSc, 1125
- Sinus tracts, revision total hip arthroplasty and, 1939**
- Sjögren's syndrome**
 anti-NOR 90 in, 1313
 autoantibodies in, 1308, 1643
 circulating T cell receptor γ/δ cells in, 1733
 complete heart block in, 1427
 cytokine mRNA in, 1376
 HTLV-1 in, 1410, 1609
 International Symposium on (V), 195
 long-term followup of, 297
 lymphocyte apoptosis in, 1875
 primary, 297, 767
 prognostic factors in, 1765
 risk of lymphoma in, 767
 secondary, 57, 297
 sicca syndrome, hepatitis C virus and, 1166
 soluble bone marrow stromal cell antigen 1 in RA and, 629
 spindle kinesin-like protein, HsEg5 in SLE and, 1635
 SS-B/La antigen in labial salivary glands in, 783
 xerostomia and saliva substitutes in, 57
- SK&F 106615 in rat adjuvant arthritis, 504**
- Skeletal maturation, aging and, neopeptide marker of, 1234**
- Skin**
 anti-PCNA in chronic intestinal pseudoobstruction and, 877
 in cryocryoglobulinemia, 335
 human synovial mast cells and, 1222
 in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
 nodules, low-dose MTX in fibroblastic rheumatism and, 2070
 nucleotide pyrophosphohydrolase in articular cartilage and, 245
 in RA, 152
 revision total hip arthroplasty and, 1939
 in SLE, 9, 370, 704
 in SSc, 152, 1132, 1161, 1338
 T cells and, in psoriatic arthritis, 137
 vasculitis of, in monoclonal cryo-antifibrinogenemia, 1066
- Sleep**
 in fibromyalgia, 682, 1852, 2086
- Sleep (cont'd)**
 in RA, 713
- Slow-acting antirheumatic drugs (SAARD) in early RA, 996**
- Small arteries in systemic vasculopathy in multiple myeloma, 330**
- Small intestine, perforation of, in systemic vasculopathy in multiple myeloma, 330**
- Small joints in early undifferentiated connective tissue disease, 403**
- Small nuclear RNP, anti-Ro and anti-La anti-DNA antiidiotypes and, 522**
- Small vessels**
 in multiple myeloma, 330, 698
 thrombosis of, vascular injury in SLE and, 9
 vasculitis in, polyarteritis nodosa, microscopic polyangiitis and, 1208
- Smoking**
 glucocorticoid-induced osteoporosis and, 1791
 interstitial lung disease in RA and, 1711
 running, musculoskeletal pain, age and, 64
 twins, risk of RA, 732
- Smooth muscle cells, matrix metalloproteinase 9 in giant cell arteritis and, 1747**
- S-nitrosoglutathione, effect of nitric oxide on chondrocytes and, 1905**
- Social factors**
 acute musculoskeletal symptoms and, 1
 depression in scleroderma and, 1035
 in musculoskeletal conditions, 1931
 in OA, 357
 in RA, 357, 427
- Sodium fluoride in glucocorticoid-induced osteoporosis, 1791**
- Soft tissue**
 acute musculoskeletal symptoms and, 1
 collagen degradation and, 1455
 in dactylitis in seronegative spondylarthropathy, 1524
 revision total hip arthroplasty and, 1939
- Soluble bone marrow stromal cell antigen I in RA, 629**
- Soluble Fas, in SLE, 1611, 1612**
- Soluble HLA class I antigens in SLE, 792**
- Soluble human IL-1 receptor I, recombinant, in active RA, 257**
- Soluble IL-2 receptors in childhood-onset scleroderma, 1041**
- Spanish outcome questionnaire, 93**
- Spindle apparatus, mitotic, human autoantibodies to, 1543**
- Spindle kinesin-like protein, HsEg5, in SLE, 1635**
- Spine**
 glucocorticoid-induced osteoporosis and, 1791
 lumbar, 397, 1791, 1939
 pain in, sulfasalazine in AS and, 1400
- Spleen**
 acute musculoskeletal symptoms and, 1
 antibiotics in reactive arthritis and, 1238
 cytokines in *Staphylococcus aureus* arthritis and, 959
 nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
 nucleotide pyrophosphohydrolase in articular cartilage and, 245
 T cells in lupus and, 23
- Splinter hemorrhages after arterial puncture, 169**
- Spondylarthropathy**
 juvenile, cytokines in, 1703
 seronegative, 1062, 1524
- Sports, weight-bearing, risk of OA and, 988**
- src-related tyrosine kinases, matrix metalloproteinase 1 activation by, 574**
- SS-A/Ro**
 anti-dsDNA antiidiotypes and, 522
 risk of lymphoma in primary Sjögren's syndrome and, 767
- SS-A/SS-B antibodies, seronegative, sicca syndrome, hepatitis C virus and, 1166**
- SS-B/La**
 anti-dsDNA antiidiotypes and, 522
 glutathione-S-transferase GSTM1 null alleles in SLE and, 1763

SS-B/La (cont'd)

- mixed monoclonal cryoglobulinemia in primary Sjögren's syndrome and, 767
 - in Sjögren's syndrome, 753
- Staphylococcal enterotoxin, in RA, 125, 1499
- Staphylococcus aureus* arthritis
- corticosteroids and antibiotics in, 1596
 - cytokines in, 959
- Stem cell factor, recombinant human, human synovial mast cells and, 1222
- Stenosis, subglottic, in Wegener's granulomatosis, 1754
- Steroid drugs
- acute musculoskeletal symptoms and, 1
 - cyclophosphamide and, 171, 1475
 - in glucocorticoid-induced osteoporosis, 1791
 - in HTLV-I, 610
 - in polymyalgia rheumatica, 1199, 1264
- Stiffness
- in fibromyalgia, 682
 - joint neutrophils, methylprednisolone and, in RA, 216
- Stifle joint
- degenerative joint disease in the guinea pig and, 1327
 - neopeptide marker of skeletal maturation, aging and, 1234
- Stomach, watermelon, in SSc, 341, 1439
- Stomatitis, drug therapy in RA and, 723
- Strength, progressive resistance training in RA and, 415
- Streptococcal antigens, penicillin in Behçet's disease and, 2062
- Streptococcal infection, group A, musculoskeletal manifestations of, 1260
- Streptolysin, TAP alleles, HLA-B27 binding peptides and, 1892
- Stress, revision total hip arthroplasty and, 1939
- Stromal cells, bone marrow stromal cell antigen 1 in RA, 629
- Stromelysin
- collagenase, adenosine and, 923
 - IL-1 and, 478, 1292
 - IL-1 receptor antagonist in experimental OA and, 1535
 - N-[4-hydroxyphenyl] retinamide in RA and, 1021
- Subchondral sclerosis, degenerative joint disease in the guinea pig and, 1327
- Subcutaneous air pouch model, in TGF β 1 in MSU crystal-induced inflammation, 1192
- Subcutaneous calcinosis in SSc, 796
- Subcutaneous fat necrosis, polyarthritis, pancreatic disease and, 1922
- Subcutaneous recombinant human IL-1 receptor I in RA, 257, 1092
- Subglottic stenosis in Wegener's granulomatosis, 1754
- Sublabial salivary gland biopsy in Sjögren's syndrome, 297
- Subsarcolemmal oxidative accumulations, carnitine in muscle in idiopathic inflammatory myopathy and, 1869
- Substance P, human synovial mast cells and, 1222
- Sulfamethoxazole, in disease remission in generalized Wegener's granulomatosis, 2052
- Sulfapyridine, sulfasalazine in AS and, 1400
- Sulfasalazine
- in AS, 1400, 2004
 - in psoriatic arthritis, 711, 2013
 - in reactive arthritis (Reiter's syndrome), 2021
 - in RA, 34, 616, 723
- Sulfate, ketatan, antibodies to aggrecan in SF and, 1990
- Sunflower seed oil, γ -linolenic acid in RA and, 1808
- Superantigens
- bacterial, in RA, 125, 1499
 - cytokines in *Staphylococcus aureus* arthritis and, 959
- Supernatants
- bone marrow-derived CD14 cells in RA and, 836
 - effect of MTX on mouse bone cells and, 489

Surface membranes

- autoantibodies against muscle-cell membrane proteins in myositis and, 1860
 - in SLE, 592, 600
- Surface protein, T cells in lupus and, 23
- Surgery
- in gastric antral vascular ectasia in SSc, 341
 - in OA, 357, 1535
 - pain and, 357
 - in RA, 357, 713
 - revision total hip arthroplasty, 1939
- Survival
- cyclosporine in early RA and, 1006
 - mortality in rheumatoid vasculitis and, 266
- SV40 large T antigen nuclear localization signal, Ki antigen epitope homology in lupus and, 855
- Swelling
- collagen and, 495, 623
 - digital extremity, pitting edema and, in polymyalgia rheumatica, 73
 - in focal myositis and MCTD, 1254
 - hand, HLA type, anti-U1 RNP and, 938
 - joint, 1071, 2013, 2021
 - in RA, 257, 415, 713, 1027, 1092, 1818
 - in secondary erythralgia, 1761
- Swimming, protein metabolism, aging and, in RA 1115
- Synergy, T cell receptor β gene, HLA-DR4 and, in RA, 931
- Synovial biopsy
- acute musculoskeletal symptoms and, 1
 - in RA, 181, 1021, 1077
- Synovial cavity, antibodies to aggrecan in SF and, 1990
- Synovial cells
- adhesion of, on EDA-containing fibronectin, 1685
 - dendritic, CD80/CD86 in chronic arthritis and, 1287
 - endothelial, human, adhesion molecules and, 467
 - mast, 1222
 - osteonection in cartilage and, 539
 - in RA, 115, 183, 629, 1267, 1277
 - transcription factor NF- κ B, TNF α and, 197, 583
 - stromal, HTLV-I, autoimmune disorders and, 1410
- Synovial collagenase genes, adenosine receptor and, 923
- Synovial cytokine mRNA in *Staphylococcus aureus* arthritis, 959
- Synovial effusions, matrix metalloproteinase 9 in RA and, 1576
- Synovial endothelium
- α_v /CD18 leukointegrin and, 1913
 - vascular, adhesion molecules, pulse methylprednisolone and, in RA 1970
- Synovial fibroblasts
- adhesion of, lymphocytes and, 226
 - direct gene delivery to synovium and, 820
 - matrix metalloproteinase 1 activation by *src*-related tyrosine kinases and, 574
 - matrix metalloproteinase 9 in RA and, 1576
 - MTX and, 1951
- Synovial fluid (SF)
- acute musculoskeletal symptoms and, 1
 - antibodies to aggrecan in, 1990
 - autoreactivity to heat-shock protein 60 in oligoarticular JRA and, 1826
 - Borrelia burgdorferi* DNA in synovium and, 736
 - CD80/CD86 in chronic arthritis and, 1287
 - in cryoglobulinemia, 335
 - CT of the knee in gout and, 1406
 - cutaneous lymphocyte antigen, T cells and, in psoriatic arthritis, 137
 - detection of *Chlamydia trachomatis* by polymerase chain reaction in, 1740
 - hepatocyte growth factor and, 1566
 - in HTLV-I in the macaque, 610

Synovial fluid (SF) (cont'd)

- inflammatory, human chondrocyte integrins and, 1430
- insulin-like growth factor in arthritis and, 1556
- monoalide in IL-1 α -induced arthritis and, 1292
- in molecular diagnosis of venereal arthritis, 950
- osteonectin in cartilage and, 539
- in RA, 52, 110, 183, 216, 386, 454, 829, 844, 904, 1277, 1576, 1693, 1781, 1961

Synovial hyperplasia

- apoptosis of rheumatoid synovial cells and, 1267
- fibroblast-like synoviocytes in RA and, 1781

Synovial inflammation

- granulomatous microcrystalline, in cryocryoglobulinemia, 335
- in RA, 183, 1781

Synovial joints, anti-TNF α antibody in RA and, 1082

Synovial lining

- adhesion molecules and, 810, 1970
- α_5 /CD18 leukointegrin and, 1913
- direct gene delivery to synovium and, 820
- HTLV-I, autoimmune disorders and, 1410
- in RA, 115, 1781, 1970
- transcription factor NF- κ B and, 583

Synovial macrophages, α_5 /CD18 leukointegrin and, 1913

Synovial membrane

- cutaneous lymphocyte antigen and T cells in, in psoriatic arthritis, 137
- IL-1 receptor antagonist in experimental OA and, 1535
- in RA, 115, 904, 1781, 1970

Synovial microvasculature, anti-TNF α antibody in RA and, 1082

Synovial neovascularization, hepatocyte growth factor and, 1566

Synovial sheath, in dactylitis in spondylarthropathy, 1524

Synovial thickening, acute musculoskeletal symptoms and, 1

Synovial tissue

- α_5 /CD18 leukointegrin and, 1913
- Borrelia burgdorferi* DNA in synovium and, 736
- cytokines and, in JRA and juvenile spondylarthropathy, 1703
- detection of *Chlamydia trachomatis* by polymerase chain reaction in, 1740
- hepatocyte growth factor and, 1566
- HTLV-I, autoimmune disorders and, 1410
- human inflamed, transcription factor NF- κ B in, 583
- human synovial mast cells and, 1222
- MTX and, 1951
- in RA, 110, 115, 125, 181, 183, 325, 446, 844, 914, 1077, 1576, 1781, 2080
- in shoulder synovitis in polymyalgia rheumatica, 1199
- in *Staphylococcus aureus* arthritis and, 959

Synoviocytes

- direct gene delivery to synovium and, 820
- fibroblast-like, in RA, 1781
- HTLV-I, autoimmune disorders and, 1410

Synovitis

- acute musculoskeletal symptoms and, 1
- hepatocyte growth factor and, 1566
- in polymyalgia rheumatica, 73, 1199
- in RA, 713, 1246, 1781
- silicone immunology and, 1615, 1619

Synovium

- α_5 /CD18 leukointegrin and, 1913
- collagen and, 797, 1455
- corticosteroids and antibiotics in *Staphylococcus aureus* arthritis and, 1596
- CT of the knee in gout and, 1406
- cytokines and, in JRA and juvenile spondylarthropathy, 1703
- direct gene delivery to, 820
- human mast cells in, 1222
- IL-1 receptor antagonist in experimental OA and, 1535

Synovium (cont'd)

- MTX and, 1951, 2070
- osteonectin in cartilage and, 539
- in RA, 110, 446, 454, 1371, 1781
- shoulder synovitis in polymyalgia rheumatica and, 1199
- T cells in, in psoriatic arthritis, 137

Synthetic peptides, autoimmunity to RNA polymerase II and, 1886

Synthetic polymers, silicone immunology and, 1615, 1619

Systemic autoimmune diseases, human autoantibodies to the spindle mitotic apparatus and, 1643

Systemic cytokine mRNA in *Staphylococcus aureus* arthritis, 959

Systemic glucocorticoids, low-dose, in RA, 723

Systemic inflammation, serum pro-matrix metalloproteinase 3 in RA and, 884

Systemic JRA

- heat-shock protein 60 and, 1826
- prevalence of, 1385

Systemic immunosuppressive drugs in subglottic stenosis in Wegener's granulomatosis, 1754

Systemic lupus erythematosus (SLE)

See also Lupus

Activity Measure, 1178

acute musculoskeletal symptoms and, 1

anti- β_2 -glycoprotein I in, 1441, 1444, 1466

antibodies to heterogeneous nuclear RNP in SSc and, 1669

anti-CD45 autoantibodies in, 592

antigen-presenting cell function in, 600

antiidiotypic antibodies in, 1980

anti-La in anti-dsDNA idiotype in, 522

anti-P in, 1483

anti-PCNA in chronic intestinal pseudoobstruction and, 877

antiphospholipid antibodies and, 1441, 1444, 1466

anti-Ro in, 522, 1654

CD56 cells in, 1840

cognitive and psychological deficits without central nervous system disease in, 20335

corticosteroids in, 2028

cost of, 979

cyclophosphamide in, 1475, 2028

disease activity and molecular markers of hemostasis in, 287

Disease Activity Index, 287, 370, 792, 1178

disease severity and IL-10:IFN- γ -secreting cells in, 379

ear and discoid lesions in, 2078

early undifferentiated connective tissue disease and, 403

ENA in, 1055

fatal postpartum vasculitis in, 352

geographic clusters of, 1935

hair dye use and, 657

hepatitis C and porphyria cutanea tarda in, 352

hereditary C1q deficiency in, 663

hypercalcemia and, 2066

intravenous immunoglobulins in, 704

laboratory tests and disease exacerbation in, 370, 2083

lupus nephritis in, 2028

malignancy in, 1050

mannose-binding protein polymorphisms in black patients with, 2046

myositis and, 292, 1860

nephritogenic autoantibodies in, 894

pediatric, antiribosomal P antibodies and psychosis in, 671

peptides in, 1654

RA and, 629, 792, 931

ribosomal P autoantibodies in, 1833

SLICC/ACR damage index in, 363

soluble Fas in, 1611, 1612

soluble HLA class I antigens in, 792

Spanish-language outcome questionnaire in, 93

Systemic lupus erythematosus (SLE) (*cont'd*)
 T cells in, 23
 vascular injury in, 9
 Systemic pseudovasculitis, from scurvy in anorexia nervosa, 532
 Systemic rheumatic diseases, acute musculoskeletal symptoms and, 1
 Systemic sclerosis (SSc)
See also Scleroderma
 Amerindian HLA haplotype in, 1362
 antibodies to heterogeneous nuclear RNP in, 1669
 antifibrillar in, 1151
 anti-NOR 90 in, 1313
 anti-PCNA in chronic intestinal pseudoobstruction and, 877
 antithymocyte globulin in, 1132
 anti-topoisomerase I autoantibody and lung cancer in, 686
 augmentation mammoplasty and, 1125
 cardiac involvement in, 1138
 centromere kinesin-like protein, CENP-E, autoantibodies in, 1355
 cutaneous, 1041, 1439
 early pathologic analysis of, 1161
 gastric antral vascular ectasia in, 341, 1439
 heterogeneity in skin fibroblasts in, 1338
 limited, 1138, 1439
 myositis and, 292, 1860
 RA and, 152
 renal vascular damage in, 1030
 subcutaneous calcinosis in, 792
 thallium perfusion defects and cardiac dysfunction in, 677
 topical tretinoin in, 1070
 watermelon stomach in, 341, 1439
 Systemic vasculitis, polyarteritis nodosa, microscopic polyangiitis and, 1208
 Systemic vasculopathy
 cryoglobulinemia as cause of, 335
 in multiple myeloma, 330
 Systolic pulmonary arterial hypertension, in cardiac involvement in limited

T

T cells
 autoreactive, 183, 1826
 CD80/CD86 in chronic arthritis and, 1287
 in childhood-onset scleroderma, 1041
 γ/δ , in rat adjuvant arthritis, 204
 HTLV-1 in PM/DM, 535
 hydroxychloroquine and, in AIDS and inflammatory arthritis, 157
 MTX and, 1951
 in psoriatic arthritis, 137
 in RA, 110, 125, 183, 446, 844, 904, 914, 931, 1077, 1102, 1277, 1499, 1693, 1961
 receptors for, 23, 195, 446, 454, 904
 in shoulder synovitis in polymyalgia rheumatica, 1199
 in Sjögren's syndrome, 773
 in SLE, 23, 379, 592, 1840
 in *Staphylococcus aureus* arthritis, 959, 1596
 T14+ anti-DNA antibodies, antiidiotypic antibodies in SLE and, 1980
 TAP alleles, HLA-B27 binding peptides and, 1892
 Tartrate-resistant acid phosphatase, bone mineral metabolism in JRA and, 746
 Tear fluid lysozymes in Sjögren's syndrome, 297
 Telangiectasia, cutaneous, in gastric antral vascular ectasia in SSc, 341
 Telephone interviews
 in fibromyalgia, 682
 in OA, 1391
 in RA, 427, 1391
 Temporal arteritis, glucocorticoid-induced osteoporosis and, 1791
 Temporal artery biopsy, matrix metalloproteinase 9 in giant cell arteritis and, 1747

Tender points, fluoxetine, amitriptyline and, in fibromyalgia, 1852
 Tenderness
 in early undifferentiated connective tissue disease, 403
 joint, 216, 623, 1027, 1818, 2013, 2021
 point, acute musculoskeletal symptoms and, 1
 Tendons
 Achilles, nucleotide pyrophosphohydrolase in articular cartilage and, 245
 rupture of, acute musculoskeletal symptoms and, 1
 Tenidap in RA, 1263
 Tenosynovitis
 dactylitis in seronegative spondylarthropathy and, 1524
 distal extremity swelling with pitting edema in polymyalgia rheumatica and, 73
 Teratogenicity, drug therapy in RA and, 723
 Tetanus toxoid, antigen-presenting cell function in SLE and, 600
 Tetranoic-dicarboxylic acid, in free radical injury in scleroderma, 1146
 Th1 cytokines
 mRNA in Sjögren's syndrome and, 1376
 in RA, 1961
 Th2 cytokines
 mRNA in Sjögren's syndrome and, 1376
 in RA, 1961
Staphylococcus aureus arthritis and, 959
 Th3 cytokines, *Staphylococcus aureus* arthritis and, 959
 Thiazide diuretics in glucocorticoid-induced osteoporosis, 1791
 Thioredoxin/adult T cell leukemia-derived factor, in Sjögren's syndrome, 773
 Thrombin-antithrombin III complex, disease activity in SLE and, 287
 Thrombocytopenia
 antiphospholipid antibodies and, 1441, 1444, 1466
 drug therapy in RA and, 723
 Thrombocytosis, all-trans-retinoic acid in POEMS syndrome and, 1423
 Thrombosis
 antiphospholipid antibodies and, 1441, 1444, 1466
 in SLE, 9, 1441, 1444, 1466
 venous, antithymocyte globulin in SSc and, 1132
 Tibial plateau, IL-1 receptor antagonist in experimental OA and, 1535
 Tibiofemoral joints, sports, OA and, 988
 Tissue
 collagen degradation and, 1455
 connective, 1435, 1455, 1576
 homing, T cells and, in psoriatic arthritis, 137
 nitric oxide and, in adjuvant arthritis and collagen arthritis, 1677
 nucleotide pyrophosphohydrolase in articular cartilage and, 245
 in OA, 308, 357, 648
 peripheral, colchicine in breast milk in familial Mediterranean fever and, 1213
 prostate biopsy, in molecular diagnosis of venereal arthritis, 950
 in RA, 357, 844, 914, 1077, 1781, 1808, 2080
 salivary gland, in Sjögren's syndrome, 773, 783
 silicone immunology and, 1615, 1619
 soft, 1, 1455, 1524, 1939
 in SSc, 341, 1146
 vascular, matrix metalloproteinase 9 in giant cell arteritis and, 1747
 Tissue inhibitor of metalloproteinases 1 (TIMP-1)
 articular cartilage and, 478, 560
 collagenase, adenosine and, 923
 in RA, 1576, 1781
 Tophi, intraarticular, in CT of the knee in gout, 1406
 Topoisomerase I (topo I), in SSc, 686, 1362
 Total hip replacement
 revision, 1939
 total knee replacement, pain and, in RA and OA, 357
 Toxicity
 azathioprine, 1016, 1435
 MTX, 272, 1016, 1435, 1951
 in RA, 257, 272, 713, 723, 1016, 1021, 1435

- Toxicity (cont'd)**
 sulfasalazine in psoriatic arthritis and, 711
- Trabecular bone**
 degenerative joint disease in the guinea pig and, 1327
 glucocorticoid-induced osteoporosis and, 1791
- Tracheostomy, radiography and, 1076**
- Tracheostomy, in subglottic stenosis in Wegener's granulomatosis, 1754**
- Trait Anxiety Inventory, psychiatric diagnosis, health care-seeking and, in fibromyalgia, 436**
- Transaminase, sicca syndrome, hepatitis C virus and, 1166**
- Transcription factor NF- κ B**
 in human inflamed synovial tissue, 583
 human synovial cells, TNF α and, 197
- Transcription factor NOR 90/hUBF, nucleolar, anti-NOR 90 in rheumatic diseases and, 1313**
- Transfer RNA (tRNA)**
 in antisyndetase syndrome, 692
 autoantibodies and, 146, 1308
- Transforming growth factor β (TGF β)**
 in Sjögren's syndrome, 195, 1376
Staphylococcus aureus arthritis and, 959
 TIMP-1, oncostatin M and, in articular cartilage, 560
- Transforming growth factor β 1 (TGF β 1)**
 apoptosis of rheumatoid synovial cells and, 1267
 articular chondrocytes and, 552, 1896
 osteonectin in cartilage and, 539
 in MSU crystal-induced inflammation, 1192
- Transfusions**
 blood, maternal-fetal immunology, autoimmune disease and, 191
 in gastric antral vascular ectasia in SSc, 341
 NSAID-induced enteropathy, chronic anemia and, in RA, 321
- Transplantation, bone marrow, progression of RA after, 1246**
- Transracial gene mapping, of major histocompatibility complex in myositis, 1507**
- Transverse leukonychia, 151**
- Trauma**
 acute musculoskeletal symptoms and, 1
 antioxidant micronutrients in knee OA and, 648
 childhood-onset scleroderma and, 1041
 revision total hip arthroplasty and, 1939
- Tretinoin in POEMS syndrome, 1423**
- Triamcinolone acetonide, corticosteroids, bone and, in RA, 277**
- Trimethoprim**
 in disease remission in generalized Wegener's granulomatosis, 2052
 in RA, 723
- Tritiated thymidine, IL-10 in RA and, 386**
- Trunk, upper, photosensitive pruritic rash on, in amyopathic DM, 1419**
- Trypsin, procollagenase, doxycycline and, 235**
- Tryptase, human synovial mast cells and, 1222**
- Tryptophan, Mi-2 antibodies, HLA-DR and, in DM, 868**
- Tumor necrosis factor α (TNF α)**
 all-*trans*-retinoic acid in POEMS syndrome and, 1423
 collagen arthritis and, 797
 early pathologic analysis of SSc and, 1161
 HTLV-I, autoimmune disorders and, 1410
 IL-10 and, 386, 495
 in JRA and juvenile spondylarthropathy, 1703
 lymphocyte-fibroblast adhesion and, 226
 MTX and, 1951
 osteonectin in cartilage and, 539
 in RA, 125, 183, 386, 829, 1115, 1693, 1781
 in Sjögren's syndrome, 195
Staphylococcus aureus arthritis and, 959
 synovial endothelial cell adhesion molecules and, 467
 TSG-6 in articular chondrocytes and, 552
 vascular injury in SLE and, 9
- Tumor necrosis factor β (TNF β)**
 in JRA and juvenile spondylarthropathy, 1703
Staphylococcus aureus arthritis and, 959
- Tumor necrosis factor microsatellite polymorphisms in RA, 1109**
- Tumor necrosis factor receptor p75, disease activity in JRA and, 883**
- Tumor necrosis factor-stimulated gene 6 (TSG-6) in articular chondrocytes, 552**
- Tumors, thioredoxin/adult T cell leukemia-derived factor in Sjögren's syndrome and, 773**
- Twin studies**
 CD56 cells in SLE, 1840
 cigarette smoking and risk of RA, 732
- Tyrosine**
 kinase, 23, 574
 ribosomal P autoantibodies in SLE and, 1833
- U**
- Ulcers**
 acute musculoskeletal symptoms and, 1
 drug therapy in RA and, 723
 orogenital, in Behçet-type vasculopathy without Behçet's disease, 1926
 in scleroderma, 1035, 1146
- Ultrasound**
 color-flow Doppler, to study renal vascular damage in SSc, 1030
 in dactylitis in seronegative spondylarthropathy, 1524
 of joint and connective tissue, shoulder pain and, 1435
- Umbilical vein, synovial endothelial cell adhesion molecules and, 467**
- Undifferentiated connective tissue disease, early, 403**
- Undifferentiated seronegative spondylarthropathy, pyoderma gangrenosum and, 1062**
- Unemployment due to arthritis and musculoskeletal disorders, 101**
- United States Public Health Service hospitals, RA in, 283**
- Unproven remedies, Chinese herbs, 354**
- Upper extremities, distal swelling of, pitting edema and, in polymyalgia rheumatica, 73**
- Upper gastrointestinal hemorrhage, gastric antral vascular ectasia in SSc and, 341**
- Urate, monosodium monohydrate crystal, inflammation, TGF β 1 and, 1192**
- Ureaplasma, molecular diagnosis of venereal arthritis and, 950**
- Uridine diphosphoglucose dehydrogenase, enzymes, fibroblast-like synoviocytes in RA and, 1781**
- Urinalysis, acute musculoskeletal symptoms and, 1**
- Urinary hydroxyproline, bone mass, pamidronate and, in RA, 397**
- Urinary nitrate, nitric oxide and, 643, 1677**
- Urinary pyridinoline, corticosteroids, bone and, in RA, 277**
- Urine**
 collagen degradation and, 1455
 complement split products in SLE and, 1178
 in free radical injury in scleroderma, 1146
 glucocorticoid-induced osteoporosis and, 1791
- Uveitis**
 acute anterior, HLA-DR8 and, in AS, 351
 in the macaque with HTLV-I, 610
- V**
- Vaccines, rubella, chronic arthropathy and musculoskeletal symptoms after, 1529**
- Vascular cell adhesion molecule 1 (VCAM-1)**
 α_v /CD18 leukointegrin and, 1913
 anti-endothelial antibodies in Wegener's granulomatosis and, 758
 lymphocyte-fibroblast adhesion and, 226
 in RA, 1077, 1082, 1781
 synovial endothelial cells and, 467
- Vascular damage, renal, in SSc, 1030**

Vascular ectasia, gastric antral, in SSc, 341

Vascular endothelial cells, cytokines and, in JRA and juvenile spondylarthropathy, 1703

Vascular endothelium

- antiphospholipid antibody syndrome and, 1441, 1444, 1466
- anti-TNF α antibody in RA and, 1082
- transcription factor NF- κ B and, 583

Vascular inflammation, anti-endothelial antibodies in Wegener's granulomatosis and, 758

Vascular injury in SLE, 9

Vascular involvement in childhood-onset scleroderma, 1041

Vascular lesions, antral, in gastric antral vascular ectasia in SSc, 341

Vascular proliferation

- hepatocyte growth factor and, 1566
- in shoulder synovitis in polymyalgia rheumatica, 1199

Vascular tissue, matrix metalloproteinase 9 in giant cell arteritis and, 1747

Vasculitis

- cutaneous leukocytoclastic, after azathioprine and MTX in RA, 1016
- fatal postpartum, 352
- in IgA multiple myeloma presenting as Henoch-Schönlein purpura/polyarteritis nodosa, 698
- in monoclonal cryo-antifibrinogenemia, 1066
- necrotizing, in systemic vasculopathy in multiple myeloma, 330
- rheumatoid, 266, 1937
- in SLE, 9, 352, 370
- systemic, polyarteritis nodosa, microscopic polyangiitis and, 1208
- systemic pseudovasculitis from scurvy in anorexia nervosa, 532

Vasculopathy

- Behçet-type, without Behçet's disease, 1926
- occlusive, cryocryoglobulinemia and, 335
- systemic, 330, 335
- vascular injury in SLE and, 9

Vasodilatation, joint swelling, nitric oxide and, 1071

Veins

- Behçet-type vasculopathy without Behçet's disease and, 1926
- jugular, in focal myositis and MCTD, 1254
- umbilical, synovial endothelial cell adhesion molecules and, 467

Vena cava, nucleotide pyrophosphohydrolase in articular cartilage and, 245

Venereal arthritis, molecular diagnosis of, 950

Venous thrombosis, axillary, antithymocyte globulin in SSc and, 1132

Ventriculoperitoneal shunts, silastic, silicone immunology and, 1615, 1619

Venules, postcapillary, self peptides, dendritic cells and, in RA, 183

Vertebrae, glucocorticoid-induced osteoporosis and, 1791

Virology, in HTLV-I in the macaque, 610

Viruses

- adeno-, 820
- autoreactivity to heat-shock protein 60 in oligoarticular JRA and, 1826
- baculo-, 863
- Epstein-Barr, 325, 638, 773
- hepatitis C, 1027, 1074, 1166
- herpes simplex, 820
- HIV, 157, 197
- HTLV-I, 463, 535, 610, 1410
- hydroxychloroquine and, in AIDS and arthritis, 157
- lenti-, 1410
- oncorna-, 1410
- parvo-, human B19, 880
- retro-, 820
- simian immunodeficiency, 610
- Sjögren's syndrome and, 195

Viscoelasticity, of saliva substitutes in xerostomia in Sjögren's syndrome, 57

Visual analog scale

- fluoxetine, amitriptyline and, in fibromyalgia, 1852
- methylprednisolone, joint neutrophils and, in RA, 216

Visual impairment, drug therapy in RA and, 723

Vital statistics, in epidemiology of Wegener's granulomatosis, 87

Vitamins

- antioxidant micronutrients in knee OA and, 648
- bone mineral metabolism in JRA and, 746
- C, deficiency of, 1422
- D, glucocorticoid-induced osteoporosis and, 1791

Vomiting, sulfasalazine in psoriatic arthritis and, 2013

von Willebrand factor in childhood-onset scleroderma, 1041

W

Walking time

- oral type II collagen in JRA and, 623
- progressive resistance training in RA and, 415
- on Spanish-language outcome questionnaire, 93

Watermelon stomach in SSc, 341, 1439

Wegener's granulomatosis

- anti-endothelial antibodies in, 758
- epidemiology of, 87
- generalized, disease remission in, 2052
- human model of, 1262
- of the lungs, 615
- subglottic stenosis in, 1754

Weight, in OA, 648, 988

Weight bearing

- guidelines for evaluation of acute musculoskeletal symptoms and, 1
- sports, risk of OA and, 988

White blood cells

- scans of, in NSAID enteropathy and chronic anemia in RA, 321
- in SLE, 370, 1475
- TGF β 1 in MSU crystal-induced inflammation and, 1192

Whitlockite crystals, basic calcium phosphate crystals, inflammation and, 1319

Work, barriers to return to, in arthritis, 101

Work status

- acute musculoskeletal symptoms and, 1
- in fibromyalgia, 682, 1627
- in RA, 427, 713

World Health Organization (WHO)

- fibromyalgia, disability and, 1627
- response criteria for RA and, 34

Wound drainage, revision total hip arthroplasty and, 1939

Wound healing, drug therapy in RA and, 723

Wrist, in cryocryoglobulinemia, 335

X

Xerostomia, saliva substitutes in Sjögren's syndrome and, 57

X-ray absorptiometry, dual-energy, glucocorticoid-induced osteoporosis and, 1791

Xiphoid process, neoepitope marker of skeletal maturation, aging and, 1234

Xylocaine, bone and, in RA, 277

Y

Yersinia enterocolitica, antibiotics in reactive arthritis and, 1238

Z

Zinc, exogenous, procollagenase, doxycycline and, 235